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ABSTRACT 
This thesis investigates changes to paracetamol toxicity susceptibility and mechanisms 
in ageing, frailty and non-acute paracetamol exposures. It investigates whether the 
current paracetamol hepatotoxicity therapy, N-acetyl cysteine (NAC), is protective in 
non-acute paracetamol exposures, and explores the potential for interventions aimed at 
increasing lifespan and healthspan to provide novel mechanisms of paracetamol 
hepatotoxicity protection. Furthermore this thesis investigates the potential of both 
paracetamol, and lifespan and healthspan interventions in delaying or preventing frailty. 
 
Chapter one of this thesis will summarise the relevant literature on paracetamol toxicity 
prevalence mechanisms and therapies; pharmacokinetic and pharmacodynamic changes 
with age and frailty in particular in regards to paracetamol; animal models of ageing, 
frailty and toxicity; and interventions to slow ageing and frailty, and the role they may 
play in paracetamol toxicity. 
 
Chapter two looks at changes in acute paracetamol toxicity with old age and frailty in 
mice. There is increased use of the analgesic paracetamol in old age, and extensive age-
related physiological changes that may affect paracetamol pharmacokinetics and 
pharmacodynamics. Despite this there are limited human studies and few animal studies 
on the changes to acute paracetamol hepatotoxicity risk and mechanisms in old age and 
in frailty. The changing risk of paracetamol hepatotoxicity with age has not been looked 
at in an ageing mouse model, and has not been explored with frailty in an animal model.  
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Chapter three explores changes to paracetamol toxicity with age and frailty in mouse 
models of chronic and sub-acute paracetamol exposure. It also looks at whether NAC is 
protective against chronic and sub-acute paracetamol exposure, and how this is altered 
with age. It is clear that in old age there is a different type of clinical over-exposure to 
paracetamol, with older people more likely to have chronic and accidental exposures 
rather than acute over-exposures. The risk of toxicity, with age and frailty, to these 
types of paracetamol exposures, is unknown. Furthermore, there is very little evidence 
for the use of the current clinical therapy for paracetamol hepatotoxicity, NAC, in non-
acute paracetamol exposures.  
 
Chapter four investigates pharmacological manipulation of the sirtuin 1 (SIRT1) 
pathway with resveratrol treatment as a potentially protective mechanism against 
paracetamol toxicity in three models: primary hepatocytes, young mice with concurrent 
resveratrol and paracetamol dosing, and young and old mice pre-exposed to resveratrol, 
then treated with paracetamol. There is a need for new paracetamol toxicity therapies, as 
we can see from the lack of evidence for the use of NAC in non-acute over-exposures, 
and the prevalence of patients who still develop acute liver failure from paracetamol 
toxicity. The lifespan and healthspan increasing interventions provide novel targets that 
can be investigated as potential paracetamol toxicity protective therapeutics. 
 
Chapter five examines whether genetic manipulation of the SIRT1 pathway through 
transgenic mouse models is protective against paracetamol toxicity in young and old 
mice. Chapter four provides inconclusive results in regards to resveratrol protection 
against paracetamol hepatotoxicity, so chapter five explicitly addresses whether SIRT1 
      iv 
plays a protective role in paracetamol toxicity, with the use of young and old SIRT1 
transgenic mice treated with acute paracetamol. 
 
Finally, chapter six investigates frailty, and whether chronic paracetamol exposure, or 
activation of the SIRT1 pathway, through chronic resveratrol treatment, or calorie 
restriction, can delay frailty in ageing mice. This chapter investigates the effect of 
pharmaceutical and dietary interventions on a novel mouse clinical frailty index for the 
first time. 
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1 INTRODUCTION 
1.1 Introduction 
Paracetamol (acetaminophen) is a commonly used analgesic, especially in old age. The 
older population has a high prevalence of pain, and paracetamol is often the first-line 
analgesic prescribed to treat this pain (Makris et al. 2014; Nikles et al. 2005). 
Overexposure to paracetamol can cause acute liver toxicity (Larson 2007). 
Susceptibility to and mechanisms of paracetamol hepatotoxicity may change in old age, 
and in frailty, because of changes in pharmacokinetics, pharmacodynamics and 
homeostatic responses, although there are limited clinical and animal studies (Sarah J 
Mitchell, Kane, et al. 2011; Schmidt 2005). While the overall change in risk of toxicity 
in old age remains uncertain, there is evidence that there is a change in the type of 
exposure to paracetamol in old age. Older patients are more likely to have chronic and 
non-intentional exposures, rather than the acute and intentional exposures that are 
common in the younger population (Kane et al. 2012). The two most common reasons 
for accidental paracetamol overdose are poorly controlled pain (Michna et al. 2012), and 
the use of multiple paracetamol-containing medications (Civan et al. 2014), and both of 
these risk factors are common in the older population.  
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The increased rate of non-acute paracetamol overexposures in the older population is 
particularly problematic as the effectiveness of the current clinical paracetamol 
hepatotoxicity therapy, N-acetyl cysteine (NAC), in non-acute paracetamol exposures is 
unknown (Daly et al. 2008). Furthermore, clinical evidence has shown that there is a 
need for new paracetamol toxicity therapies, as there are patients, especially older 
people and those who present late to hospital or have staggered ingestions that still 
develop acute liver failure from paracetamol exposure and are unlikely to benefit from 
NAC (Craig et al. 2011; Ferner et al. 2011).  
 
There has been an increasing body of research in the recent years investigating ageing 
mechanisms and pathways, and interventions that increase longevity. Two of these 
interventions are calorie restriction (the reduction in the daily intake of calories, without 
nutritional deficiencies), and the calorie-restriction ‘mimetic’, resveratrol (Bordone & 
Guarente 2005; Baur et al. 2006; Weindruch et al. 1986). The mechanisms of these 
interventions are still not fully understood but two of the main targets involved are the 
sirtuin (SIRT)1 and 5' adenosine monophosphate-activated protein kinase (AMPK) 
pathways (Le Couteur et al. 2012). There is increasing evidence to show that these 
ageing-related pathways also play a role in response to stresses, such as over-exposure 
to paracetamol (Michan & Sinclair 2007). There is some evidence from animal studies 
that resveratrol, and calorie restriction, protect against paracetamol toxicity (Harper et 
al. 2006; Masubuchi et al. 2009; Du et al. 2015). Exploration of these potentially 
protective targets, especially in old age, may provide novel insight into mechanisms of 
paracetamol toxicity development and new potentially protective therapies for all ages. 
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Frailty is an increasingly important concept in ageing research, with a recent shift of 
focus on the development of interventions to extend healthspan and delay frailty, rather 
than increase lifespan (Kirkland & Peterson 2009). The recent development of validated 
animal assessments of frailty (Whitehead et al. 2014; Liu et al. 2013), enables the effect 
of interventions, such as resveratrol, calorie restriction or exercise, on delaying or 
preventing frailty to be assessed in ageing animal models. Furthermore it allows the 
assessment of changes in vulnerability to stressors, such as paracetamol toxicity, to be 
assessed with both ageing and frailty in animal models. 
 
1.2 Paracetamol Use and Toxicity 
1.2.1 Paracetamol Use and Toxicity in Australia and Internationally 
Paracetamol, also known as acetaminophen, is a widely used analgesic and antipyretic 
(Burke et al. 2009). It is believed to be safe and effective at therapeutic doses, but has 
serious overdose consequences, particularly hepatotoxicity (Larson 2007) with 
paracetamol hepatotoxicity being the most common cause of acute liver failure (ALF) in 
the United States (US) and the United Kingdom (UK) (Craig et al. 2011; Ostapowicz et 
al. 2002). 
 
In Australia, paracetamol is one of the most commonly used medications (Morgan et al. 
2011; Sood et al. 2013), and also the most common cause of acute liver failure (Gow et 
al. 2004), although the rates of liver failure appear to be less than in the UK (Hiles et al. 
2015; Sood et al. 2013). A study of paracetamol overdoses at a regional Australian 
hospital found there were approximately 23 cases per 100,000 people each year 
(Ayonrinde et al. 2005), whilst a study of paracetamol poisoning and adverse events in 
Victoria, found there were 39-46 cases per 100,000 people per year in 2001 to 2006, and 
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26 deaths related to paracetamol toxicity over the seven year study period (Sood et al. 
2013). One to two percent of patients with paracetamol overdose have associated 
nephrotoxicity (Boutis & Shannon 2001). 
 
Paracetamol is available as both an over-the-counter medication, and a prescription 
medication for conditions including osteoarthritis and low back pain (Graham et al. 
2013). It is available in several formulations both alone (as tablets, liquids, 
suppositories, slow-release) and in combinations with other medications including 
aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), opioids, pseudoephedrine 
and antihistamines (MIMS 2013). The maximum recommended therapeutic dose of 
paracetamol in Australia is four grams per 24 hours (Larson 2007; Lancaster et al. 
2014). The Food and Drug Administration (FDA) recently reduced the maximum 
recommended therapeutic daily dose to 3.25g in the US (Lee 2010). 
1.2.2 Pharmacokinetics of Paracetamol Toxicity 
Paracetamol is predominantly metabolised in the liver via the phase II conjugation 
pathways, with the glucuronide (55%) and sulphate (30%) conjugates the two 
predominant metabolites, which are excreted in the urine and bile (Burke et al. 2009). A 
small amount of paracetamol (5%) is also oxidised by the cytochrome P450 (CYP450) 
enzymes of the liver to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) 
(Holt & Ju 2006). The most important isoform responsible for this CYP450 mediated 
metabolism is CYP2E1, but CYP3A4 and CYP1A2 are also involved (Lee et al. 1997) 
At therapeutic doses of paracetamol, NAPQI is immediately conjugated with hepatic 
glutathione (GSH) which de-toxifies it and allows it to be excreted via the kidneys 
(Mitchell et al. 1973) NAPQI may also be reduced by NAD(P)H:quinone 
oxidoreductase 1 (NQO1) back into paracetamol (Moffit et al. 2007). Following an 
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overdose of paracetamol, there is saturation of the conjugation metabolism pathways 
and GSH depletion (Larson 2007). Build-up of the toxic NAPQI occurs which can 
result in liver cell damage, predominately centrilobular necrosis (Jollow et al. 1973) 
(Figure 1.1). 
 
Renal toxicity can also occur, following paracetamol overdose. The mechanisms of this 
are not well understood but may involve renal CYP2E1 enzymes or nephrotoxic 
glutathione-conjugates (Mazer & Perrone 2008). The focus of this thesis is paracetamol-
induced hepatotoxicity. 
 
 
Figure 1.1 Pharmacokinetics and Pharmacodynamics of Paracetamol Hepatotoxicity. 
CYP2E1 = Cytochrome 2E1, NAPQI = N-acetyl-p-benzoquinone imine 
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1.2.3 Pharmacodynamics of Paracetamol Hepatotoxicity 
The mechanisms of paracetamol-induced liver injury involve the initial formation of the 
toxic metabolite, NAPQI, the mitochondrial dysfunction associated with this metabolite, 
the induction of cell death, and an inflammatory response (Jaeschke et al. 2012).  
1.2.3.1 Role of Mitochondria in Paracetamol Hepatotoxicity 
Mitochondria play a central role in the development of paracetamol hepatotoxicity in 
both mice and humans (McGill et al. 2012). Mouse studies have shown that NAPQI 
covalently binds to cellular proteins, particularly in the mitochondria (Jollow et al. 
1973; Myers et al. 1995) and results in induction of mitochondrial oxidant stress 
(Jaeschke 1990) and the formation of peroxynitrate (Hinson et al. 1998). These reactive 
oxygen and nitrogen species cause mitochondrial protein and deoxyribonucleic acid 
(DNA) damage, and activate c-Jun N-terminal kinase, JNK, resulting in its 
phosphorylation and translocation to the mitochondria, which amplifies the oxidant 
stress (Saito, Zwingmann, et al. 2010; Hanawa et al. 2008). This oxygen and 
peroxynitrite stress results in permeabilization of the outer membrane of the 
mitochondria either by the formation of mitochondrial permeability transition (mPT) 
pores at low levels of stress, or by another mPT independent mechanism with higher 
levels of chemical stress (Loguidice & Boelsterli 2011). This ultimately causes 
inhibition of respiration, depletion of adenosine triphosphate (ATP) and a decrease in 
membrane potential (Masubuchi et al. 2005; Kon et al. 2004).  This process results in 
the release of proteins such as apoptosis-inducing factor, endonuclease G and 
cytochrome C from the mitochondria, which translocate to the nucleus and cause 
nuclear DNA fragmentation (Jaeschke & Bajt 2006). These processes trigger necrotic or 
apoptotic cell death (Jaeschke et al. 2012). A similar process is believed to occur in 
humans, although there is only indirect evidence such as reduced serum glutathione 
after paracetamol treatment (Lauterburg & Mitchell 1987) and the detection of 
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paracetamol-protein adducts (Muldrew et al. 2002; Davern et al. 2006) and 
mitochondrial and nuclear DNA fragments in serum of patients after paracetamol 
overdose (Mcgill et al. 2012). 
 
Autophagy is a cellular process by which the cytoplasm and organelles are sequestered 
into vesicles and delivered to the lysosome, where they are broken down and the 
macromolecules recycled (Glick et al. 2010). There has been recent evidence of a role 
of autophagy in paracetamol hepatotoxicity (Ni et al. 2012). Although the exact 
mechanisms are still not known, it is thought that the production of reactive oxygen 
species can induce autophagy (Ding et al. 2010; Y. Chen et al. 2008), which acts to 
remove mitochondria damaged by NAPQI. Further pharmacological induction of 
autophagy was protective against paracetamol hepatotoxicity (Ni et al. 2012), and loss 
of autophagy increases paracetamol induced hepatotoxicity (Igusa et al. 2012). 
1.2.3.2 Necrosis and Apoptosis in Paracetamol Toxicity 
Cell death in paracetamol toxicity is predominantly caused by cell necrosis, 
characterised by nuclear breakdown, release of cell contents and enzymes and cell 
swelling (Gujral et al. 2002).  
 
The extent to which apoptotic cell death contributes to the development of paracetamol 
hepatotoxicity is controversial (Malhi et al. 2006). Paracetamol treatment involves 
factors including the translocation of Bax and Bid (death proteins involved in the 
apoptosis pathway) to the nucleus (Adams et al. 2001; Bajt et al. 2008), the release of 
cytochrome C from the mitochondria (El-Hassan et al. 2003), DNA fragmentation 
(Cover et al. 2005) and positive cell terminal deoxynucleotidyl transferase dUTP nick 
end labelling (TUNEL) staining (Lawson et al. 1999), which are historically 
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characteristic of apoptosis. Jaeschke et al. (2012) claim that none of these parameters 
are in fact specific for apoptosis, and there is no evidence of caspase activation (Mcgill 
et al. 2012; Adams et al. 2001) probably due to ATP depletion (Antoine et al. 2010) so 
question the role of apoptosis in paracetamol toxicity. However, a recent clinical 
observational study, found that hepatic apoptosis was seen in the early stages of 
paracetamol induced acute liver failure (as ATP levels were not completely depleted), 
and serum levels of apoptosis-associated markers (caspase-cleaved CK-18) were 
associated with poor outcomes (Possamai et al. 2013).  
1.2.3.3 Inflammatory Response in Paracetamol Toxicity 
The formation of NAPQI, and the subsequent mitochondrial damage is an important 
initiating factor for paracetamol induced liver injury. It has been suggested, however, 
that it is the inflammatory immune response, and the balance between the protective and 
toxic signalling processes of the cells involved in this response that determines the 
severity and progression of liver injury (Antoine et al. 2008). Studies suggest that 
hepatocyte stress or death, as a result of the reactive metabolite induced damage, causes 
the release of signals (known as Damage-Associated Molecular Patterns, DAMPS) that 
stimulate activation of the innate immune cells of the liver (Holt & Ju 2006; Jaeschke et 
al. 2011). These cells produce pro-inflammatory cytokines and mediators such as tumor 
necrosis factor TNF-α, interleukin IL-1β and interferon IFN-γ (Ishida et al. 2002; 
Bourdi et al. 2002; Gardner et al. 2003). Other mediators released by these immune 
cells are protective and anti-inflammatory such as IL-10 (Bourdi et al. 2002) and IL-6 
(Masubuchi et al. 2003). Kupffer cells and neutrophils can also generate reactive 
oxygen species (Jaeschke & Smith 1997; Liu et al. 1995). However there is much 
disagreement between the studies and the exact role of each of the cell types and 
mediators in drug induced liver injury (DILI) generally, as well as in paracetamol-
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induced liver injury, have yet to be fully determined (Holt & Ju 2006; Jaeschke et al. 
2012)  
1.2.4 Clinical Assessment of Paracetamol Toxicity 
An acute paracetamol overdose is defined as a single dose of 10-15g in adults (Larson 
2007). Clinically, acute paracetamol overdose is associated with three main stages. The 
first lasts for approximately 24 hours and involves non-specific gastrointestinal 
symptoms such as nausea, vomiting and abdominal pain with minimal elevation in 
serum liver enzyme concentrations. The second stage, from 24-72 hours, involves few 
clinical symptoms although there is release of enzymes from the liver (the mechanism 
of which is actually unknown), most notably elevation of serum aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) concentrations. The third 
stage develops in the next 24 hours (72-96 hours) and the symptoms and outcomes vary 
from full recovery to death depending on the severity of the liver damage (Larson 2007; 
Lancaster et al. 2014). 
 
In a clinical setting, if there is suspected paracetamol toxicity, blood tests are performed 
including a paracetamol level, liver function tests (LFTs) and coagulation profile to 
assess the degree of liver damage (Daly et al. 2008). Clinical signs of paracetamol 
toxicity include elevated AST and ALT serum concentrations (up to many 1000s U/L in 
cases of extreme paracetamol-induced liver toxicity), as well as abnormal results for the 
other LFTs (Larson 2007) and high serum concentrations of paracetamol. Peak serum 
concentrations after therapeutic doses do not usually exceed 130μmol/L (20 mg/L) 
(Daly et al. 2008; Graham et al. 2013).  
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Although these blood tests can provide some evidence of the extent of the liver damage, 
better indicators of prognosis at presentation and during treatment, are needed to guide 
treatment choice (Ferner et al. 2011; Rumack & Bateman 2012). Antoine et al. (2013), 
identified serum microRNA(miR)-122 (a highly liver specific mRNA), high mobility 
group box-1 (HMGB1, a marker of necrosis) and keratin-18 (K18, a marker of necrosis) 
measured at first presentation to hospital, as better predictors of acute liver injury, than 
serum ALT or paracetamol concentration. Other potential biomarkers of paracetamol 
induced liver damage are reviewed by Mcgill & Jaeschke (2014). 
1.2.5 Current treatment: N-Acetyl Cysteine 
The current first line therapy for paracetamol hepatotoxicity is N-acetyl-cysteine 
(NAC). NAC prevents liver toxicity by increasing glutathione stores as well as by 
acting as a glutathione substitute that itself binds to NAPQI to de-toxify it (Corcoran, 
Racz, et al. 1985), although recent evidence has also shown it can also protect by 
maintaining mitochondrial energy metabolism (Saito, Zwingmann, et al. 2010). Table 
1.1 outlines the changes to factors involved in the paracetamol toxicity pathway with 
NAC treatment. Clinically, the Rumack-Matthew nomogram is used to guide the 
treatment of acute paracetamol overdose provided time since overdose is known 
(Rumack & Matthew 1975). Those with serum paracetamol concentrations above the 
treatment line will be administered NAC, a glutathione precursor, orally or 
intravenously (Larson 2007). Cases in the UK of patients with levels below this 
treatment line not being given NAC, and developing acute liver failure, has led the UK 
to decrease this treatment threshold by approximately 50% (Lancaster et al. 2014; 
Bateman 2015). The treatment regimen for NAC is complex, requiring body weight 
adjustments and several different intravenous infusions, and errors are common (Ferner 
et al. 2001). NAC can also cause side-effects in up to 45% of patients, ranging from 
nausea to anaphylaxis (Kerr et al. 2005), and the risk of these reactions is inversely 
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related to serum paracetamol levels (Waring et al. 2008). As such it is important to 
optimise NAC treatment and not use it in patients for whom it will be ineffective or 
unnecessary (Bateman 2015). 
 
NAC guidelines are designed for protection against a single high dose of paracetamol 
and there is little evidence to guide risk assessment and optimal treatment for staggered 
over-exposures, chronic exposures or repeated supra-therapeutic exposures (Daly et al. 
2008; Ferner et al. 2011). One animal study found that several weeks of NAC pre-
treatment protected against toxicity induced by twice-weekly paracetamol dosing (Chen 
et al. 2012), but post-treatment has not been studied. Patients with these types of 
paracetamol exposures, especially late presentation to hospital or repeated paracetamol 
ingestion, are also more at risk of adverse outcomes including liver failure (Craig et al. 
2012; Daly et al. 2008; Ferner et al. 2011).  
 
The presence of side effects, high incidence of treatment errors, and the lack of evidence 
to guide NAC treatment in non-acute exposures had led to much research into other 
potential therapeutics to prevent or treat paracetamol hepatotoxicity. These include 
many natural product extracts with anti-inflammatory or anti-oxidant capacities 
(Jaeschke et al. 2011; Zhang 2015; Imaeda & Watanabe 2009), compounds which act 
on the liver sinusoidal endothelial cells (Lin et al. 2010), that provide mitochondrial 
protection (Reid et al. 2005) and compounds that prevent the promotion of oxidant 
stress in the hepatocytes (Saito, Yan, et al. 2010). The potential for longevity and 
ageing-related interventions to protect against paracetamol toxicity will be further 
explored in section 1.4.5. 
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Table 1.1 Changes to factors and mechanisms involved in paracetamol toxicity pathway with factors that may increase or decrease the risk of 
paracetamol toxicity: N-Acetyl cysteine treatment, Ageing, Frailty, Resveratrol treatment and Calorie Restriction. ‘-‘ indicates this effect is not 
applicable, ‘?’ indicates this effect is not yet known, ‘’ indicates the effect is an increase, ‘’ indicates the effect is a decrease. ALF=Acute Liver 
Failure, ALT= Alanine aminotransferase, CYP450=cytochrome P450, NQO1= NAD(P)H:quinone oxidoreductase 1, NAPQI= N-acetyl-p-
benzoquinone imine, AMPK= 5' adenosine monophosphate-activated protein kinase, SIRT1= Sirtuin 1 
Paracetamol	Use	and	Toxicity‐Related	
Mechanisms	
Change	with	factors	explored	in	this	thesis	
N‐Acetyl	cysteine	 Ageing	 Frailty	 Resveratrol	 Caloric	Restriction	
Paracetamol	Use	 Common	 ‐	 (Pearson	et	al.	2007)	 (Blyth	et	al.	2008)	 ‐	 ‐	
Toxicity:	
	‐	Type	of	Exposure	 Acute,	sub‐acute	and	
chronic	
No	evidence	for	use	
in	non‐acute	
exposure	(Daly	et	al.	
2008)	
More	chronic	
exposures	(Kane	et	al.	
2012)	
?	 ‐	 ‐	
	‐	Incidence/Risk	 Most	common	cause	
of	ALF	
	(Daly	et	al.	2008)	 (Rikans	&	Moore	1988;	S	J	
Mitchell	et	al.	2011)	
or(Tarloff	et	al.	1996)	
(Mitchell	et	al.	2011)	 	(Masubuchi	et	al.	2009;	
Wang	et	al.	2015)	
	(Miller	et	al.	2005;	Harper	et	
al.	2006)	or		(Schenker	et	
al.	2001)	
	‐	ALT	leakage	 Marker	of	liver	
damage	
	(Corcoran,	Racz,	et	al.	
1985)	
(Le	Couteur	et	al.	2010)	 (Le	Couteur	et	al.	2010)	 	(Sener	et	al.	2006;	Du	et	al.	
2015)	
	(Miller	et	al.	2005;	Harper	et	
al.	2006)	
Pharmacokinetics:	
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	‐	CYP450	activity	 Produces	toxic	
metabolite,	NAPQI	
	(Ahmad	et	al.	2013)	 	(Mach	et	al.	2014)	or		
(Hunt	et	al.	1990)	
?	 (Wang	et	al.	2015;	Wu	et	al.	
2013)	
	(Chilakapati	et	al.	2007;	
Alterman	et	al.	1993)	
	‐	NQO1	activity	 Converts	NAPQI	to	
paracetamol	
?	 	(Mach	et	al.	2014;	Chen	et	
al.	1994),	
?	 	(Hsieh	et	al.	2006)	 	(De	Cabo	et	al.	2004)	
	‐	Phase	II	metabolism	 Produces	non‐toxic	
metabolites	
	(Corcoran,	Todd,	et	al.	
1985)	
	or		(Summerbell	et	al.	
1993;	Butler	&	Begg	2008)	
	(Wynne	et	al.	1990)	 	(Baur	&	Sinclair	2006;	Cao	
&	Li	2004)	
	or		(Leakey	et	al.	1989;	
Stott	et	al.	2004)	
Pharmacodynamics:	
	‐	Hepatic	glutathione	 De‐toxifies	NAPQI	 	(Corcoran,	Racz,	et	al.	
1985)	
	(Hazelton	&	Lang	1980)	 ?	 	(Sener	et	al.	2006;	Du	et	al.	
2015;	Wang	et	al.	2015)	
	(Mune	et	al.	1995;	Cho	et	al.	
2003)	
	‐	Necrosis	 Predominant	mode	
of	cell	death	
	(Corcoran,	Racz,	et	al.	1985;	
Rumack	&	Matthew	1975)	
	(Rikans	&	Moore	1988)	 ?	 	(Du	et	al.	2015;	Wang	et	al.	
2015)	
?	
	‐	Apoptosis	 Controversial	role	in	
cell	death		
	(Saito,	Zwingmann,	et	al.	
2010)	
	(Mach	et	al.	2015;	
Molpeceres	et	al.	2007)	
?	 	(Yu	et	al.	2012;	Lin	et	al.	
2011)	
	(Lee	et	al.	2004;	Shelke	&	
Leeuwenburgh	2003;	Cohen	et	
al.	2004)	
	‐	Mitochondrial	Oxidant	
Stress	
Induced	by	NAPQI	
and	amplified	in	the	
mitochondria	
	(Bajt	et	al.	2004)	 (Gonzalez‐Freire	et	al.	2015)	 (Wu	et	al.	2009;	Serviddio	et	
al.	2009;	Howard	et	al.	2007)	
(Sener	et	al.	2006;	Du	et	al.	
2015)	
	(Yu	&	Chung	2001;	Lin	et	al.	
2004;	Lambert	&	Merry	2004)	
	‐	Mitochondrial	Function	 Inhibition	of	
respiration	and	a	
decrease	in	
membrane	potential.	
	(Saito,	Zwingmann,	et	al.	
2010)	
	(Gonzalez‐Freire	et	al.	
2015)	
	(Mohler	et	al.	2014;	Moore	
et	al.	2010)	
	(Baur	&	Sinclair	2006;	
Lagouge	et	al.	2006;	Du	et	al.	
2015)	
	(López‐Lluch	et	al.	2006;	
Martin‐Montalvo	&	Cabo	2012)	
	‐	Inflammatory	Response	 Initial	damage	
induces	an	
inflammatory	
response.	
	(James	et	al.	2003)	 	(Starr	&	Saito	2014;	
Franceschi	et	al.	2000;	Tateda	
et	al.	1996)	
	(Walston	et	al.	2008;	
Collerton	et	al.	2012)	
	(Yoshizaki	et	al.	2010;	
Masubuchi	et	al.	2009)	
		(J.	Wang	et	al.	2013;	Ye	&	
Keller	2010)	
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	‐	Autophagy	 Induced	to	play	a	protective	role.	 	(Ni	et	al.	2012)	 	(Cuervo	et	al.	2005)	 ?	 	(Yu	et	al.	2012)	
	(Morselli	et	al.	2010;	Kume	
et	al.	2010)	
Age‐related	Mechanisms	
	‐	AMPK	
expression/activation	
Recent	studies	
suggest	reduces.	 ?	
	(Mulligan	et	al.	2005)	or	
	(Salminen	&	Kaarniranta	
2012;	Reznick	et	al.	2007)	
?	 	(Price	et	al.	2012;	Baur	&	Sinclair	2006)	 	
(Cantó	&	Auwerx	2011;	
Greer	et	al.	2007)	
	‐	SIRT1	
expression/activation	 Unknown.	 ?	
Tissue	dependent		
or	,	(Le	Couteur	&	Sinclair	
2010;	Ferrara	et	al.	2008)	
	or		(Le	Couteur	et	al.	
2011;	Kumar	et	al.	2014)	 	(Hubbard	et	al.	2013)	
	(Cohen	et	al.	2004)	
although	not	in	all	
tissues/experiments	
(Le	Couteur	et	al.	2012)	
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1.2.6 Risk Factors for Paracetamol Hepatotoxicity 
There are several factors that are believed to increase the risk of paracetamol toxicity, 
mostly due to glutathione depletion, or through the induction of CYP2E1. Alcoholism, 
and/or the regular consumption of large amounts of alcohol, are thought to increase the 
risk of paracetamol toxicity by both inducing CYP450 enzymes, and reducing total liver 
glutathione levels (Whitcomb & Block 1994; McClain et al. 1980; Myers et al. 2008), 
although the true nature of this risk remains controversial (Graham et al. 2013; Dart et 
al. 2010). Malnutrition and fasting are believed to increase the risk of paracetamol 
toxicity as a result of decreased liver glutathione (Kondo et al. 2012; Whitcomb & 
Block 1994). Early studies have implicated obesity with an increased risk of 
paracetamol toxicity with obesity (Corcoran & Wong 1987), although this was probably 
attributable to weight-based dosing as recent studies have shown either no change or a 
decreased risk of toxicity in obesity (Rutherford et al. 2006; Radosevich et al. 2013). 
However, non-alcoholic fatty liver disease (NAFLD) has been associated with increased 
risk of paracetamol toxicity due to increased CYP2E1 activity (Kucera et al. 2012; 
Tarantino et al. 2007; Michaut et al. 2014). Long-term use of other medications that 
induce CYP450 enzymes may also increase paracetamol toxicity risk, including 
isoniazid, phenobarbital, St Johns Wort and rifampicin (Ferner et al. 2011). Several 
genetic polymorphisms in enzymes of the paracetamol metabolism pathway have also 
been associated with increased paracetamol toxicity risk (Zhao & Pickering 2011; Court 
et al. 2013). Interestingly, changes in the gut microbiome  have also been shown to have 
a role in paracetamol toxicity (Possamai et al. 2015). 
 
The effect of increased age and frailty on paracetamol toxicity risk is unclear, and 
current literature is summarised in section 1.3.3.4 and in Table 1.1. Unintentional 
Chapter 1: Introduction 
Alice Kane - March 2016 16
overdose and staggered exposure to paracetamol have also been associated with 
increased risk of toxicity and are further discussed in section 1.2.7. 
1.2.7 Toxic Exposures: Intentional vs. Unintentional, Acute vs. Chronic 
Intentional paracetamol overdoses are the most common type of exposure, and thus are 
the most commonly studied. With this type of exposure, provided a patient presents to 
hospital in a timely manner, and is given NAC, the rates of mortality and need for liver 
transplant are low (Larson 2007). The rates of unintentional overdoses are increasing, 
however, and are particularly problematic as they are potentially preventable, and 
associated with increased risk of adverse outcomes (Craig et al. 2011). It is reported that 
45-55% of paracetamol overdoses in the US are unintentional (Larson et al. 2005; 
Bower et al. 2007; Michna et al. 2010), and Australian studies have found the rates of 
unintentional overdoses are between 5% (Ayonrinde et al. 2005) and 15% (Sood et al. 
2013). Sood et al. (2013) also identified that patients with unintentional overdoses were 
more likely to develop acute liver failure, and although only 1% of overdoses in their 
study resulted in death, 34% of the deaths were due to accidental exposures. The two 
main causes of unintentional overdose appear to be the unknowing use of multiple 
paracetamol containing medications (Civan et al. 2014), or an increase in the use of 
paracetamol containing medications for poorly managed pain (Michna et al. 2012). 
 
Cases of hepatotoxicity due to acute paracetamol exposures are also the most common, 
and extensively studied. However there are many other types of paracetamol exposure 
including chronic therapeutic exposure, chronic supra-therapeutic exposure and 
staggered overexposures that have been less extensively researched. There has been 
recent evidence emerging of mild liver damage in some people with therapeutic levels 
of paracetamol, since a clinical trial found that 31-44% of healthy volunteers taking the 
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recommended therapeutic paracetamol dose (4g/day) for 14 days had increased serum 
ALT activity (Watkins et al. 2006). A systematic review of observational studies in the 
UK suggested a considerable degree of paracetamol toxicity especially at the upper end 
of standard analgesic doses (Roberts et al. 2015). Blieden et al. (2014) report that long-
term paracetamol overdose due to chronic pain is very common in the US, with up to 
6% of adults prescribed more than four grams of paracetamol per day. A case study 
(Lane et al. 2002) and a large-scale retrospective hospital study (Civan et al. 2014), also 
highlight the increased risk of chronic paracetamol over-exposure in patients taking 
multiple paracetamol-containing medications. Alarmingly, patients with these types of 
chronic or staggered exposures to paracetamol are not only common, but also appear to 
be at higher risk of severe adverse outcomes. Two studies in the UK found that 
compared to acute over-exposures, staggered over-exposures to paracetamol were 
associated with an increased risk of liver failure (Craig et al. 2012; Ferner et al. 2011), 
and a Spanish study showed that patients with chronic paracetamol exposure compared 
to acute were much more at risk for hepatotoxicity and acute liver failure (Tong et al. 
2015). 
 
1.2.8 Animal Models of Paracetamol Toxicity 
Animal models of paracetamol toxicity have been extensively developed and studied, 
since the 1970s (Jollow et al. 1973; Mitchell et al. 1973). Many of the studies which led 
to crucial knowledge about the pharmacokinetics and pharmacodynamics of acute 
paracetamol toxicity, discussed in sections 1.2.2 and 1.2.3 above, were completed in 
animal models. Acute paracetamol toxicity animal models are commonly used as 
generalised DILI models to look at potentially protective therapeutics (Jaeschke et al. 
2011), and gain increased understanding of DILI mechanisms (Jaeschke et al. 2012). 
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Rats and mice are the most commonly used models of paracetamol toxicity, although 
there has been recent evidence for the use of rabbits and zebrafish (Zubairi et al. 2014; 
Maciejewska-Paszek et al. 2007). Rats and mice are usually fasted overnight before 
acute paracetamol treatment to normalise the liver glutathione levels (Price et al. 1987). 
A recent study suggested that mice are a more clinically relevant model of paracetamol 
toxicity than rats, due to similar susceptibility to toxicity and similar mechanisms of 
damage, particularly mitochondrial dysfunction and JNK activation (McGill et al. 
2012). However, there has been recent concern about differences in paracetamol 
toxicity study outcomes even in mice of the same strain and genetic background (Bourdi 
et al. 2011; Jaeschke et al. 2012). Mossanen & Tacke (2015) draw attention to the 
importance of paracetamol solution preparation, fasting period, routes of administration, 
sex and housing conditions on paracetamol toxicity outcomes. There have been several 
studies that have found differences in paracetamol-induced liver and kidney toxicity in 
male compared to female mice, with male mice having greater susceptibility (Hoivik et 
al. 1995; Hu et al. 1993; Mohar et al. 2014). Other studies have suggested that 
differences in the gut microbiome may explain some differences in susceptibility to 
paracetamol toxicity in genetically identical mice, due to changes in metabolism and 
inflammatory response (Possamai et al. 2015; Kubes & Mehal 2012). Furthermore, 
some studies have identified genetic differences between strains of mice believed to be 
genetically identical, due to genetic drift in the colonies at different breeding facilities, 
creating substrains (Bourdi et al. 2011; Zurita et al. 2011; Mekada et al. 2009). In 
particular, Bourdi et al. (2011) found that C57BL/6 mice from the Jackson laboratory, 
compared to the National Institutes of Health laboratories, were genetically different 
substrains (as assessed by Nnt genotyping), and had, as yet, unexplained differences in 
susceptibility to paracetamol toxicity, which affected the interpretation of results about 
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the role of JNK2 in paracetamol toxicity. Thus care must be taken in interpreting 
results, and comparing outcomes across mouse studies of paracetamol toxicity, 
particularly in regards to mouse substrains. 
 
Two rat studies, and one mouse study, showed that low-dose paracetamol administered 
daily did not cause liver toxicity in the absence of other risk factors (Yisarakun et al. 
2014; Kondo et al. 2012; de Meijer et al. 2012). Several rat and BALB/c mouse studies 
have found that pre-treatment with non-toxic doses of paracetamol for 4-8 days before 
exposure to a high dose of paracetamol can protect against hepatotoxicity, through 
reduction in CYP2E1 activity, and increased glutathione levels among other 
mechanisms (Ghanem et al. 2009; O’Brien et al. 2000; Shayiq et al. 1999). However, 
another rat study found that pre-treatment 24 hours earlier with a moderate dose of 
paracetamol in fact increased the degree of hepatotoxicity to a secondary paracetamol 
exposure, due to increased CYP2E1 activity (Kim et al. 2009)Ageing and Frailty 
1.3 Ageing and Frailty 
Older people are generally considered to be those aged 65 years and older. The older 
population is increasing, and is in fact the fastest growing group of the population 
(Louria 2005; Christensen et al. 2009). Ageing is the major risk factor for many 
diseases including arthritis, cancer and dementia, and is also associated with an 
increased use of drugs and increased risk of adverse drug reactions (Hajjar et al. 2007; 
McLean & Le Couteur 2004a). Ageing is also associated with both polypharmacy (the 
use of more than five drugs), frailty (Morgan et al. 2011; Hilmer et al. 2007; Collard et 
al. 2012) and physiological changes with ageing that affect pharmacokinetics and 
pharmacodynamics (section 1.3.2). 
 
Chapter 1: Introduction 
Alice Kane - March 2016 20
Frailty is a state of high vulnerability for adverse broader health outcomes, and a 
reduced capacity to react to stressors (Collard et al. 2012). It is a geriatric syndrome, 
associated with decreased muscle mass and quality (known as sarcopenia), and altered 
hormonal and inflammatory functions (Mohler et al. 2014; Evans et al. 2010; Fried et al. 
2009; Hubbard et al. 2009). Frailty increases the risk of falls, dependency, disability, 
institutionalisation, hospitalisation and mortality (Clegg et al. 2013; Mohler et al. 2014; 
Romero-Ortuno 2013), and affects drug use patterns, pharmacokinetics, 
pharmacodynamics and toxicity (Hilmer et al. 2007; Hubbard et al. 2013). Ten to fifteen 
percent of community dwelling Australians aged over 65 years are frail (Blyth et al. 
2008; Hyde et al. 2010), and a systematic review found an overall worldwide 
prevalence of 10.7% (with a range of 4-59% depending on the population) in those aged 
65 and over (Collard et al. 2012). The prevalence of frailty increases with age, and it is 
estimated that 25-50% of those aged over 85 years are frail (Collard et al. 2012; Clegg 
et al. 2013). There is very little current understanding about the molecular basis of 
frailty, its development and its mechanistic association with ageing, although there is 
increasing evidence that the physiological and functional changes in frailty are distinct 
from the changes seen with normal ageing, and other associated comorbidities (Mohler 
et al. 2014). The most common hypotheses about the pathophysiology of frailty are 
inflammatory cytokine dysregulation (Collerton et al. 2012; Walston et al. 2008), and 
mitochondrial dysregulation (Mohler et al. 2014), although it is likely that frailty 
involves a combination of physiological factors (Hubbard & Theou 2012).  
 
Clinically, frailty can be assessed using a number of scales with varying degrees of 
difficulty and clinical applicability (de Vries et al. 2011). Two of the mostly commonly 
used frailty assessments are the phenotype model and the frailty index. The phenotype 
model was developed by Fried et al. (2001) based on data from the Cardiovascular 
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Health Study. It defines frailty as the presence of three or more criteria including weight 
loss, exhaustion, weakness, slow walking speed, and low physical activity (Fried et al. 
2001). It conceptualises frailty as a functional phenotype, and defines patients are non-
frail, pre-frail or frail. The frailty index was developed by Rockwood and colleagues 
and measures the proportion of accumulated deficits in a person, and focuses on the 
number of deficits rather than the precise nature of the deficits (Mitnitski et al. 2002; 
Rockwood & Mitnitski 2007). The frailty index conceptualises frailty as a 
multidimensional syndrome, defined by deficits accumulated over the lifetime (Hubbard 
& Theou 2012). It calculates frailty index as a continuous variable between 0 and 1, 
however cut-offs have been established to define patients as frail or non-frail 
(Rockwood et al. 2011; Song et al. 2010). There is no international consensus on the 
best definition for frailty or best assessment for frailty identification clinically 
(Rodríguez-Mañas et al. 2013).  
1.3.1 Animal Models of Ageing and Frailty 
Animal models of ageing have been used for decades to investigate both the underlying 
mechanisms of ageing, and interventions to increase lifespan and healthspan (Mitchell 
et al. 2015). Studies of ageing mechanisms and lifespan interventions in humans are 
limited by our long lifespans, ethical issues and extensive genetic and environmental 
diversity. The relatively short lifespans, reduced genetic diversity, control of 
environmental factors and the ability to tests a variety of outcomes including stress 
responses, metabolic outcomes, behavioural and functional assessments and serum, 
urine and tissue analysis make animal models invaluable tools in the study of ageing 
(Mitchell et al. 2015). 
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C57BL/6 mice are the classical inbred mouse strain commonly used for ageing research 
due to the wealth of phenotypic and genotypic information available (source: 
http://phenome.jax.org/), and similar age-related changes as are seen in humans 
including reduced activity and vascular, bone and inflammation changes (Ingram 2000; 
Sindler et al. 2011; Rowlatt et al. 1976; Turturro et al. 2002). C57BL/6 mice live for 
approximately 26-30 months, and they are responsive to interventions that extend 
lifespan such as calorie restriction and pharmaceuticals (Goodrick 1975; Forster et al. 
2003). Other strains of mice are also often studied in ageing research as models of 
different ageing progressions. For example the DBA/2J substrain is considered to be 
short-lived, with studies showing median lifespan for males to be 23-25 months (Forster 
et al. 2003; Yuan et al. 2011). DBA/2J mice have also been shown to be unresponsive to 
interventions that extend lifespan, such as calorie restriction (Forster et al. 2003). Inbred 
mouse strains, due the control of both genetic and environmental factors, allow 
conclusions to be made about outcomes and interventions in small sample sizes. 
Outbred mouse strains have more genetic diversity, and as such may be considered 
more representative of the human population, but have limitations in assessing 
outcomes (Mitchell et al. 2015). Sex can also have a large impact on outcomes of both 
inbread and outbred mouse strains and should be carefully considered in ageing research 
projects (Mitchell et al. 2015; Yuan et al. 2009; Kanfi et al. 2012; Strong et al. 2008). 
There are also a wide variety of transgenic mouse models of either premature ageing, 
for example Werner syndrome and Cockayne syndrome mice (Lebel & Leder 1998; 
Scheibye-Knudsen et al. 2012), or delayed ageing, for example Growth Hormone 
receptor knockout mice and Snell dwarf mice (Flurkey et al. 2001; Hsieh et al. 2002). 
 
Rats have also been used as ageing models, usually inbred Fischer 344 rats (Do Carmo 
& Cuello 2013), but their use in ageing studies is limited as they are usually less 
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convenient and cost-effective than mice, and transgenic models are less available 
(Mitchell et al. 2015). Other less common models of ageing include naked mole rats, 
which have preserved health for most of their lifespan (Jarvis 1981; Liang et al. 2010), 
fish (Gerhard 2007), birds (Holmes & Ottinger 2005) and non-human primates (Colman 
et al. 2010; Mattison et al. 2012). The use of non-human primates in ageing studies, 
although perhaps the most appropriate for translation of research into humans, is limited 
by their long lifespans as well as the associated ethical and cost issues (Mitchell et al. 
2015). 
 
There has been a recent focus on animal models to study frailty in the context of mouse 
ageing (Howlett & Rockwood 2014). The current mouse models of frailty are 
summarised in Table 1.2. Interleukin (IL)-10 knock-out mice were developed as a 
colitis model, but were identified as showing a frailty phenotype including 
inflammation, reduced muscle strength (Walston et al. 2008), impaired cardiac and 
vascular function (Sikka et al. 2013) and increased mortality (Ko et al. 2012). Although 
not specifically a model of naturally occurring frailty in old age, these mice have 
significant potential in studies of the molecular mechanisms of frailty (Akki et al. 2014). 
Liu and colleagues developed a mouse frailty index based on the clinical phenotype 
model which assesses a mouse as frail based on its grip strength, walking speed, 
physical activity and endurance (Liu et al. 2013). As with the clinical phenotype models 
a mouse is defined as non-frail, mildly frail or frail according to their performance in 
these assessments. They used this phenotype-based model to investigate the effects of 
exercise on frailty, and found that voluntary exercise reversed frailty in old mice 
(Graber et al. 2014). Recently, a mouse frailty index which utilizes 31 simply assessed 
clinical measures to assess frailty in C57BL/6J mice was developed (Whitehead et al. 
2014; Feridooni et al. 2014). The validity of this scale was correlated against human 
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frailty index data from the Survey of Health, Ageing and Retirement in Europe 
(SHARE) and was found to have good agreement. As with the human frailty index 
assessments, this tool allows the calculation of a frailty index score for a mouse on a 
continuous variable from 0 to 1, whereby a higher score indicates a greater degree of 
frailty. As these assessment tools are recently developed, long-term studies with 
outcomes such as mortality have not been conducted, and these frailty assessment tools 
have not yet been validated against one another. These tools could be invaluable in 
assessing the effect of any intervention on the important clinical outcome of frailty in an 
animal model, or could be used to assess the effect of frailty on outcomes. 
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Table 1.2 Animal models of frailty: details of the animal types, assessments, clinically equivalent scales, validation, interventional results, strengths 
and limitations of the currently developed mouse models of frailty. IL=interleukin. 
Article	
Name	of	
model	 Animal	details	
Frailty	Assessment	
details	
Clinical	basis	
for	model	
development	
Validation	and	
Interventional	Studies?	 Strengths	 Limitations	
Walston	et	al.	
(2008)	
IL‐10	
knockout	
mice	
IL‐10tm/tm	mice	
on	a	C57BL/6	
background	
‐	 Inflammation	in	Frailty	
Decline	in	strength	and	
increase	in	inflammation	
compared	to	age‐matched	
controls.	
Can	be	used	to	
explore	biological	
mechanisms	of	
frailty	
Is	not	a	model	of	
frailty	in	natural	
ageing,	and	requires	
specific	housing	
conditions.	
Parks	et	al.	
(2012)	
Mouse	
Frailty	
Index	
Male	and	
female	
C57BL/6	mice	
31	health‐related	
variables	including	
activity	levels,	
hemodynamic	
measures,	body	
composition	and	
metabolic	status		
Frailty	Index	
(Mitnitski	et	al.	
2002;	Kulminski	
et	al.	2008)	
Correlation	with	age‐related	
declines	in	cardiac	myocytes.	
Assesses	across	a	
variety	of	health	
parameters.	
Invasive	procedures	
eg	large	blood	
samples,	and	
specialised	
equipment	
Whitehead	et	
al.	(2014)	
Mouse	
Clinical	
Frailty	
Index	
Male	and	
female	
C57BL/6	mice	
31	‘clinical’	items	
(see	appendix	1)	
Frailty	Index	
(Mitnitski	et	al.	
2002;	Kulminski	
et	al.	2008)	
Same	exponential	function	as	
human	data	from	SHARE	trial.	
Good	inter‐rater	reliability	
(Feridooni	et	al.	2014)	
Convenient,	fast,	
non‐invasive	
measures	
Does	not	include	a	
functional	
assessment	aspect.	
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Graber	et	al.	
(2013)	
C57BL/6	
neuromusc
ular	
healthspan	
scoring	
system	
Male	C57BL/6	
mice	
Functional	
assessment	–	
rotarod	and	grip	
strength.	
In	vitro	muscle	
contractility.	
Sarcopenia	in	
Frailty	
Age	related	declines	in	
individual	outcomes.	
Combined	score	
reduces	individual	
variability	within	
groups.	
Invasive	procedure	
and	time‐consuming	
measurements.	
Liu	et	al.	
(2013)	
Frailty	
Phenotype	
Index	
Male	C57BL/6	
mice	
Rotarod,	grip	
strength,	voluntary	
wheel	running	and	
derived	endurance	
score	
Frailty	
Phenotype	
(Fried	et	al.	
2001)	
Prevalence	same	as	humans	of	
equivalent	age.	
Voluntary	exercise	
intervention	reversed	frailty	
(Graber	et	al.	2014)	
Non‐invasive	
assessments.	
Provides	a	cut‐off	to	
assess	mice	as	frail	
or	non‐frail.	
Time‐consuming	
measurements,	and	
includes	derived	
factors.	
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1.3.2 Pharmacokinetic, Pharmacodynamic and Toxicological Changes with 
Ageing and Frailty 
As older people are the most common users of medications (Hajjar et al. 2007), and 
usually excluded from clinical trials (Nair 2002; Le Quintrec et al. 2005), it is important 
to understand the potential changes in drug pharmacokinetics and pharmacodynamics 
with age and frailty, in order to optimise drug treatment in all older adults (Hilmer et al. 
2007). Furthermore, adverse drug reactions are increased in older people, and are often 
more severe than in younger patients (Walker & Wynne 1994; Atkin et al. 1999), 
probably due to both pharmacokinetic and pharmacodynamic changes in old age 
(Routledge et al. 2004) as well as an increase in polypharmacy (the use of 5 or more 
medications) in old age (Veehof et al. 1999; Gnjidic et al. 2012). Furthermore falls, 
cognitive impairment and functional decline as a result of drug exposure are increased 
in old age (Agostini et al. 2004; Leipzig 1999; Moore & Keeffe 1999), and are usually 
not considered adverse drug reactions (Hilmer et al. 2007). 
 
The most significant pharmacological change with increasing age is increased 
heterogeneity of responses to medications (McLachlan et al. 2009). General changes in 
absorption, distribution, metabolism and elimination of drugs in older adults have also 
been described ( Klotz 2009; McLean & Le Couteur 2004b; Mangoni & Jackson 2004). 
There are age related changes in drug absorption from the gastrointestinal tract (GIT), 
although the effect of this on drug dosing is thought to be minimal (McLean & Le 
Couteur 2004b). The distribution of drugs can be effected by changes in body 
composition that occur in old age. Most notably, in old age there is an increase in 
percentage body fat, and a decrease in total body water which results in an increase in 
the volume of distribution of lipophilic drugs, and a decrease in the volume of 
distribution of water soluble drugs (Klotz 2009). Clearance describes the rate of 
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elimination of a drug from the blood (provided metabolism is not saturated). Hepatic 
clearance is affected by many factors including liver size, liver blood flow and 
metabolism . There is a decrease of up to 35% in liver blood flow and size from young 
adulthood to old age (Wynne et al. 1989). Furthermore, the liver sinusoidal endothelial 
cells (LSECs) undergo ultra-structural changes with old age, termed 
pseudocapillarisation which may affect the transfer of oxygen, drugs and other 
substrates between the sinusoidal blood and the hepatocytes (Le Couteur et al. 2001; Le 
Couteur et al. 2008). The implications of this age-related reduction in hepatic clearance 
are increased bioavailability for drugs with a significant first-pass effect, and reduced 
clearance of drugs with significant hepatic metabolism, which may result in increased 
risk of adverse drug reactions, or for pro-drugs requiring metabolic activation, may 
cause reduced efficacy in old age (Hilmer et al. 2007). Phase II drug metabolism was 
originally thought to not change in healthy ageing (Wynne et al. 1990; Summerbell et 
al. 1993), although recent studies suggest there is a decrease (Butler & Begg 2008). 
Although in old age there is a decrease in the total hepatic CYP450 content, there is no 
decrease in the in vitro activity of most of the CYP450 enzymes (Hilmer et al. 2007). 
Studies have shown that in old age there is reduced renal function, particularly 
glomerular filtration rate, that effects the renal clearance of some drugs (Mangoni & 
Jackson 2004) although other studies claim that renal clearance does not change in old 
age in the absence of diseases such as hypertension, chronic heart disease or kidney 
disease (McLean & Le Couteur 2004b). Pharmacodynamic changes with age result from 
general age-related physiological changes in the target organ systems and can result in 
either increased or decreased sensitivity to drug responses (Hilmer et al. 2007; McLean 
& Le Couteur 2004b; Bowie & Slattum 2007). For example, changes in the beta-
adrenergic receptors in old age can result in reduced response to beta blockers 
(Abernethy et al. 1987), but physiological changes in old age can result in increased 
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sensitivity to sedatives such as benzodiazepines (Hilmer et al. 2007; Greenblatt et al. 
2004). 
 
Pharmacokinetic and pharmacodynamic changes in frailty have not been extensively 
studied, and very little is known about drug dosing optimisation or toxicity risk in frailty 
(Hubbard et al. 2013). Frailty is associated with polypharmacy, independently of 
ageing, so understanding changes to medication effects and toxicity is especially 
important in the frail older population, due to their extensive exposure to medicines 
(Gnjidic et al. 2013; Gnjidic et al. 2012). From ageing studies we also know that the risk 
of adverse drug reactions in old age, increases in those populations more likely to be 
frail such as those who are in residential aged care. Twenty percent of community 
dwelling older adults have experienced adverse drug reactions compared to fifty percent 
of those living in residential care facilities (Wilcox et al. 1994; Somers et al. 2010). The 
heterogenity in physiology and morbidity with old age, is further increased in frailty, 
resulting in even more unpredictable responses to medicines (McLachlan et al. 2009; 
Fried et al. 2001). Johnston et al. (2014) identified only ten studies of drug 
pharmacokinetic and pharmacodynamics changes with frailty, although some general 
changes with frailty can be predicted from known physiological changes. It has been 
suggested that changes in drug absorption from the gastrointestinal tract that are mildly 
seen in old age, might be more significant in frailty (Hubbard et al. 2013). Frailty is also 
associated with increased body fat and reduced lean body mass, which may affect the 
volume of distribution of lipophilic drugs (Hubbard et al. 2010). There is a reduction in 
serum albumin in frailty, that may effect the protein binding of acidic drugs such as 
phenytoin or warfarin, and result in an increase in availability of unbound drug in the 
serum (Hubbard et al. 2013). It is also known that there is a reduction in phase II 
metabolism in frailty, but not healthy ageing, for some drugs (Hubbard et al. 2013), 
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including paracetamol and metoclopramide (Wynne et al. 1990; Wynne et al. 1993). 
There is also reduced activity of esterases, enzymes responsible for the metabolism of 
drugs such as aspirin, procaine and anaesthetics, in frailty, but not healthy ageing 
(Summerbell et al. 1990; Hubbard et al. 2008). Frailty is also often associated with renal 
impairment and kidney diseases, so there may be reduced renal clearance in frailty 
(Hubbard et al. 2013). The clearance of gentamicin, an antibiotic predominantely 
excreted by glomerular filtration in the kidneys, is reduced in frail compared to non-frail 
older people (Hilmer et al. 2011; Johnston et al. 2014). 
1.3.3 Changes in the Pharmacology and Toxicology of Paracetamol in 
Ageing and Frailty 
Changes to factors involved in the paracetamol toxicity pathway including use, 
pharmacokinetics, pharmacodynamics and toxicity outcomes, with ageing and frailty 
are summarised in Table 1.1. 
1.3.3.1 Paracetamol Use in Ageing and Frailty 
Paracetamol use is prevalent in the older and frail populations. Paracetamol is one of the 
most commonly prescribed, and used, drugs among older Australians (Pearson et al. 
2007). Seventy five percent of older Australian participants in the Pearson et al. (2007) 
study received at least one paracetamol prescription over the 6 year study period, and it 
is suggested that 20% of Australians over 50 use daily simple analgesics including 
paracetamol (Morgan et al. 2011). It is the first line analgesic for many age-related 
diseases including osteoarthritis and chronic pain (Makris et al. 2014; Toms 2008; 
Nikles et al. 2005; Jordan et al. 2003). Pain is common in the older population (Blyth et 
al. 2001; Thomas et al. 2007), and frailty has been associated with increased pain, and 
analgesic, including paracetamol, use in studies from Finland, the US and Australia 
(Koponen et al. 2013; Blyth et al. 2008; Kemp et al. 2005). Pain in the older population 
is also often under-treated (Horgas & Tsai 1998; Won et al. 2004), and it is important to 
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understand the pharmacokinetic and pharmacodynamics changes in paracetamol 
exposure in old age and frailty to be able to optimise the efficacy and safety of 
analgesics in this population. 
1.3.3.2 Paracetamol Pharmacokinetics in Ageing and Frailty 
Absorption of paracetamol, does not appear to change with increasing age, although the 
changing body composition in old age may result in a decrease in volume of distribution 
for water-soluble drugs such as paracetamol (Klotz 2009). Clearance of paracetamol 
from the liver appears to be reduced in old age due to both reduced transfer of 
paracetamol across the liver sinusoidal endothelium in old age (Mitchell, Huizer-Pajkos, 
et al. 2011) and generally reduced liver flow and size in old age (Wynne et al. 1989). 
The activity of CYP2E1, the enzyme responsible for the production of toxic NAPQI 
does not appear to change in old age (Hunt et al. 1990). However, a clinical study of 
therapeutic paracetamol after major surgery found that there was an increased shift 
towards this pathway of metabolism in old age (Pickering et al. 2011). Hepatic 
glutathione, important for the detoxification of NAPQI, is decreased with ageing in 
animals (Hazelton & Lang 1980) and human hepatic glutathione and the serum levels of 
its associated enzymes are reportedly decreased in ageing human blood samples (Erden-
Inal et al. 2002). NQO1 activity is also found to increase in old age (Mach et al. 2014; 
Chen et al. 1994; Kamzalov & Sohal 2004). 
 
Paracetamol pharmacokinetic changes with frailty have not been extensively studied. 
Early studies suggested that there was reduced paracetamol clearance via the phase II 
metabolic pathways in frail older patients, compared to fit older patients (Wynne et al. 
1990), and a recent study saw older surgical patients had reduced clearance of iv 
paracetamol compared to a younger patient group (Liukas et al. 2011). An observational 
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study of very old inpatients with polypharmacy and seven day paracetamol exposure, 
found that the pharmacokinetics of paracetamol did not change over seven days and 
there was no accumulation of paracetamol (Bannwarth et al. 2001).  
 
1.3.3.3 Paracetamol Pharmacodynamic in Ageing and Frailty 
As the pharmacodynamics of paracetamol are still not fully understood, the changes 
with age and frailty have not been extensively studied (summarised in Table 1.1). It is 
known that there is impairment of mitochondrial function with old age (reviewed in 
(Gonzalez-Freire et al. 2015), which results in increased reactive oxygen species 
production which can cause damage at high levels, but at low levels may results in 
increased stress resistance and, in fact, contribute to longevity (Owusu-Ansah et al. 
2013; Martin-Montalvo & Cabo 2012). There is also an age-related reduction in 
mitochondrial number and volume (Short et al. 2005; Conley et al. 2000). The effect of 
these age-related mitochondrial changes on paracetamol pharmacodynamics in not 
known. Ageing is associated with alteration of the liver intrinsic death pathway 
signalling (Mach et al. 2015) and increased apoptosis (Molpeceres et al. 2007; Zhang & 
Herman 2002). Changes in apoptosis in ageing may contribute to other liver diseases 
(Wang 2014), although the effect on drug induced liver injury is not well understood. 
There is also an age-related decline in autophagy (Cuervo et al. 2005), which is induced 
as a primarily protective mechanism following paracetamol toxicity. There are 
significant changes to the immune system with age (Starr & Saito 2014; Miller 2012) 
including immunosenescence which is defined as an age-related decline in the immune 
response to external stimuli, such as bacteria and viruses (Aw et al. 2007). More 
importantly for paracetamol toxicodynamics, there are also changes to the innate 
immune response in old age termed inflammaging, in which there is increased low 
grade inflammation and circulating cytokine levels, as well as dysregulation of innate 
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immune cell responses (Franceschi et al. 2000; Walston et al. 2002; Franceschi et al. 
2007; Cohen 2003). In animal studies, in particular, there is increased response of both 
pro and anti-inflammatory cytokines including IL-10 and TNF-alpha, in response to 
stimuli in old compared to young animals (Tateda et al. 1996; Starr et al. 2013; 
Okamura et al. 2012; Saito et al. 2003), although in humans there appears to be no 
initial difference in cytokine induction but a prolonged response after activation by 
stressors such as sepsis or lipopolysaccharide (LPS) (Starr & Saito 2014). Further 
mitochondrial, oxidative stress or inflammatory dyregulation in frailty (Mohler et al. 
2014; Fried et al. 2001; Walston et al. 2008; Serviddio et al. 2009; Wu et al. 2009) may 
affect paracetamol pharmacodynamics and toxicodynamics in frailty. 
1.3.3.4 Paracetamol Toxicity in Ageing and Frailty 
The consequences of the above-described changes with ageing on the hepatotoxicity of 
paracetamol are not fully understood, and were recently reviewed (Mitchell, Kane, et al. 
2011). There are few clinical studies of paracetamol toxicity in ageing and frailty. One 
study found that although the majority of paracetamol induced hepatotoxicity occurs in 
young adults, the majority of deaths associated with paracetamol exposure occur in old 
age (Schmidt 2005). Although, another study of hospitalised fit and frail older patients 
found that frail older people taking therapeutic paracetamol for five days had higher 
blood paracetamol concentrations than younger patients, without associated increased 
liver enzymes (Mitchell et al. 2011)  
 
An Australian study identified that the older population have a different clinical 
presentation of paracetamol toxicity to younger patients, with older people more likely 
to have chronic low-dose exposure or accidental over-exposure to paracetamol, than 
acute or intentional exposures (Kane et al. 2012). The increase in both medication use, 
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and chronic pain in the older population may contribute to this finding as the two main 
causes of unintentional overdose are thought to be multiple paracetamol containing 
medications, or poorly managed pain (Civan et al. 2014; Michna et al. 2012). Another 
Australian study specifically looked at the ability of arthritis patients to recognise 
paracetamol-containing medications, found that older people were often not able to do 
this (Ellis et al. 2015). Malnutrition is a risk factor for paracetamol toxicity, as it can 
lower glutathione liver stores, and is common in old age and frailty (Hickson 2006; 
Kaiser et al. 2010). 
 
There have been several animal studies, using Fischer 344 rat studies that have shown a 
decreased risk of acute paracetamol toxicity in old age (Rikans & Moore 1988), due to a 
reduction in CYP2E1 activity (Mach et al. 2014) or reduced transfer into the liver 
(Mitchell, Huizer-Pajkos, et al. 2011). Studies in Sprague Dawley rats, however, found 
an increased susceptibility to toxicity in old rats (Tarloff et al. 1996). This may have 
been related to increased dosing due to weight-gain in this ageing model (Mach et al. 
2014). The only mouse studies investigating the effect of old age on paracetamol 
toxicity, did not look at direct toxicity outcomes, but suggested reduced glutathione 
capacity in old age (Chen et al. 1990; Al-Turk & Stohs 1981). 
1.4 Interventions to Slow Ageing and Frailty  
1.4.1 Lifespan and Healthspan Interventions 
There has been much research in the last 20 years about interventions to increase 
lifespan and promote longevity (Le Couteur et al. 2012; Kenyon 2010; Sinclair & 
Guarante 2006; Sebastiani et al. 2012). As old age is the major risk factor for many 
diseases including arthritis, cancer and dementia, it was hypothesised that by delaying 
the overall ageing process we could delay all age-related diseases, rather than targeting 
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specific diseases (Olshansky et al. 2007). Even more recently, there has been a focus on 
finding interventions that can increase a person’s healthspan, rather than their lifespan 
(Kirkland & Peterson 2009). It is increasingly being recognised that it is important to 
not just increase longevity but also to delay frailty, increase function and maintain 
independence and quality of life (Curtis & Cabo 2013). Healthspan is a term that can be 
used to describe this outcome as how long a person lives healthily with reasonable 
quality of life (Curtis & Cabo 2013).  
1.4.2 Calorie Restriction and the Ageing-Related Molecular Pathways 
The most extensively studied intervention in increasing lifespan is calorie restriction. 
The mechanisms of this intervention have been extensively studied, especially in animal 
models, and several main molecular pathways involved in the ageing process have been 
identified and investigated as targets for interventions to delay lifespan and healthspan.  
 
Calorie restriction involves the ingestion of a fully nutritious diet with a reduced amount 
of calories (50-80% of ad libitum diet), and was first studied in the 1920s (Le Couteur et 
al. 2012). It was the first laboratory intervention shown to extend life span in many 
species including yeast, fruit flies, worms and mammals (Bordone & Guarente 2005; 
Speakman & Mitchell 2011), as well as reduce the risk of age-related diseases in 
mammals (Weindruch et al. 1986; Everitt et al. 2006). Recent work has shown that the 
macronutrient balance, rather than just the restriction of calories, is also important for 
the lifespan and healthspan outcomes (Solon-Biet et al. 2014; Solon-Biet et al. 2015). 
There have been several molecular pathways implicated in the lifespan and healthspan 
increasing effects of calorie restriction. Four of the most commonly researched 
pathways are insulin-like growth factor-1 (IGF-1), sirtuins, mammalian target of 
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rapamycin (mTOR), and 5' adenosine monophosphate-activated protein kinase (AMPK) 
(Le Couteur et al. 2012) (Figure 1.2). 
 
 
Figure 1.2 Interaction of four of the pathways implicated in the lifespan and healthspan 
increasing effects of calorie restriction (source:Solon-Biet et al. (2015)). mTOR= 
Mammalian target of rapamycin, AMPK= 5' adenosine monophosphate-activated 
protein kinase, SIRT1= Sirtuin 1, IGF1= Insulin-like growth factor-1, NAMPT= 
Nicotinamide phosphoribosyltransferase, PGC1= Peroxisome proliferator-activated 
receptor gamma coactivator 1, FOXO= Foxhead box protein, p53= Tumor protein 53, 
AKT= Protein kinase B. 
 
Calorie restriction causes reduced glucose, insulin, IGF-1 and increased insulin 
sensitivity (Anisimov 2003; Argentino et al. 2005). The downregulation of these 
pathways in calorie restriction is believed to cause some of the beneficial healthspan 
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and lifespan effects, although the exact mechanisms are still not known (Speakman & 
Mitchell 2011). It may be related to oxidative stress (Lambert & Merry 2004) or 
autophagy (Bergamini et al. 2003). One of the main identified targets of IGF-1 is the 
phosphatidylinositol-3-kinase/protein kinase B (PI(3)K/Akt) pathway, which is 
important for cell growth and survival (Dudek et al. 1997; Rommel et al. 2001). 
 
The sirtuins are a class of nicotinamide adenine dinucleotide (NAD+) dependent 
deacylases (Wagner & Hirschey 2014) that regulate proteins related to longevity, energy 
metabolism and cell survival (Michan & Sinclair 2007). These proteins have a range of 
downstream deacylase target proteins including peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1) (Rodgers et al. 2005; Gerhart-Hines et 
al. 2007) and foxhead box protein O/tumor protein 53 (FOXO/p53) (Giannakou et al. 
2004; Hori et al. 2013). PGC-1 is a transcriptional co-activator which regulates 
mitochondrial biogenesis and function (Liang & Ward 2006), FOXO proteins are 
transcription factors that are phosphorylated by factors such as Akt signalling, and 
involved in the apoptosis pathways, stress resistance and gluconeogenesis (Hori et al. 
2013; Calnan & Brunet 2008), and p53 is tumor suppressor protein, also involved in 
apoptosis (Fridman & Lowe 2003). SIRT1 is believed to be activated in calorie 
restriction (Cohen et al. 2004), although SIRT1 expression is not increased with calorie 
restriction in all tissues or all studies (Le Couteur et al. 2012). However, SIRT1 knock 
out mice have a decreased life span that is not extended by calorie restriction, and 
SIRT1 over-expressing mice have similar effects to calorie restriction, implying a 
critical role of SIRT1 in calorie restriction mechanisms (Boily et al. 2008; Bordone et 
al. 2007). Important roles of SIRT3 and 6 have also been identified in calorie restriction 
(Kanfi et al. 2012; Shi et al. 2005), with SIRT3 playing a particular role in the 
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mitochondrial antioxidant response system (Someya et al. 2011). Studies have shown 
interactions between SIRT1 and the other ageing-related pathways including mediation 
of insulin sensitivity (Sun et al. 2007) and inhibition of mTOR signalling (Ghosh et al. 
2010).  
 
mTOR is a specific protein that forms a family of kinase complexes responsive to stress, 
nutrients and growth factors, with the defining feature that they bind the drug 
rapamycin, which allosterically inhibits their kinase activity (Speakman & Mitchell 
2011). The mTOR complexes can be broadly grouped into mTORC1 and mTORC2 
based on their binding partners. mTORC1 is the complex involved in autophagy, and is 
believed to be important in ageing. It acts as a nutrient sensor (Zoncu et al. 2011), that 
inhibits autophagy and promotes protein synthesis, cell growth and division (Fingar et 
al. 2004; Wang 2006) in the presence of nutrients, amino acids and glucose, and has the 
opposite effect when nutrients levels are low (Harrison et al. 2009). Autophagy is thus 
induced by inhibition of mTOR, and the process generates nutrients during fasting. The 
mechanisms by which mTOR acts to increase lifespan and healthspan are not clear but 
may involve a prevention of an age-related decline in autophagy (Bergamini et al. 2003; 
Johnson et al. 2013), the promotion of mitochondrial function via PGC1-alpha with 
mTOR inhibition (Cunningham et al. 2007), an anti-inflammatory action (Johnson et al. 
2013) or the preservation of stem cell function (Yilmaz et al. 2012; Chen et al. 2009). 
There are also clear studies to show the interaction of the mTOR pathway with the other 
ageing pathways, and it has been hypothesised that mTOR may be the central nutrient 
sensing pathway, through which the IGF-1 and AMPK pathways act (Le Couteur et al. 
2012; Johnson et al. 2013).  
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AMPK is an enzyme, (a trimer with 3 subunits) that is allosterically activated by 
adenosine monophosphate (AMP), and is also regulated by upstream kinases and other 
factors (Speakman & Mitchell 2011). It is essentially a sensor of the energy status of a 
cell, so is activated (phosphorylated) by increased AMP, and reduced adenosine 
triphosphate (ATP), as is seen with calorie restriction (Edwards et al. 2010; Cantó & 
Auwerx 2011). AMPK activation results in phosphorylation of downstream target 
protein PGC-1 (Cantó & Auwerx 2009; Wan et al. 2014), and an increase in 
expression of nicotinamide phosphoribosyltransferase (NAMPT), which is an enzyme 
involved in regulating NAD+ content (Brandauer et al. 2013; Fulco et al. 2009). The 
AMPK pathway is changed in old age (Salminen & Kaarniranta 2012), and the 
mechanism by which AMPK acts to increase lifespan and healthspan is also not 
completely understood. AMPK activation results in the promotion of fat oxidation, and 
a reduction in fatty acid synthesis in the liver, and a shift from carbohydrate to fat 
metabolism (Hardie 2011). There is also interaction of AMPK with the other ageing 
pathways, including inhibition of mTOR, promotion of glycolysis and activation of 
SIRT1 (in certain conditions) (Price et al. 2012). 
 
1.4.3 Calorie Restriction Mimetics 
Calorie-Restriction mimetics are drugs with the potential to replicate the beneficial 
effects of calorie restriction, without the need for actual restriction of calories (Le 
Couteur et al. 2012). Many drugs have been developed targeting the four main pathways 
of calorie restriction, although many act across several of these pathways (Le Couteur et 
al. 2012; Athar et al. 2009). 
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The IGF-1/Insulin pathway was targeted with biguanides such as metformin, 
phenformin and pioglitazone, that are insulin sensitisers (Tosca et al. 2010; Anisimov 
2003). Metformin, in particular was shown to cause lifespan extension (Martin-
Montalvo et al. 2013), but there are some side effect concerns. Rapamycin acts to 
inhibit the mTOR proteins and thus induce autophagy (Ballou & Lin 2008). It has been 
shown to extend lifespan in mouse studies (Harrison et al. 2009; Miller et al. 2011) 
although there are immunosuppressant side effect concerns, which would limit its 
clinical use.  
 
Resveratrol, a polyphenol found in grapes, was shown to be an activator of SIRT1 in a 
large scale screening study (Howitz et al. 2003). Resveratrol has been shown to extend 
lifespan in high-fat diet-fed mice (Baur et al. 2006), and increase healthspan but not 
longevity in standard diet-fed mice (Pearson et al. 2008; Miller et al. 2011) and Werner 
mice (Labbé et al. 2011). Resveratrol has also been shown to play a protective role in 
many age-related diseases including diabetes (Palsamy & Subramanian 2009), cancer 
(Jang et al. 1997), cardiovascular disease (Rimbaud et al. 2011) and many neurological 
conditions (Yu et al. 2012). Resveratrol is known to have a variety of protective effects 
including effects on DNA repair, apoptosis, inflammation, insulin secretion, 
mitochondrial biogenesis (Baur & Sinclair 2006; Lagouge et al. 2006; B. P. Hubbard et 
al. 2013; King et al. 2005; Park et al. 2012). The mechanism of resveratrol’s action is 
controversial (Borra et al. 2005; Kaeberlein et al. 2005) and it is likely there are several 
relevant targets. A recent study clearly showed that one of resveratrol’s mechanisms of 
action is direct allosteric SIRT1 agonism (Hubbard et al. 2013). Resveratrol may also 
activate AMPK via phosphorylation at Thr172 (Baur et al. 2006; Ido et al. 2015; 
Suchankova et al. 2009), although AMPK activation by resveratrol appears to be 
dependent on SIRT1 at low doses, but independent of SIRT1 at high doses (Price et al. 
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2012). The protein complex, nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF- κB), which regulates DNA transcription in response to stimuli such as stress, 
is thought to be inhibited by resveratrol (Ren et al. 2013). Other SIRT1 agonists have 
also been developed and investigated, such as SIRT1720 (Mitchell et al. 2014), as 
resveratrol has a relatively low bioavailability (Baur & Sinclair 2006; Walle 2011) and 
activates a variety of targets (Speakman & Mitchell 2011).  
 
Although it was definitely not developed as a calorie restriction mimetic, and its 
mechanism in this capacity has not been investigated there is some evidence to show 
that paracetamol may have beneficial healthspan effects. Mouse studies have shown that 
paracetamol was able to normalise glucose homeostasis in mouse models of diabetes 
(Shertzer et al. 2008; Kendig et al. 2008), and a study of rat aorta showed that 
paracetamol protected against age-related effects (Rice et al. 2012). Furthermore, 
AMPK activation has been seen to be affected by paracetamol in other studies (Saberi et 
al. 2014; Kim et al. 2015) demonstrating a potential effect of paracetamol on these 
ageing-related pathways. 
1.4.4 Interventions to Delay Frailty 
The increasing focus on improving healthspan and quality of life, rather than lifespan, 
with interventions has also led to an increased focus on interventions to delay frailty. 
Possible interventions that have been investigated include exercise training (strength, 
endurance and balance training) (Theou et al. 2011; Cadore et al. 2013), dietary 
interventions (protein, calories, amino acids, fish oil, vitamins) (Mohler et al. 2014), 
reduced polypharmacy (Tjia et al. 2013), and some pharmaceuticals, usually hormones 
or drugs to target muscle wastage (Neto et al. 2013; Muller et al. 2006; Kenny et al. 
2010; Srinivas-Shankar et al. 2010; Hennessey et al. 2001). 
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A systematic review of exercise interventions for frailty, assessed by physical function, 
found that of 19 completed trials, overall exercise was associated with improved gait 
speed and improved short physical performance battery, but there was no conclusive 
effect on balance, endurance, and activities of daily living functional mobility (Giné-
Garriga et al. 2014). Another review of specific frailty interventions identified eight 
high quality studies, and found that exercise interventions improved outcomes in 5/6 
studies, hormone replacement therapy had no effect and multifactorial interventional 
studies were inconclusive (Lee et al. 2012). A third review of randomised control trials 
of frailty interventions, although frailty was not necessarily the primary outcome, found 
38 studies, with overall small sample sizes and short follow-up. Overall the studies 
found that exercise training was beneficial, although often the benefits were lost once 
the program stopped, and that some pharmaceutical and dietary interventions improved 
bone mineral density and lean body mass (Bibas et al. 2014). An Australian study of a 
multifactorial personally-targeted intervention randomised control trial with the frailty 
phenotype and mobility as the primary outcomes found a 15% difference between 
intervention and control groups (Cameron et al. 2013), and are following this up with a 
pre-frailty interventional study (Cameron et al. 2015). There have also been a variety of 
interventional studies aimed at improving sarcopenia, a distinct feature of frailty 
(Walston 2012). These are usually nutritional and exercise interventions (Fiatarone et al. 
1994; Timmerman et al. 2012; Aagaard et al. 2010). 
 
Mouse studies of frailty interventions are very limited. Graber et al. (2014) used the 
mouse frailty phenotype assessment to show that voluntary exercise reversed frailty in 
old mice. Another mouse study showed that losartan, an angiotensin II antagonist, 
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improved activity, inflammation and oxidative stress in old mice, although it didn’t 
assess frailty as a specific outcome (Lin et al. 2014). The recently developed mouse 
frailty assessment tools (Liu et al. 2013; Whitehead et al. 2014) provide an ideal 
opportunity to investigate the effect of a wide range of interventions on frailty as an 
outcome in mouse models. 
1.4.5 Ageing Mechanisms as Potential Targets to Reduce Paracetamol 
Toxicity 
1.4.5.1 Calorie Restriction and Paracetamol Toxicity 
Calorie restriction involves several mechanisms that may also be involved in the 
paracetamol toxicity pathways (summarised in Table 1.1). With calorie restriction there 
is increased NQO1 activity (De Cabo et al. 2004), potentially increased phase II 
metabolism (Leakey et al. 1989) and increased glutathione capacity (as calorie 
restriction involves a reduction in calories, but not a loss of nutritional balance) (Cho et 
al. 2003; Mune et al. 1995), which may all be pharmacokinetic protective mechanisms 
against paracetamol toxicity. Furthermore, calorie restriction is associated with reduced 
oxidative stress (Lambert & Merry 2004; Yu & Chung 2001; Lin et al. 2004), increased 
mitochondrial function/biogenesis (López-Lluch et al. 2006; Martin-Montalvo et al. 
2011), decreased inflammation (Ye & Keller 2010; J. Wang et al. 2013) and increased 
autophagy (Harrison et al. 2009; Morselli et al. 2010; Kume et al. 2010), which may 
also contribute towards paracetamol toxicity protection.  
 
Two animal studies have found that calorie restriction protects the liver against 
paracetamol hepatotoxicity. Harper et al. (2006) found that young BALBc X C57BL/6 
mice fed a calorie restriction diet for 8 months had reduced ALT and lactate 
dehydrogenase (LDH) levels after toxic paracetamol dosing, compared to those fed ad 
libitum. Another study found that a methionine-deficient diet resulted in similar 
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protection from paracetamol hepatotoxicity in mice (Miller et al. 2005), although again 
ALT and LDH were the only measured outcomes. A human study found that patients on 
a calorie restricted diet receiving two grams of paracetamol daily for five days had no 
change in paracetamol metabolism or liver function tests, compared to control patients 
(Schenker et al. 2001).  
 
This potentially protective role of calorie restriction is an intriguing finding since, given 
that calorie restriction reverses many of the effects of ageing, and ageing is associated 
with changes that may protect against paracetamol toxicity, it may have been expected 
that there would be increased risk of paracetamol hepatotoxicity with calorie restriction. 
The mechanisms by which calorie restriction and ageing protect against paracetamol 
hepatotoxicity are not well understood and better understanding of the mechanisms of 
this protection would be beneficial. The changes with calorie restriction and ageing to 
factors involved in paracetamol hepatotoxicity are summarised in Table 1.1. 
1.4.5.2 Resveratrol and Paracetamol Toxicity 
Resveratrol has a variety of potentially protective effects upon factors involved in the 
paracetamol toxicity pathway (summarised in Table 1.1). Resveratrol has been seen to 
reduce CYP2E1 activity (Wu et al. 2013), induce NQO1 activity (Hsieh et al. 2006) and 
induce phase II metabolic enzymes (Cao & Li 2004), which may all provide 
pharmacokinetic protection against paracetamol toxicity. Furthermore, resveratrol has 
shown anti-oxidant effects (Yu et al. 2012), improvements in mitochondrial function 
(Baur et al. 2006; Lagouge et al. 2006; Hubbard et al. 2013), anti-inflammatory effects 
(Yoshizaki et al. 2010) and induction of autophagy (Yu et al. 2012) which may also 
contribute to a protective effect against paracetamol toxicity. The effect of increased 
apoptosis with resveratrol on paracetamol toxicity is unknown and may be either 
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beneficial or contribute to toxicity development (Lin et al. 2011). Resveratrol has also 
been found to be protective against many other causes of hepatotoxicity such as 
hydrogen peroxide (Yang et al. 2005), tert-butyl hydroperoxide (Rubiolo & Vega 2008), 
ethanol (Bujanda et al. 2006) and carbon tetrachloride (Dani et al. 2008; Rivera & 
Shibayama 2008; Vitaglione et al. 2009). 
 
Several animal studies have investigated the potential protection from resveratrol 
against paracetamol toxicity (summarised in Table 1.3). Sener et al. (2006) showed 
concurrently administered paracetamol and resveratrol in BALB/c mice of both sexes, 
attenuated paracetamol-induced increases in ALT and TNF- at 4 hours, and attributed 
this to its anti-oxidant effects in preventing depletion of glutathione, and accumulation 
of 3,4-methylenedioxyamphetamine (MDA) (a marker of lipid peroxidation). 
Masubuchi et al. (2009) found similar results when resveratrol was given to CD-1 mice, 
one and six hours after paracetamol, and serum tested for ALT and TNF- at eight 
hours, however protection from hepatotoxicity was not seen at 24 hours. Du et al. 
(2015) found similar protective results when C57BL/6 mice were dosed with resveratrol 
1.5 hours after paracetamol. They attributed the protective effect to antioxidant effects 
and an inhibition of mitochondrial dysfunction (Du et al. 2015). Only one study has 
looked at resveratrol dosing before paracetamol dosing, in which they treated C57BL/6 
mice twice daily for three days with resveratrol then a single dose of paracetamol 
(Wang et al. 2015). They also saw protection, and attributed this to reduced CYP2E1 
activity, and an induction of hepatocyte proliferation (Wang et al. 2015). Noticeably, the 
strain used, timing, dose, route of administration and resveratrol vehicle and outcome 
measurements varied significantly across these studies. Furthermore only one of these 
studies investigated the downstream effects of resveratrol, and confirmed its molecular 
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action in these animal models (Wang et al. 2015). Thus, confirmation and further 
examination of the mechanisms of the protective role of resveratrol against paracetamol 
toxicity would be beneficial. 
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Table 1.3 Animal studies of resveratrol as a therapeutic to protect against paracetamol toxicity: Consideration of strain, paracetamol and resveratrol 
dose, route of administration and vehicle, timing of dosing, outcomes measured and study conclusions. ALT= Alanine aminotransferase, LDH= 
Lactate dehydrogenase, TNF= Tumor necrosis factor, MDA= 3,4-methylenedioxyamphetamine, IL= interleukin , CYP= cytochrome, GSH= 
glutathione, SIRT1 = sirtuin 1 
Study	
Animal	Model	
details	
Paracetamol	Dose,	
and	Route	of	
Administration	
Resveratrol	Dose,	
Vehicle	and	Route	of	
Administration	 Timing	 Outcomes	 Conclusion	
Sener	et	al.	
(2006)	
Male	and	female	
BALB/c	mice,	
age	not	reported	
900mg/kg	via	
intraperitoneal	
injection	
30mg/kg,	vehicle	and	
route	of	administration	
not	reported	
Concurrent	
resveratrol	and	
paracetamol.	Tissue	
collected	at	4	hours.	
ALT,	LDH,	TNF‐
,	GSH,	MDA	
Resveratrol	protected	against	
paracetamol	toxicity	via	antioxidant	
actions..	
Masubuchi	
et	al.	
(2009)	
Male	8‐9	week	
CD‐1	mice	
300mg/kg	via	
intraperitoneal	
injection	
75mg/kg	in	10ml/kg	
60%	polyethylene	
glycol/saline	via	
intraperitoneal	injection	
Resveratrol	dosed	1	
and	6	hours	post	
paracetamol.	Tissue	
collected	at	8	and	24	
hours.	
ALT,	TNF‐,	IL‐
6	
Resveratrol	protected	at	8	but	not	24	
hours	via	anti‐inflammatory	actions.	
Wang	et	al.	
(2015)	
Male	6‐8	week	
C57BL/6	mice	
400mg/kg	via	
intraperitoneal	
injection	
25‐100mg/kg	in	0.5%	
sodium	carboxymethyl	
cellulose,	given	orally	
Resveratrol	pre‐
dosed	every	12	hours,	
7	times.	Paracetamol	
dosed	after	final	
resveratrol	dose.	
Tissue	collected	at	6	
hours.	
ALT,	CYP2E1	
activity,	GSH,	
SIRT1	
Resveratrol	protected	against	
paracetamol	toxicity	via	reduced	
CYP2E1	activity	and	increased	
hepatocyte	proliferation.	
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Du	et	al.	
(2015)	
Male	8‐12	week	
C57BL/6	mice	
(and	primary	
hepatocytes)	
300mg/kg	via	
intraperitoneal	
injection	
50mg/kg	in	40%	DMSO	
via	intraperitoneal	
injection	
Resveratrol	dosed	1.5	
hours	post	
paracetamol.	Tissue	
collected	at	0,	6,	24	
and	48	hours.	
ALT,	LDH,	GSH,	
endonuclease	
release,	
nitrotyrosine	
staining	
Resveratrol	protected	against	
paracetamol	toxicity	via	antioxidant	
effects	and	inhibition	of	Endonuclease	
release	from	mitochondria.	
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1.4.5.3 SIRT1 and Paracetamol Toxicity 
It is hypothesised that the mechanism of protection against paracetamol toxicity with 
calorie restriction and resveratrol may be SIRT1 activation. SIRT1 allosteric activation 
is one of the central actions of resveratrol (Hubbard et al. 2013), and one paracetamol 
and resveratrol study showed that SIRT1 expression was increased with resveratrol 
treatment in paracetamol toxicity (Wang et al. 2015). Furthermore, SIRT1 activation is 
associated with a variety of potentially protective mechanisms, and is thought to play an 
important role not only in longevity and delaying age-related changes, but also in 
regulation of response to stressors and nutrients (Michan & Sinclair 2007; Raynes et al. 
2013). In particular, SIRT1 has been shown to play a role in the regulation of 
inflammation (Purushotham et al. 2009; Yoshizaki et al. 2010), apoptosis (Yamakuchi 
et al. 2008) and mitochondrial function (Price et al. 2012), important factors in the 
development of paracetamol hepatotoxicity. Clarification of the role of SIRT1 in 
paracetamol toxicity may provide further insight into the mechanisms of paracetamol 
toxicity, and allow the identification of novel targets for protective therapeutics. 
1.5 Aims and Hypotheses of the Thesis 
The objective of this project was to improve the safety of paracetamol use for patients 
of all ages. The aim of this thesis was to investigate the impact of old age and frailty on 
the risk, exposure-type and mechanisms of paracetamol toxicity. Furthermore, this 
thesis aimed to investigate whether the current paracetamol hepatotoxicity therapy, 
NAC, is effective in old age and in non-acute exposure to paracetamol; and to test 
whether the age-related interventions of resveratrol and activation of the SIRT1 
pathway may provide novel potential therapeutic targets. Finally, this thesis aimed to 
look at the effect of paracetamol and these potential age-related therapies on frailty. 
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It was hypothesised that there would be changes in susceptibility to, and mechanisms of, 
paracetamol toxicity with old age and frailty. It was also hypothesised that NAC would 
not be effective in protecting against paracetamol hepatotoxicity in non-acute exposure 
situations. It was hypothesised that the interventions of resveratrol and SIRT1 activation 
would protect against paracetamol hepatotoxicity, although this protection may be 
different across age groups. Finally it was hypothesised that paracetamol, resveratrol 
and calorie restriction would delay frailty in old mice. 
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2 ACUTE PARACETAMOL 
TOXICITY IN OLD AND/OR 
FRAIL MICE 
2.1 Introduction 
Paracetamol is a commonly used analgesic that is usually well tolerated but can have 
severe toxicity following acute or chronic overdose. The pharmacokinetic and 
toxicological mechanisms of an acute over-exposure to paracetamol in young adults 
have been well established (see chapter 1.2). Following an acute overdose of 
paracetamol, there is saturation of the conjugation metabolism pathways and glutathione 
depletion (Larson 2007). This results in build-up of the toxic NAPQI, which can result 
in liver cell damage (Jollow et al. 1973). The mechanisms of how cell damage occurs 
involve covalent binding of NAPQI to cytoplasmic and mitochondrial proteins, 
oxidative stress (Jaeschke 1990), an inflammatory response (Antoine et al. 2008), and 
ultimately the stimulation of cell death, either apoptosis or necrosis (Jaeschke et al. 
2012). 
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With old age, and frailty, there are both pharmacokinetic and pharmacodynamic 
changes that occur which may affect the pharmacology and toxicology of paracetamol 
(Summarised in section 1.3.4). Despite these significant physiological changes with old 
age and frailty, the increased intake of drugs, including paracetamol, in old age and 
frailty (Pearson et al. 2007; Koponen et al. 2013; Blyth et al. 2008), and the higher 
prevalence of adverse drug reactions in old age (Burgess et al. 2005), there are very 
limited studies on the changing risks of toxicity with paracetamol in old age and frailty. 
A study of hospitalised fit and frail older patients found that frail older people taking 
therapeutic paracetamol for five days had higher blood paracetamol concentrations than 
younger patients, without associated increased liver enzymes (Mitchell et al. 2011). A 
study of paracetamol self-poisoning in Denmark, found that although the majority of 
paracetamol induced hepatotoxicity occurs in young adults, the majority of deaths 
associated with paracetamol exposure occur in old age (Schmidt 2005).  
 
There have been several animal studies, using Fischer 344 rats that have shown a 
decreased risk of acute paracetamol toxicity in old age (Rikans & Moore 1988), due to a 
reduction in CYP2E1 activity (Mach et al. 2014) or reduced transfer into the liver 
(Mitchell, Huizer-Pajkos, et al. 2011). Studies in Sprague Dawley rats, however, found 
an increased susceptibility to toxicity in old rats (Tarloff et al. 1996). This may have 
been related to weight-based dosing in the context of obesity in this ageing model 
resulting in relatively higher doses (Mach et al. 2014). A recent paper, suggested that 
mice are a more clinically relevant model of paracetamol toxicity than rats, due to 
similar susceptibility and mechanisms of damage (McGill et al. 2012). The only mouse 
studies investigating the effect of old age on paracetamol toxicity, did not look at direct 
toxicity outcomes, but suggested reduced glutathione capacity in old age (Chen et al. 
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1990; Al-Turk & Stohs 1981). This study seeks to establish for the first time the risk of 
paracetamol toxicity in old age and frailty in mice. 
 
The recent development of frailty assessment tools for animals, allows the study of not 
only age-related changes, but also frailty-related changes in animals models (Liu et al. 
2013; Whitehead et al. 2014). Liu et al. (2013) developed and validated a mouse frailty 
index based on the clinical phenotype model of frailty that assesses a mouse as frail 
based on its grip strength, walking speed, physical activity and endurance. This 
assessment is non-invasive, and has been used to investigate the effect of exercise 
intervention on frailty (Graber et al. 2014), however the functional assessments may be 
time-consuming. Whitehead et al. (2014) developed and validated a mouse frailty index 
based on the deficit accumulation model of frailty, which assesses a mouse as frail 
based on 31 clinical measures. Although this assessment includes no functional 
measures, it is non-invasive and fast, so easily included as part of a larger study 
protocol. This tool has not yet been used to look at changes in drug toxicity or 
mechanisms with frailty. 
 
This chapter aims to assess changes to acute paracetamol toxicity risk and mechanisms 
in old age and frailty in C57BL/6 mice. Understanding the risk of paracetamol 
hepatotoxicity in old age and frailty is essential for optimising the treatment of pain in 
the older population. 
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2.2 Methods 
2.2.1 Animals 
Two cohorts of young and old male C57BL/6 mice were used to test acute paracetamol 
toxicity. Cohort 1 was made up of young (age=7.3±0.3 months, n=23) and old 
(age=18.9±2.3 months, n=25) male C57BL/6 mice, aged inhouse at the National 
Institute on Aging (NIA, Baltimore, MD). Mice were fed a 2018 Teklad Global 18% 
Protein Rodent diet (Harlan laboratories). A second cohort of young (age=10±0.0 
months, n=12) and old (age=23.7±0.02 months, n=16) male C57BL/6 mice were also 
aged at the NIA (Baltimore, MD). They were fed a standard AIN-93G diet (Harlan 
laboratories). The median lifespan of C57BL/6 mice is 26-30 months. These two 
cohorts of mice were also used as the control groups for other studies of paracetamol 
toxicity interventions and mechanisms (see chapter four and five of this thesis). 
 
Mice were group housed in cages of 4 with ad libitum access to food and water. Animal 
rooms were maintained on a 12 hr light/dark cycle at 20-22°C, and 30-70% humidity. 
Animals were randomly assigned to treatment or control groups prior to the treatment 
day. All animal protocols were approved by the Animal Care and Use Committee of the 
National Institute on Aging (429-TGB-2017 and 405-TGB-2016).  
2.2.2 Frailty Index Assessment 
The Mouse Clinical Frailty Index, is a simple, noninvasive tool for the assessment of 
frailty in mice. A frailty index score is calculated for each mouse using a 31 item frailty 
index (Whitehead et al. 2014) of in vivo assessments, plus mouse weight and 
temperature (items explained in detail in Appendix 1). Young (12 week) C57BL/6J and 
DBA/2J weight and temperature means and standard deviations were obtained from the 
Jacksons Laboratory (http://jaxmice.jax.org/support/weight/000664.html). 
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Old mice from cohort two were assessed for frailty, after randomization to treatment 
group, the day before being dosed with paracetamol. Frailty testing was carried out by 
two raters. The raters were blinded to the scores assigned by the other rater. The final 
reported frailty index scores were calculated from the mean of the two rater’s scores. 
2.2.3 Paracetamol Treatment and Tissue Collection 
Animals were fasted overnight (16 hours) to reduce and normalise glutathione levels, 
then dosed with 300mg/kg paracetamol (Panadol Color-free Baby Drops, 100mg/ml, 
GlaxoSmithKline, Australia) or saline vehicle via oral gavage between 8 and 10am. 
This paracetamol dose was chosen as a standard dose to induce toxicity in C57BL/6 
mice (McGill et al. 2012). Food was returned to the mice two hours after dosing. Six 
hours after dosing mice were anaesthetized with an i.p injection of ketamine (75 mg/kg, 
DVR Pharmacy, Bethesda MD) and xylazine (10 mg/kg, DVR Pharmacy Bethesda 
MD). A midline laparotomy was performed and blood taken from the Inferior Vena 
Cava. The portal vein was then cannulated with a 21G intravenous catheter (BD, 
Sydney, Australia) through which the liver was perfused in-situ at 1–1.5 mL/min/g of 
liver with oxygenated Krebs-Henseleit bicarbonate buffer (95% O2–5% CO2, 37°C). 
Sections of the liver were snap frozen in liquid nitrogen for subsequent enzyme activity 
assays, protein and RNA extraction and fixed in 10% neutral formalin for subsequent 
histopathological analysis. 
2.2.4 Serum Biochemistry to Assess Liver and Renal Function 
Blood was stored at 4°C for up to two hours before separating the serum by 
centrifugation at 10,000g for 10 minutes. Serum was stored in aliquots at -80°C. Serum 
liver function tests (total protein, albumin, bilirubin, alkaline phosphatase (ALP), 
gamma glutamyltransferase (GGT), alanine aminotransferase (ALT)), for both cohorts, 
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and creatinine, for cohort one, were measured by a National Association of Testing 
Authorities accredited hospital laboratory, PaLMS (Pacific Laboratory Medicine 
Services) at Royal North Shore Hospital (Sydney, Australia) using an Architect 
i1000SR immunoassay analyser (Abbott Diagnostics, IL, USA). Vitamin B6 is added to 
the ALT activity assay to accommodate for the age related decline in this vitamin, an 
integral cofactor for the assay (Krishnamurthy et al. 1967; Bordoni et al. 1998). 
2.2.5 Liver Histology 
Fixed liver tissue was embedded in paraffin, 5µm sections were cut on a microtome and 
mounted on slides. Slides were stained with Haemotoxylin and Eosin in the National 
Association of Testing Authorities accredited hospital laboratory of the Pathology 
department of Royal Prince Alfred Hospital, Sydney, Australia. Histopathology was 
scored by an anatomical pathologist, who was blinded to the age and treatment of the 
samples. Necrosis was scored as a percentage of the liver tissue on each slide. Images 
were taken on an Olympus BX51 microscope connected to an Olympus DP26 camera 
(Olympus, Sydney, Australia). 
2.2.6 Biochemical Examination of Enzymes and Glutathione in Frozen 
Liver Samples 
Liver microsomes were isolated, according to the method of Shoaf et al. (1987). Liver 
samples were homogenised with a glass homogeniser, in ice cold buffer (0.25M 
sucrose, 0.1M Tris-Hydrochloride (HCl), pH 7.4), then centrifuged at 9000g for 20 
minutes at 4°C. The supernatant was collected, then spun at 100,000g for one hour, at 
4°C. The supernatant was collected (cytosolic fraction), the cell pellet re-suspended in 
buffer, then centrifuged at 100,000g for 30 minutes. The supernatant was discarded, and 
the microsomes re-suspended in 0.1M Tris-HCl (pH 7.4) with 20% (v/v) glycerol 
(Sigma Aldrich, #G7757), before being aliquoted and stored at -80°C. 
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CYP2E1 activity measured in the microsomes using absorption of p-aminophenol, 
converted from aniline via aniline hydroxylase activity, as described by Roberts et al. 
(1995) and Mach et al. (2014). Microsomal samples were made up to a concentration 
0.325g/l in 0.1M Tris-HCl (pH 7.4) with 20% (v/v) glycerol. 61.57ul of microsomal 
solution for each sample was then added to 24.56ul reaction mixture (6mM MgCl2, 1.2 
mM nicotinamide adenine dinucleotide phophate (NADP), 9.8mM Isocitric acid, 8mM 
aniline hydrochloride, 2% (v/v) glycerol, 0.46% (w/v) KCl, 18mM Tris-HCl pH 7.4), 
and 13.89ul of isocitric dehydrogenase (1/10 diluted for a total activity of 0.2U). An 
equal volume of 10% trichloroacetic acid (TCA, Sigma Aldrich #522082) was added to 
the solution to stop the reaction after either 0 or 30 minutes. The samples were then 
centrifuged at 1000g for 15 minutes, and the supernatant added, along with the 
standards (0-100nM p-aminophenol in 79.57mM Tris-HCl pH 7.4) to a 96 well plate 
with an equal volume of 1% phenol (in 0.1M NaOH), and ½ volume of 10% Na2CO3. 
Plates were incubated in the dark for 23 hours (the time required for consistent colour 
development) then absorbance read at 629nm. 
 
NQO1 activity was measured in the cytosol as described by Aleksunes et al. (2006) in 
which NQO1 enzymatic activity is measured over 1 minute using the reduction of 
dichlorophenolindophenol (DCPIP) at 595 nm with NADPH as the reducing cofactor. 
NQO1 activity was determined at 27°C in a reaction mixture containing liver cytosol, 
200 μmol/L NADPH, 40μmol/L DCPIP, 25 mmol/L Tris–HCl buffer pH 7.4, and 0.7 
mg/mL bovine serum albumin (BSA). Parallel reactions were conducted with 20 
μmol/L of selective NQO1 inhibitor dicumarol. The rates of dicumarol-sensitive NQO1 
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activity were determined by the difference between uninhibited and dicumarol-inhibited 
rates. 
 
Liver concentrations of total glutathione were determined with a Glutathione Assay kit 
(Cayman Chemicals, #703002), according to the manufacturers instructions. Tissue was 
homogenised in phosphate-buffered saline (PBS) supplemented with 1mM 
ethylenediaminetetraacetic acid (EDTA), then centrifuged at 10,000g for 15 minutes at 
4°C, and the supernatant collected. Samples were deproteinated by adding an equal 
volume of metaphosphoric acid (MPA, 1g/10ml), incubating at room temperature for 5 
minutes, centrifuging samples at 2000g for 2 minutes, and collecting the supernatant. 
Triethanolamine (TEAM) was added to each sample at 50ul/ml, then samples were 
diluted 1/50 in 2-(N-morpholino)ethanesulfonic acid (MES) buffer, and added with 
standards to a 96 well plate (50ul). 150 ul of assay cocktail (MES buffer plus cofactor 
mixture, enzyme mixture, and beta dystrobrevin (DTNB) was added, the plates 
incubated in the dark, and absorbance measured at 405nm after 25 minutes. 
2.2.7 mRNA Expression Measurement with qPCR 
For livers of mice from cohort 1 only, RNA was extracted from liver tissue using the 
Trizol reagent (Invitrogen, Carlsbad CA), according to the manufacturer’s instructions. 
Briefly, tissue was homogenized in Trizol reagent. Chloroform was added, the sample 
centrifuged, and the aqueous phase collected. RNA was precipitated with isopropanol, 
the sample centrifuged and the supernatant discarded. The RNA pellet was washed with 
70% ethanol then re-dissolved in nuclease-free water, and the concentration determined. 
Complementary DNA (cDNA) was synthesized from the extracted RNA using a 
Reverse Transcription Kit (Applied Biosystems, #4368814) and in a BioRad 
thermocycler (PTC-200, CA, USA). PCR plates were then loaded in triplicate with 
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sample, appropriate primers and SYBR Green Mastermix (Qiagen #330523). Plates 
were run in the 7300 Real-Time PCR System (Applied Biosystems). Primers used were 
CYP2E1, NQO1, TNF-α, IL-1β, IL-10, NF-κB, Caspase 3, BAX, PGC-1α, PGC-1β and 
normalised to the housekeeper GAPDH (sequences in Appendix 2). 
2.2.8 Statistics 
Data are expressed as mean ± standard error of the mean (SEM) unless otherwise 
indicated. Differences between mean values across groups were calculated with one-
way or two-way analysis of variance (ANOVA) with Tukey’s honest significance 
difference (HSD) post-hoc test where appropriate. The prevalence of necrosis in each 
treated group compared to the saline group was compared with Chi squared. The 
calculation of mRNA expression was performed by the 2-CT method. Spearman 
correlation coefficients (r) were used to analyse the correlation between Frailty Index 
and other outcomes, and linear regression was used to calculate slopes of best fit for 
each treatment group. Analysis of covariance (ANCOVA) was used to compare the 
regression slopes between paracetamol or saline treated groups, with frailty index as a 
covariate. Data analysis was completed using the statistics program SPSS (Version 
21.0, SPSS Inc., Chicago, Illinois, USA) and GraphPad Prism (Version 6.04, GraphPad 
Software, La Jolla California USA). 
2.3 Results 
2.3.1 Assessment of Paracetamol Toxicity 
Table 2.1 and  
Table 2.2 show mouse and liver weights and serum liver function test and creatinine 
results, for all mouse groups for cohorts 1 and 2. There was no difference across any 
group, for either cohort of mice, for total protein, albumin, ALP, GGT or liver weight 
(as percentage of body weight). For cohort 1 young and old mice, and cohort 2 young 
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mice, groups treated with paracetamol had higher bilirubin serum concentrations 
(p=0.004), than those treated with saline. In cohort 1, but not cohort 2, the old mice 
weighed significantly more than the young mice (p<0.001). Creatinine was measured 
for cohort 1 mice, and there was no change in serum creatinine level with either age or 
paracetamol treatment (Table 2.1). 
 
Table 2.1 Characteristics and serum biochemistry results for young (7.3±0.3 months) 
and old (18.9±2.3 months) male C57BL/6 mice from cohort 1, 6 hours after treatment 
with 300mg/kg paracetamol or saline. Data expressed as mean (SD). *p<0.05 compared 
to corresponding saline treated group, # p<0.05 compared to corresponding young 
group. ALP= Alkaline phosphatase, GGT= Gamma glutamyltransferase. 
	
Young	 Old	 One‐way	
ANOVA	
Saline	
n=10	
Paracetamol	
n=13	
Saline	
n=10	
Paracetamol	
n=15	
Total	protein	
(g/L)	 50.0	(2.9)	 50.7	(3.1)	 52.3	(5.1)	 49.8	(5.9)	 NS	
Albumin	(g/L)	 26.5	(1.3)	 27.8	(1.8)	 27.6	(2.6)	 24.9	(3.9)	 NS	
Bilirubin	
(mol/L)	 1.6	(0.5)	 2.5	(0.5)*	 1.7	(0.5)	 2.6	(1.1)*	
F(3,42)=5.34,	
p=0.004	
ALP	(U/L)	 73.0	(10.2)	 87.0	(19.1)	 91.1	(20.1)	 85.3	(30.1)	 NS	
GGT	(U/L)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.1	(0.3)	 NS	
Creatinine	(mol	
/L)	 33.4	(2.8)	 33.1	(4.1)	 41.4	(16.1)	 47.3	(31.2)	 NS	
Body	weight	(g)	 27.6	(1.7)	 27.8	(3.3)	 41.0	(6.7)#	 39.2	(7.2)#	 F(3,44)=18.15,	p=0.000	
Liver	weight	(%	
body	weight)	 4.8	(0.6)	 5.4	(0.4)	 4.4	(0.7)	 5.0	(0.9)	 NS	
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Table 2.2 Characteristics and serum biochemistry results for young (10.0±0.0 months) 
and old (23.7±0.0 months) male C57BL/6 mice from cohort 2, 6 hours after treatment 
with 300mg/kg paracetamol or saline.. Data expressed as mean (SD). *p<0.05 compared 
to corresponding saline treated group. ALP= Alkaline phosphatase, GGT= Gamma 
glutamyltransferase. 
	
Young		 Old		 One‐way	
ANOVA	
Saline	
n=6	
Paracetamol	
n=6	
Saline	
n=8	
Paracetamol	
n=8	
Total	protein	
(g/L)	
50.2	(1.6)	 49.6	(3.3)	 55.8	(11.0)	 51.2	(4.8)	 NS	
Albumin	(g/L)	 27.0	(1.1)	 28.0	(1.6)	 27.8	(5.4)	 27.6	(2.1)	 NS	
Bilirubin	
(mol/L)	
2.3	(0.5)	 6.8	(3.0)*	 1.4	(0.7)	 4.0	(2.4)	 F(3,25)=9.39,	
p=0.000	
ALP	(U/L)	 62.0	(5.2)	 70.0	(13.9)	 65.3	(21.6)	 82.2	(16.8)	 NS	
GGT	(U/L)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 NS	
Body	weight	(g)	 34.9	(3.1)	 35.2	(2.9)	 37.1	(6.9)	 41.2	(4.2)	 NS	
Liver	weight	(%	
body	weight)	
3.7	(0.4)	 5.8	(0.7)	 5.2	(3.3)	 4.8	(0.7)	 NS	
Food	intake,	last	
week	of	diet	(g/g	
mouse/day)	
0.07	(0.01)	 0.07	(0.01)	 0.06	(0.01)	 0.06	(0.01)	 NS	
 
All paracetamol treated groups, in both cohorts, had increased mean ALT (Figure 2.1) 
and increased hepatic necrosis on histology (Figure 2.2) when compared to their 
corresponding saline treated groups (p<0.05), except for young mice in cohort 1, where 
there was only a trend towards increased necrosis (p=0.11). Two-way ANOVA showed 
that there was no age effect, nor any age-treatment interaction effect on the degree of 
hepatotoxicity as measured by serum ALT concentrations or the mean percentage of 
liver necrosis, in either cohort of mice. 
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Figure 2.1 Serum alanine aminotransferase (ALT) concentrations for young (cohort 1, 
7.3±0.3 months; cohort 2 = 10±0.0 months) and old (cohort 1, 18.9±2.3 months; cohort 
2, 23.7±0.0 months) male C57BL/6 mice from cohort 1 (A) or cohort 2 (B), 6 hours 
after treatment with 300mg/kg paracetamol (grey bars) or saline (black bars). Data 
expressed as mean±SEM. One-way ANOVA cohort 1, F(3,43)=10.37 p=0.00. One-way 
ANOVA cohort 2, F(3,26)=9.21 p=0.00.  *=p<0.05 compared to corresponding saline 
treated group with Tukey’s HSD post-hoc test. n=6-15 per group. 
 
 
Figure 2.2 Liver necrosis (as a percentage of liver tissue) for young (cohort 1, 7.3±0.3 
months; cohort 2 = 10±0.0 months) and old (cohort 1, 18.9±2.3 months; cohort 2, 
23.7±0.0 months) male C57BL/6 mice from cohort 1 (A) or cohort 2 (B), 6 hours after 
treatment with 300mg/kg paracetamol (grey bars) or saline (black bars). Data expressed 
* 
* 
*
*
* * *
n=13 n=15n=10 n=10 n=6 n=8n=6 n=8
n=13 n=15n=10 n=10 n=6 n=8n=6 n=8
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as mean±SEM. One-way ANOVA cohort 1, F(3,43)=5.47 p=0.003. One-way ANOVA 
cohort 2, F(3,24)=20.69 p=0.00. *=p<0.05 compared to corresponding saline treated 
SIRT1 activation does not provide an alternative protective mechanismgroup with 
Tukey’s HSD post-hoc test. n=6-15 per group 
Figure 2.3 Representative Haemotoxylin and Eosin stained liver histology images for 
young (cohort 1, 7.3±0.3 months; cohort 2 = 10±0.0 months) and old (cohort 1, 
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18.9±2.3 months; cohort 2, 23.7±0.0 months) male C57BL/6 mice 6 hours after 
treatment with 300mg/kg paracetamol or saline. Images taken at 100X. 
2.3.2 Assessment of Factors Influencing Paracetamol Pharmacokinetics 
Activity of microsomal CYP2E1, the enzyme that metabolises paracetamol to its 
hepatotoxic metabolite, NAPQI, was significantly decreased for old cohort 1 mice 
treated with paracetamol, compared to saline control (Figure 2.4) whilst this effect was 
only a trend for young cohort 1 mice, and for both age groups of cohort 2 mice 
(p=0.10). Two-way ANOVA showed an overall significant effect of only treatment for 
both cohorts (cohort 1 p=0.001, cohort 2 p=0.015) (Figure 2.4).  
 
Figure 2.4 Cytochrome P450 (CYP)2E1 activity in the livers of young (cohort 1, 
7.3±0.3 months; cohort 2 = 10±0.0 months) and old (cohort 1, 18.9±2.3 months; cohort 
2, 23.7±0.0 months) male C57BL/6 mice from cohort 1 (A) or cohort 2 (B), 6 hours 
after treatment with 300mg/kg paracetamol (grey bars) or saline (black bars). Data 
expressed as mean±SEM. One-way ANOVA cohort 1, F(3,40)=4.64 p=0.007. One-way 
ANOVA cohort 2, non-significant. *=p<0.05 compared to corresponding saline treated 
group with Tukey’s HSD post-hoc test. n=6-15 per group 
 
*
n=13 n=15n=10 n=10 n=6 n=8n=6 n=8
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Total liver glutathione (GSH), which binds and detoxifies NAPQI, was not significantly 
reduced with acute high dose paracetamol treatment in young or old mice in cohort 1 
(p=0.05) (Figure 2.5). For cohort 2 mice, glutathione was significantly decreased with 
paracetamol treatment in both young and old mice (p=0.002, p<0.001) (Figure 2.5). 
Additionally older mice in cohort 2 had higher total liver GSH levels, than younger 
mice, for both saline and paracetamol treated mice, with two-way ANOVA showing a 
significant effect of both age and treatment individually (p<0.001), as well as a 
significant age x treatment effect (p=0.036).  
 
Figure 2.5 Total liver glutathione (GSH) for young (cohort 1, 7.3±0.3 months; cohort 2 
= 10±0.0 months) and old (cohort 1, 18.9±2.3 months; cohort 2, 23.7±0.0 months) male 
C57BL/6 mice from cohort 1 (A) or cohort 2 (B), 6 hours after treatment with 
300mg/kg paracetamol (grey bars) or saline (black bars). Data expressed as mean±SEM. 
One-way ANOVA cohort 1, non-significant. One-way ANOVA cohort 2, 
F(3,27)=42.97 p=0.00. *=p<0.05 compared to corresponding saline treated group. 
#=p<0.05 compared to corresponding young group with Tukey’s HSD post-hoc test. 
n=6-15 per group 
 
*
*#
# 
n=13 n=15n=10 n=10 n=6 n=8n=6 n=8
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The activity of cytosolic NQO1, which transforms NAPQI back to paracetamol was 
found to be increased with age (p<0.001) but unchanged with paracetamol treatment 
(Figure 2.6) for cohort 1, and was not assessed for cohort 2. 
 
Figure 2.6 NAD(P)H:quinone oxidoreductase 1 (NQO1) activity for young (7.3±0.3 
months) and old (18.9±2.3 months) male C57BL/6 mice from cohort 1, 6 hours after 
treatment with 300mg/kg paracetamol (grey bars) or saline (black bars). Data expressed 
as mean±SEM. One-way ANOVA, F(3,40)=5.33 p=0.004. #=p<0.05 compared to 
corresponding young group with Tukey’s HSD post-hoc test. n=10-15 per group 
2.3.3 mRNA expression of Inflammatory, Apoptosis and Mitochondrial 
Function Markers 
Livers from cohort 1 mice were analysed for changes in mRNA expression of: pro-
inflammatory cytokines TNF-α and IL-1β; anti-inflammatory cytokine IL-10; the 
cytokine-production regulating protein complex, NF-κB; the apoptosis marker Caspase 
3; apoptosis promoting protein BAX; and the mitochondrial regulator proteins, PGC1-α 
and PGC1-β, with age and paracetamol treatment. Figure 2.7 shows that with 
paracetamol treatment there is an increase in liver mRNA expression of the 
inflammatory markers TNF-α, IL-1β, IL-10 and NF-κB for old, but not young mice 
(p<0.05). Two-way ANOVA only identified a significant age x treatment interaction 
effect for TNF-α (p=0.024), with a greater increase in TNF-alpha seen after acute high 
# 
n=13 n=15n=10 n=10
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dose paracetamol in old than in young mice. There was no change in the ratio of pro-
inflammatory to anti-inflammatory cytokine expression (TNF-α/IL-10), for any age or 
treatment group. 
 
 
Figure 2.7 mRNA expression of inflammatory markers; (A) Tumor necrosis 
factor(TNF)-α (B) Interleukin (IL)-1β (C) IL-10 and (D) Nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) for young (7.3±0.3 months) and old 
(18.9±2.3 months) male C57BL/6 mice from cohort 1, 6 hours after treatment with 
300mg/kg paracetamol (grey bars) or saline (black bars). Data expressed as mean 
normalized to young wild-type saline group ±SEM. One-way ANOVA TNF-α, 
F(3,36)=6.28 p=0.002. One-way ANOVA IL-1β, F(3,36)=3.09 p=0.04. One-way 
ANOVA IL-10, F(3,36)=4.72 p=0.008. One-way ANOVA NF-κB, F(3,36)=4.03 
*# * 
* 
* 
n=10 n=10n=8 n=10 n=10 n=10n=8 n=10
n=10 n=10n=8 n=10 n=10 n=10n=8 n=10
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p=0.015. *=p<0.05 compared to corresponding saline treated group, #=p<0.05 
compared to corresponding young group with Tukey’s HSD post-hoc test. n= 3-10 per 
group 
 
There is no change in apoptosis marker, Caspase 3 mRNA expression with age or 
paracetamol treatment. BAX mRNA expression is increased in old mice treated with 
paracetamol, compared to saline controls, and young mice treated with paracetamol 
(p<0.05) (Figure 2.8) mRNA expression of mitochondrial regulator protein, PGC1-α 
does not change with age or treatment, whilst PGC1-β mRNA expression is increased in 
old mice treated with paracetamol only (p=0.013). Two-way ANOVA shows a 
significant age x treatment interaction effect for BAX and PGC1-β (p=0.027, p=0.023), 
with a greater response to treatment seen in old age. 
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Figure 2.8 mRNA expression of (A) Caspase 3 (B) BAX (C) Peroxisome proliferator-
activated receptor gamma coactivator 1 (PGC1)-α and (D) PGC1-β for young (7.3±0.3 
months) and old (18.9±2.3 months)  male C57BL/6 mice from cohort 1, 6 hours after 
treatment with 300mg/kg paracetamol (grey bars) or saline (black bars). Data expressed 
as mean normalized to young wild-type saline group ±SEM. One-way ANOVA Caspase 
3, non-significant. One-way ANOVA BAX, F(3,36)=5.46 p=0.004. One-way ANOVA 
PGC1-α, non-significant. One-way ANOVA PGC1-β, F(3,36)=4.21 p=0.013. *=p<0.05 
compared to corresponding saline treated group, #=p<0.05 compared to corresponding 
young group with Tukey’s HSD post-hoc test.  n= 3-10 per group 
2.3.4 Correlation between Frailty and Paracetamol Toxicity Outcomes 
To assess whether frailty affected the risk or mechanisms of paracetamol hepatotoxicity, 
we investigated the correlation between frailty index and associated outcomes, for 
paracetamol and saline treated old mice from cohort 2 (Figure 2.9). 
*# 
*
n=10 n=10n=8 n=10 n=10 n=10n=8 n=10
n=10 n=10n=8 n=10 n=10 n=10n=8 n=10
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There was no correlation between frailty and serum ALT, percentage of hepatic 
necrosis, microsomal CYP2E1 activity or total liver GSH for paracetamol or saline 
treated mice (p<0.05). There was a significant negative correlation between serum total 
protein, and serum albumin, and frailty index (r=-0.963, p=0.000 and r=-0.871, 
p=0.011) for paracetamol treated mice (Figure 2.9). An ANCOVA showed no 
significant difference between the regression slopes for either outcome (serum protein 
or albumin) for treatment group, when adjusted for frailty index as a covariate, implying 
that this correlation is probably not specific to the paracetamol treatment group, and 
rather an overall correlation with frailty.  
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Figure 2.9 Correlation between frailty index and (A) serum alanine aminotransferase 
(ALT), (B) percentage liver necrosis, (C) liver cytochrome P450 (CYP)2E1 activity, 
(D) total liver glutathione (GSH), (E) serum total protein, (F) serum albumin, (G) liver 
weight (as % of body weight) and (H) serum alkaline phosphatase (ALP), for old 
r=0.11 
p=0.81 
r=0.21 
p=0.77 
r=0.21 
p=0.66 
r=-0.39 
p=0.31 
r=-0.96 
p<0.01 
r=-0.87 
p<0.01 
r=0.23 
p=0.54 
r=-0.32 
p=0.41 
r=-0.09 
p=0.78 
r=-0.34 
p=0.35 
r=-0.63 
p=0.07 
r=0.25 
p=0.20 
r=0.54 
p=0.06 
r=-0.25 
p=0.25 
r=-0.12 
p=0.41 
Chapter 2: Acute Paracetamol Toxicity in Old and/or Frail Mice 
Alice Kane - March 2016 72
(23.7±0.0 months) male C57BL/6 mice from cohort 2, 6 hours after treatment with 
300mg/kg paracetamol (grey) or saline (black). n=6-8 per group 
2.4 Discussion 
This study, which is the first to look at the effect of age on paracetamol toxicity in mice, 
found that there was no effect of age on susceptibility to acute paracetamol toxicity, as 
assessed by liver necrosis and serum ALT concentration. This is in contrast to the 
previous studies of acute paracetamol hepatotoxicity in rats, demonstrating increased 
risk in Sprague-Dawley rats with age (Tarloff et al. 1996) and decreased risk in old age 
in Fischer 344 rats (Rikans & Moore 1988; Mach et al. 2014). There was no change in 
CYP2E1 activity in old mice compared to young, from any cohort. Interestingly, in old 
age rats have a reduction in CYP2E1 activity (Mach et al. 2014), and this provides one 
mechanism for the observed interspecies difference in toxicity risk. Old rats, but not 
young, were also found to have an increase in creatinine with paracetamol treatment, 
indicating potential increased risk of paracetamol induced nephrotoxicity in old rats, 
which was not seen for old mice in the current study (Mach et al. 2014; Beierschmitt et 
al. 1986). 
 
Recent research has identified mice as a more clinically relevant model of paracetamol 
toxicity, due to similar susceptibility to, and mechanisms of, toxicity in mice and 
humans, but not rats (McGill et al. 2012). This implies that the current finding of no 
change in hepatotoxicity risk due to acute paracetamol exposure in old age in mice, may 
be translatable to humans. Research confirming this finding in a clinical setting, may 
enable the optimisation of the use of paracetamol for pain relief in the older population, 
as a well-tolerated analgesic at therapeutic doses, with no increased risk of 
hepatotoxicity in old age. However, it must be noted that older patients are more likely 
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to have chronic, staggered or accidental over-exposures to paracetamol, rather than 
single acute over-exposures (Kane et al. 2012), and the effect of these types of 
paracetamol over-exposures on the risk of hepatotoxicity in old age has not been 
established. This will be explored in chapter 3. 
 
Total liver GSH concentration was decreased with paracetamol treatment in cohort 2, 
with a trend towards a decrease in cohort 1. Previous studies have shown that total liver 
glutathione is maximally reduced at 0.5-1 hour post acute paracetamol treatment, and 
steadily recovers back to baseline over the following hours (Mitchell et al. 1973; Mcgill 
et al. 2012). Our results are consistent with these findings. In cohort 2 only, young mice 
had significantly lower GSH concentrations than old mice, although this did not 
translate into a difference in degree of toxicity. Previous animal studies have seen a 
reduction or no change in total liver GSH concentrations with old age (Mune et al. 
1995; Mach et al. 2014; Suh et al. 2004), although none of these studies were in 
C57BL/6 mice. Vogt & Richie (1993) found that a decrease in liver GSH was only seen 
at 29 months of age in mice, so the old mice in our study may have been too young to 
have significant decreases in liver GSH concentration. 
 
This study found increased basal NQO1 activity in old mice compared to young, as has 
been seen in other animal studies (Mach et al. 2014; Kamzalov & Sohal 2004; Chen et 
al. 1994). Increased NQO1 activity may be a protective mechanism against paracetamol 
toxicity, and may explain the lack of increased risk to paracetamol toxicity in old age in 
our study. This study also saw an increased inflammatory response to acute paracetamol 
in the old mice compared to the young. Interestingly, this increased response was seen 
for both pro- and anti-inflammatory cytokines, with no change in the ratio of pro/anti- 
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inflammatory cytokines, and did not translate into a change in degree of paracetamol 
toxicity. This increased inflammatory response in old age is consistent with previous 
ageing animal studies of inflammatory response to stressors (Starr et al. 2013; Okamura 
et al. 2012; Tateda et al. 1996; Saito et al. 2003), although the relevance in human 
studies remains to be determined (Starr & Saito 2014). 
 
Another interesting age related paracetamol effect observed in this study was changes to 
the mRNA expression levels of BAX and PGC1-β in old mice, but not young, after 
paracetamol treatment. Changes in the expression of PGC1 proteins have been 
associated with ageing in several studies (Dillon et al. 2012), and studies have seen age-
related changes in apoptosis associated proteins (Mach et al. 2015), and increased 
apoptotic response to other stressors in age (Turnbull et al. 2004). Further exploration of 
age-related changes in the role of the mitochondria and apoptosis, as well as other 
related mechanisms such as autophagy, in paracetamol toxicity would be interesting, 
and may provide targets for therapeutic interventions to prevent or treat paracetamol 
toxicity. 
 
This study was the first to investigate the effect of frailty on paracetamol toxicity in an 
animal model. There was no overall effect of frailty on the degree of paracetamol 
toxicity from acute exposure, as assessed with serum ALT and prevalence of necrosis. 
The lack of correlation between frailty index and microsomal CYP2E1 activity or total 
liver GSH provides a mechanism for this finding. The single clinical study on 
paracetamol exposure in frailty, suggested that with exposure to therapeutic doses of 
paracetamol, frailer older patients may have been less at risk of toxicity (Mitchell, Kane, 
et al. 2011). Although, this initial finding implies that it is safe to use similar doses of 
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paracetamol in frail, older patients, as in young, further research is needed to clarify the 
effect of frailty on paracetamol toxicity clinically, in order to optimise pain treatment in 
these patients.  
 
The lack of an effect on the degree of paracetamol toxicity with frailty was unexpected, 
as frailty is often recognised as a reduced capacity to respond to stressors (Collard et al. 
2012). This negative finding may be a result of experimental design. It is possible that 
the time-frame of our experiment was too short to see a reduced capacity to recover 
with frailty, and it would be interesting to look at a longer time-frame after paracetamol 
insult in future studies. It would also be interesting to look at a wider range of 
paracetamol toxicity-associated outcomes such as inflammatory cytokine response, and 
the association with frailty. It is also possible that with a different mouse assessment 
tool, especially one that involved functional assessments (Liu et al. 2013) or 
biomarkers, we may have seen a more significant correlation between frailty and degree 
of hepatotoxicity. It would be interesting, in future studies, to look at both mouse frailty 
assessment tools (Whitehead et al. 2014; Liu et al. 2013), in an acute paracetamol 
toxicity model. Clinically, the patients identified as frail with the frailty index, are not 
always identified as frail with the phenotype approach that includes measures of 
functional performance, and vice versa (Rockwood et al. 2007; Kulminski et al. 2008), 
and it would be interesting to see if this was also true in mice. It would also be 
interesting, with larger mouse numbers, to dichotomise the mice into frail and non-frail 
groups, by using either the Liu et al. (2013) assessment, or introducing a cut-off point 
for the Whitehead et al. (2014) scale as has been done clinically (Rockwood et al. 2011; 
Song et al. 2010), and assessing changes in paracetamol outcomes in frail compared to 
non-frail mice. 
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There was a significant correlation of frailty index with serum protein and albumin 
levels in the paracetamol treated old mice, but not the saline treated. However, an 
ANCOVA showed no difference in the regression slopes for these 2 groups. Thus it is 
hard to conclude whether this was an effect of frailty on these outcomes with 
paracetamol treatment, or just an overall effect of frailty. Interestingly, several clinical 
studies have identified low albumin serum levels as a potential frailty biomarker 
(Schalk et al. 2004; Kitamura et al. 2012). It would be interesting, in future studies, to 
look at the association between frailty index and other markers associated with frailty 
clinically, such as inflammatory cytokines IL-6 or TNF-alpha (Hubbard et al. 2009). 
 
Limitations of this study include the use of two separate cohorts of mice with some 
baseline differences (diet, weights, ages), smaller numbers than a large single cohort 
study would have provided, and the fact that data was not collected on all outcomes for 
each cohort. Furthermore, as only mRNA data is available for some outcomes, these 
findings should be confirmed with protein expression experiments. Strengths of this 
study include the novelty of being the first study to investigate the effect of frailty and 
age on paracetamol toxicity in the clinically relevant model of ageing mice, and the 
quality of our data, with the use of validated assays to assess enzyme activities and 
qPCR to assess mRNA expression. 
 
Overall, the experiments in this chapter found that there is no difference in the degree of 
hepatotoxicity induced by acute paracetamol toxicity in old age or frailty in mice. There 
were some age related changes in the paracetamol toxicity mechanistic pathway 
including potentially protective increased liver GSH concentrations in one mouse 
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cohort, potentially protective increased NQO1 activity, an increased pro and anti 
inflammatory response to paracetamol with uncertain impact and potentially protective 
increased mRNA expression of BAX and PGC1β with paracetamol treatment in old age. 
However, none of these changes translated into detectable changes in risk of 
hepatotoxicity. Frailty related changes included a negative correlation between frailty 
index and serum protein and albumin concentrations. The next chapter will explore 
changes with age and frailty to chronic and sub-acute paracetamol exposure, and the 
effectiveness of the current therapy, NAC, in protecting against these exposure types. 
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3 CHRONIC AND SUB-ACUTE 
PARACETAMOL EXPOSURE 
IN YOUNG AND OLD MICE, 
AND THE ROLE OF N-
ACETYL CYSTEINE 
3.1 Introduction 
The majority of paracetamol toxicity studies have explored single, acute doses, and 
there have been limited studies on the risk of paracetamol toxicity from chronic or 
repeated paracetamol exposure. Chapter two of this thesis showed that in mice, there 
was no difference in the degree of hepatotoxicity induced by acute paracetamol toxicity 
in old age or frailty. However, older people are more likely to have chronic low-dose 
exposure or accidental over-exposure to paracetamol, than acute exposures (Kane et al. 
2012), and the changing risk of toxicity to these types of paracetamol exposures in old 
age and frailty has not been investigated. 
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In humans, two studies found that staggered over-exposures to paracetamol were 
associated with an increased risk of liver failure (Craig et al. 2012; Ferner et al. 2011). 
Another found that 31-44% of patients taking the recommended therapeutic paracetamol 
dose (4g/day) for 14 days had increased serum ALT concentrations, an indicator of liver 
damage (Watkins et al. 2006). A case study (Lane et al. 2002) and a large-scale 
retrospective hospital study (Civan et al. 2014), highlight the increased risk of chronic 
paracetamol over-exposure in patients taking multiple paracetamol-containing 
medications. As older patients are more likely to be taking multiple medications 
including over the counter medications (Qato et al. 2008), there is the possibility that 
they are at increased risk of chronic high exposure due to multiple paracetamol-
containing medications or other medications that increase the risk of paracetamol-
induced hepatotoxicity. 
 
There have been few animal studies of non-acute paracetamol exposure, and these are 
summarised in section 1.2.8. More research is needed to clarify the effect of 
species/strain, timing, and dose on the effect of paracetamol pre-treatment on 
susceptibility to toxicity. There have been no animal studies on chronic or sub-acute 
paracetamol exposure in old age. 
 
Current treatment of paracetamol overdose to prevent hepatotoxicity is the glutathione 
precursor N-acetyl-cysteine (NAC) (Corcoran, Racz, et al. 1985). NAC guidelines are 
designed for protection from a single high dose of paracetamol and there is little 
evidence to guide risk assessment and optimal treatment for staggered over-exposures, 
chronic exposure or repeated supra-therapeutic exposures (Daly et al. 2008). One 
animal study found that several weeks of NAC pre-treatment protected against toxicity 
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induced by twice-weekly paracetamol dosing (Chen et al. 2012). However this study 
does not model the clinically relevant situation, in which a patient would have post 
rather than pre-treatment with NAC. There have been no studies, to our knowledge on 
the effectiveness of NAC in old age. As older patients are more likely to have the types 
of exposures for which the NAC treatment evidence is lacking (Kane et al. 2012), 
optimisation of treatment for staggered or chronic paracetamol exposures, would be 
particularly of benefit to the older population.  
 
This chapter models these clinically relevant paracetamol exposure situations in mice. 
The study aim was to examine the effect of chronic paracetamol and sub-acute 
paracetamol exposure in both young and old mice, and investigate whether NAC was 
effective at preventing paracetamol toxicity induced by chronic and sub-acute exposure. 
3.2 Methods 
3.2.1 Animals 
Young (4.0±0.3 months, n=59) or old (26.8±0.5 months n=56) male C57BL/6 mice 
were obtained from, and housed at the Kearns Facility (Sydney, NSW). The median 
lifespan of C57BL/6 mice is 26-30 months The mouse numbers chosen for this study 
allowed for n=6 per group. This number was chosen based on previous work by Miller 
et al (2005), to account for expected variability and to detect a clinically significant 
difference in the main outcome of serum ALT. Unfortunately, the loss of more old mice 
than expected before the experimental timeframe required the use of n=4 for some old 
mouse groups.Mice were group housed in cages of 1-5 with ad libitum access to food 
(Rat and Mouse Premium Breeder Diet, Gordon’s Specialty Stockfeeds, NSW, 
Australia) and water. Animal rooms were maintained on a 12 hr light/dark cycle at 20-
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22°C, and 30-70% humidity. Animals were randomly assigned to diet groups by cage, 
and then individually randomly assigned to treatment groups prior to the treatment day. 
Mice were euthanized if moribund, and where possible necropsied. Animal protocols 
were approved by the Animal Care Ethics Committee at Royal North Shore Hospital. 
3.2.2 Frailty Index Assessment 
The Mouse Clinical Frailty Index was used to assess frailty as detailed in section 2.2.2. 
Young (12 week) weight and temperature means and standard deviations were obtained 
from the mean of young male C57BL/6 mice (n=5) from the Kearns Facility 
(weight=26.0 0.8 grams, temperature=31.6 1.0°C). 
 
All old mice were assessed for frailty, the day before being randomised to a diet group. 
Frailty testing was carried out by 2 raters. The raters were blinded to the scores assigned 
by the other rater. The final reported frailty index scores were calculated from the mean 
of the 2 rater’s scores. 
3.2.3 Chronic and Sub-Acute Paracetamol Treatment of Mice, and Tissue 
Collection 
Mice were randomized at 4.0±0.3 months of age (young, n=59) or 26.8±0.5 months of 
age (old, n=56) to either a control diet (Standard Meat Free Mouse and Rat Feed, 20 % 
Protein, 60% Carbohydrate, 5% Fat, Specialty Feeds, Australia), or control diet 
supplemented with paracetamol at a concentration of 1.33g/kg feed, both diets fed ad 
libitum. All mice were fed control diet for two weeks prior to the experimental period to 
adjust to the new diet. Body weight and food intake for all mice were monitored 
weekly. Mice remained on their respective diets for a further 6 weeks.  
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Following six weeks of their control or experimental diet, mice were given, via oral 
gavage, sub-acute paracetamol or saline treatment. Mice were dosed an additional 
paracetamol dose (250mg/kg, Panadol Color-free Baby Drops, 100mg/ml, 
GlaxoSmithKline, Australia), or saline, three times per day for two days. The mice were 
gavaged at 8am, 1pm and 6pm. On the third day the mice were fasted at 6am, then 
gavaged two more doses of paracetamol (250mg/kg), or saline, at 8am and 1pm. For the 
paracetamol diet group only, immediately following the final sub-acute paracetamol 
dose, mice were also dosed, via oral gavage, NAC (1200mg/kg in saline, pH=7.0, 
Sigma-Aldrich, MO, USA) or saline. At 3pm these mice were given a second NAC dose 
(1200mg/kg), or saline, via oral gavage. This created eight treatment groups for each 
age group: control diet+saline, control diet+paracetamol, paracetamol diet+saline, 
paracetamol diet+paracetamol, paracetamol diet+saline+NAC, paracetamol 
diet+paracetamol+NAC, paracetamol diet+saline+2xNAC, paracetamol 
diet+paracetamol+2xNAC. 
 
For all mice, three hours after the final sub-acute paracetamol dose (4pm), each mouse 
was anaesthetized with an i.p. injection of ketamine (75 mg/kg, Cenvet Australia, 
#K1500) and xylazine (10 mg/kg, Cenvet Australia, #X5010). A midline laparotomy 
was performed and blood taken from the Inferior Vena Cava (IVC). The portal vein was 
then cannulated with a 21G intravenous catheter (BD, Sydney, Australia) through which 
the liver was perfused in-situ at 1–1.5 mL/min/g of liver with oxygenated Krebs-
Henseleit bicarbonate buffer (95% O2–5% CO2, 37°C) to remove the blood. Sections of 
the liver were snap frozen in liquid nitrogen for subsequent enzyme activity assays and 
fixed in 10% neutral buffered formalin for subsequent histopathological analysis. See 
Table 3.1 for the experimental timeline. 
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The chronic paracetamol daily dose was chosen based on a previous study that 
determined this dose caused analgesia in mice (Minville et al. 2011), and a weight-
based calculation of the equivalent of an average person taking twice the recommended 
daily dose (8g/80kg person/day = 100mg/kg/day). Pilot studies were conducted in 
young C57BL/6 mice to determine the minimum sub-acute paracetamol dose that would 
cause an ALT over three times the upper limit of normal in 50% of mice. Six mice fed a 
paracetamol-containing diet for six weeks, were treated with either 50mg/kg (n=2), 
100mg/kg (n=2) or 250mg/kg (n=2) paracetamol via oral gavage three times per day for 
three days. Only one of the mice, who was dosed 250mg/kg, had ALT levels that that 
were more than three times the upper limit of normal so this dose was chosen to ensure 
there was sufficient detectable hepatotoxicity. 
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Table 3.1 Chronic and Sub-acute Paracetamol Dosing Timeline 
DIET	 Weeks	0‐2	 Weeks	2‐8	
Week	9,	Day	1	
8am,	1pm,	6pm	
Week	9,	Day	2	
8am,	1pm,	
6pm	
Week	9,	Day	
3	
6am	
Week	9,	Day	3	
8am	
Week	9,	Day	3	
1pm	
Week	9,	Day	
3	
3pm	
Week	9,	Day	
3	
4pm	
Control	Diet	 Control	Diet	 Control	Diet	
Sub‐acute	
Paracetamol,	or	
Saline,	Dosing	
(250mg/kg)	
Sub‐acute	
Paracetamol,	or	
Saline,	Dosing	
(250mg/kg)	
Mice	fasted	
Sub‐acute	
Paracetamol,	
or	Saline,	
Dosing	
(250mg/kg)	
Sub‐acute	
Paracetamol,	or	
Saline,	Dosing	
(250mg/kg)	
‐	
Mice	
euthanized,	
serum/liver	
collected	
Paracetamol	
Diet	 Control	Diet	
Paracetamol	
Diet	
(1.33mg/kg	
feed)	
Sub‐acute	
Paracetamol,	or	
Saline,	Dosing	
(250mg/kg)	
Sub‐acute	
Paracetamol,	or	
Saline,	Dosing	
(250mg/kg)	
Mice	fasted	
Sub‐acute	
Paracetamol,	
or	Saline,	
Dosing	
(250mg/kg)	
Sub‐acute	
Paracetamol,	or	
Saline,	Dosing	
(250mg/kg)	
+	
NAC	or	saline	
Dosing	
(1200mg/kg)	
NAC	or	Saline	
Dosing	
(1200mg/kg)	
Mice	
euthanized,	
serum/liver	
collected	
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3.2.4 Serum Biochemistry to Assess Liver and Renal Function 
Blood was stored and serum extracted as detailed in section 2.2.4, serum liver function 
tests (total protein, albumin, bilirubin, alkaline phosphatase (ALP), gamma 
glutamyltransferase (GGT)), creatinine and serum paracetamol concentrations were 
measured by a National Association of Testing Authorities accredited hospital 
laboratory, PaLMS (Pacific Laboratory Medicine Services) at Royal North Shore 
Hospital (Sydney, Australia) using an Architect i1000SR immunoassay analyser 
(Abbott Diagnostics, IL, USA). The lower limit of the paracetamol serum concentration 
test was 20μmol/L. Vitamin B6 is added to the ALT activity assay to accommodate for 
the age related decline in this vitamin, an integral cofactor for the assay (Krishnamurthy 
et al. 1967; Bordoni et al. 1998). 
3.2.5 Liver Histology 
Liver samples for all mice, and spleens and macroscopically abnormal tissue from old 
mice with macroscopically suspected cancer, were assessed for histopathology. Fixed 
tissue was embedded in paraffin, 5µm sections were cut on a microtome and mounted 
on slides. Slides were stained with Haemotoxylin and Eosin in the National Association 
of Testing Authorities accredited hospital laboratory of the Pathology department of 
Royal Prince Alfred Hospital, Sydney, Australia. Histopathology was scored by an 
anatomical pathologist (CM), who was blinded to the treatment of the samples. 
Inflammation was scored as either present or not, based on the presence of lymphocytes, 
histiocytes and neutrophils. Necrosis was scored as a percentage of the liver tissue on 
each slide, which was then converted to a dichotomous variable (present or not present) 
for analysis. Images were taken on an Olympus BX51 microscope connected to an 
Olympus DP26 camera (Olympus, Sydney, Australia). 
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3.2.6 Biochemical Examination of CYP2E1 in Frozen Liver Samples 
Liver microsomes were isolated according to the method of Shoaf et al. (1987), and 
CYP2E1 activity was measured according to the method of Roberts et al. (1995) and 
Mach et al. (2014), as detailed in section 2.2.6. 
3.2.7 Biochemical Examination of Glutathione and DNA Fragmentation in 
Frozen Liver Samples 
Liver concentrations of total glutathione were determined with a Glutathione Assay kit 
(Cayman Chemicals, #703002) as detailed in section 2.2.6. 
 
DNA fragmentation was determined using an enzyme-linked immunosorbent assay 
(ELISA) Cell Death detection kit (#11544675001, Roche, Switzerland) according to the 
manufacturer’s specifications. In brief, frozen liver was homogenised in 5 times the 
volume of incubation buffer to liver weight. The homogenate was then centrifuged at 
13,000 g at 4°C for 20 min. The supernatant was diluted 250-fold before following the 
rest of the ELISA protocol. 
3.2.8 Statistics 
Data are expressed as mean ± SEM unless otherwise indicated. Differences between 
mean values across treatment and age groups were calculated with one- two- or three-
way ANOVA with Tukey’s HSD post-hoc test where appropriate. Chi-squared tests 
were used for comparisons of proportions across groups. Spearman correlation 
coefficients (r) were used to analyse the correlation between Frailty Index and other 
outcomes, and linear regression was used to calculate slopes of best fit for each 
treatment group. Analysis of covariance (ANCOVA) was used to compare the 
regression slopes between paracetamol or saline treated groups, with frailty index as a 
covariate. Data analysis was completed using the statistics program SPSS (Version 
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21.0, SPSS Inc., Chicago, Illinois, USA) and GraphPad Prism (Version 6.04, GraphPad 
Software, La Jolla California USA). 
3.3 Results 
3.3.1 Animal Characteristics 
Weights, food consumed and serum biochemistry results for each mouse group are 
shown in Table 3.2 and Table 3.3. One-way ANOVA across the eight treatment groups 
for young and old mice, with Tukey’s HSD post-hoc testing, showed no difference in 
animal weights, food consumed or any serum biochemistry results across any of the old 
groups. For the young mice, compared to control diet-saline dosed controls, there was a 
significant increase in liver weight (as a percentage of body weight), bilirubin and total 
protein, in some paracetamol treated groups. The paracetamol doses received in the diet 
ranged from 167 to 188 mg/kg/day. Several old mice had suspected cancer, as assessed 
via histology (Table 3.3). These mice were not excluded from analysis, in order to 
mimic a true model of an aged population with multimorbidity, and these mice were 
randomly spread across the treatment groups. 
 
Several mice died or were moribund, and thus euthanized, during the experiment. One 
young mouse on paracetamol diet, died after two days of sub-acute paracetamol dosing 
(suspected severe paracetamol-induced liver toxicity, serum ALT concentration of 
32545 U/L with 80% liver necrosis). Three old mice on control diet, and three old mice 
on paracetamol diet died before the subacute dosing was started (unable to be 
necropsied). Three old mice fed paracetamol diet, died after starting the sub-acute 
dosing regimen, though they were receiving saline, and are not suspected of 
paracetamol-induced liver toxicity (one unable to be necropsied; one suspected kidney 
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failure with serum creatinine of 348 µmol/L and ALT of 63 U/L; one macroscopically 
suspected liver cancer with ALT of 78 U/L). 
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Table 3.2 Animal characteristics and serum biochemistry results for young male C57BL/6 mice fed either a control diet or paracetamol containing 
(1.33g/kg feed) diet for 6 weeks, then treated with 3 days of saline or paracetamol (250mg/kg x 3/day) plus a single or double dose of N-Acetyl 
Cysteine (NAC) (1200mg/kg) for the paracetamol diet group. Serum and liver collected 3 hours after the final paracetamol/saline dose.*p<0.05 
compared to control diet; saline group #p<0.05 compared to corresponding saline group with Tukey’s HSD post-hoc test. ALP= Alkaline phosphatase, 
GGT= Gamma glutamyltransferase, NAC=N-Acetyl Cysteine, NS=Non-significant 
	
Control	Diet	 Paracetamol	Diet	 One‐way	
ANOVA	
Saline	
(n=8)	
Paracetamol	
(n=8)	
Saline	
(n=6)	
Paracetamol	
(n=8)	
Saline	
+	NAC	
(n=6)	
Paracetamol	
+	NAC	
(n=8)	
Saline	
+	2	x	NAC	
(n=7)	
Paracetamol	
+	2	x	NAC	
(n=7)	
Age		at	sac(monthss)	 5.7	(0.0)	 5.6	(0.1)	 5.8	(0.1)	 5.5	(0.1)	 5.8	(0.1)	 5.5	(0.1)	 5.3	(0.1)	 5.3	(0.0)	 NS	
Paracetamol	dose,	
week	6	of	diet	(mg/kg	
mouse/day)	
‐	 ‐	 174.6	(5.7)	 187.8	(10.8)	 173.4	(5.1)	 167.3	(4.4)	 187.1	(3.1)	 187.6	(3.9)	
NS	
Weight	pre‐	subacute	
dosing	(g)	 29.6	(0.6)	 28.8	(0.6)	 30.7	(0.7)	 28.4	(0.8)	 28.1	(0.6)	 30.6	(0.6)	 28.2	(0.7)	 27.5	(0.7)	
NS	
Weight	post‐	subacute	
dosing	(g)	 27.6	(0.6)	 25.0	(0.9)	 28.2	(0.4)	 24.9	(0.7)	 25.8	(1.2)	 27.3	(0.6)	 26.3	(0.7)	 24.7	(0.6)	
NS	
Food	eaten,	day	2	of	
subacute	dosing	
(g/mouse/day)	
2.2	(0.2)	 2.1	(0.3)	 2.6	(0.4)	 2.6	(0.2)	 2.5	(0.3)	 1.9	(0.1)	 2.3	(0.5)	 2.3	(0.7)	
NS	
 Alice Kane - March 2016 90 
Liver	weight	(%	body	
weight)	 3.8	(0.1)	 4.3	(0.3)	 3.7	(0.2)	 4.6	(0.2)	 4.3	(0.2)	 4.8	(0.1)*	 3.9	(0.2)	 4.8	(0.3)*#	
F(7,46)=4.55,	
p=0.001	
Total	protein	(g/L)	 44.7	(0.9)	 49.3	(1.3)	 45.5	(2.2)	 49.5	(1.5)	 44.0	(1.9)	 50.7	(1.0)*#	 49.1	(1.2)	 53.7	(1.4)*	 F(2,38)=5.81,	p=0.000	
Albumin	(g/L)	 24.3	(0.8)	 26.4	(0.7)	 25.0	(1.0)	 26.3	(0.8)	 25.2	(0.2)	 26.3	(0.3)	 26.0	(0.7)	 28.0	(0.6)*	 F(7,40)=2.78,	p=0.018	
Bilirubin	(µmol/L)	 1.4	(0.3)	 3.2	(0.3)*#	 3.	0	(0.4)	 5.0	(1.1)*	 ‐	 3.6	(0.2)*	 2.7	(0.3)	 3.5	(0.2)*	 F(7,35)=6.44,	p=0.000	
ALP	(U/L)	 99.7	(9.4)	 96.7	(6.9)	 112.5	(4.2)	 93.8	(12.3)	 104.6	(6.9)	 110.6	(5.2)	 110.4	(2.2)	 110.8	(6.7)	 NS	
GGT	(U/L)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 NS	
Creatinine	(µmol/L)	 32.0	(1.7)	 32.5	(2.9)	 29.5	(1.7)	 30.7	(0.7)	 27.0	(0.0)	 30.2	(0.5)	 28.4	(1.1)	 29.0	(0.6)	 NS	
 
Table 3.3 Animal characteristics and serum biochemistry results for old male C57BL/6 mice fed either a control diet or paracetamol containing 
(1.33g/kg feed) diet for 6 weeks, then treated with 3 days of saline or paracetamol (250mg/kg x 3/day) plus a single or double dose of N-Acetyl 
Cysteine (NAC) (1200mg/kg) for the paracetamol diet group. Serum and liver collected 3 hours after the final paracetamol/saline dose. ALP= Alkaline 
phosphatase, GGT= Gamma glutamyltransferase, NAC=N-Acetyl Cysteine. 
	 Control	Diet	 Paracetamol	Diet	 One‐way	
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Saline	
(n=6)	
Paracetamol	
(n=7)	
Saline	
(n=6)	
Paracetamol	
(n=7)	
Saline	
+	NAC	
(n=6)	
Paracetamol	
+	NAC	
(n=7)	
Saline	
+	2	x	NAC	
(n=4)	
Paracetamol	
+	2	x	NAC	
(n=4)	
ANOVA
Age	at	sac	(weeks)	 28.6	(0.0)	 28.6	(0.0)	 28.6	(0.0)	 28.5	(0.0)	 28.6	(0.0)	 28.6	(0.0)	 26.9	(0.1)	 27.1	(0.2)	 NS	
Paracetamol	dose,	
week	6	of	diet	(mg/kg	
mouse/day)	
‐	 ‐	 140.6	(9.4)	 126.9	(5.8)	 133.1	(3.7)	 139.6	(6.9)	 151.8	(13.9)	 159.5	(9.8)	
NS	
Weight	pre‐	subacute	
dosing	(g)	 29.6	(2.2)	 28.3	(2.2)	 32.0	(1.5)	 34.2	(0.7)	 32.0	(0.4)	 32.1	(0.6)	 31.6	(1.4)	 28.4	(2.2)	
NS	
Weight	post‐	subacute	
dosing	(g)	 28.6	(2.0)	 26.5	(1.6)	 32.0	(1.6)	 30.6	(0.9)	 29.9	(0.3)	 28.6	(0.5)	 30.6	(1.3)	 26.1	(1.6)	
NS	
Food	eaten,	day	2	of	
subacute	dosing	
(g/mouse/day)	
2.8	(0.3)	 2.2	(0.3)	 2.8	(0.6)	 1.5	(0.4)	 1.7	(0.3)	 1.8	(0.3)	 2.5	(0.5)	 2.7	(0.6)	
NS	
Liver	weight	(%	body	
weight)	 4.1	(0.3)	 4.5	(0.2)	 4.4	(0.2)	 4.6	(0.2)	 6.7	(1.4)	 4.8	(0.4)	 4.2	(0.2)	 5.1	(0.2)	
NS	
Total	protein	(g/L)	 48.6	(1.7)	 50.0	(1.7)	 49.4	(1.1)	 47.8	(2.1)	 48.2	(1.1)	 48.8	(1.1)	 51.3	(0.8)	 52.3	(2.2)	 NS	
Albumin	(g/L)	 23.8	(0.7)	 23.7	(1.4)	 23.2	(0.5)	 23.1	(1.1)	 23.0	(0.4)	 23.3	(0.5)	 25.5	(0.3)	 25.0	(0.7)	 NS	
Bilirubin	(µmol/L)	 2.2	(0.5)	 2.7	(0.6)	 2.0	(0.4)	 2.6	(0.5)	 3.2	(0.5)	 3.6	(0.8)	 2.5	(0.3)	 3.0	(0.4)	 NS	
ALP	(U/L)	 99.6	(12.7)	 100.8	(12.2)	 90.6	(4.7)	 115.6	(17.4)	 173.7	(75.8)	 115.9	(21.1)	 146.3	(21.6)	 144.3	(7.6)	 NS	
GGT	(U/L)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.7	(0.7)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 NS	
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Creatinine	(µmol/L)	 46.3	(15.3)	 24.7	(2.2)	 35.7	(4.2)	 37.7	(6.2)	 31.7	(1.2)	 30.5	(1.2)	 40.8	(7.8)	 40.5	(13.2)	 NS	
Suspected	cancer	(n,	
%)	 1	(16.7)	 0	(0)	 0	(0)	 0	(0)	 1	(16.7)	 1	(14.3)	 0	(0)	 0	(0)	
NS	
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3.3.2 Assessment of Toxicity with Chronic Paracetamol Exposure 
Chronic dietary paracetamol exposure did not result in an increase in serum ALT in 
young or old mice (Figure 3.1A and B). To determine whether there was low-grade bio 
molecular liver damage that serum ALT did not reveal, we investigated the level of 
DNA fragmentation in the livers of young and old, control or paracetamol diet, saline 
treated mice groups (Figure 3.2). There was no increase in DNA fragmentation with 
dietary paracetamol exposure in young or old mice (young p=0.91, old p=0.72). For 
those mice receiving sub-acute saline, with the paracetamol diet compared to the control 
diet, there was no significant difference in the proportion of young mice with necrosis 
(p=0.27) (Figure 3.1C), and a trend towards an increase in the proportion of young and 
old mice with inflammation (young p=0.14, old p=0.12) (Figure 3.1C and D). The 
average percentage of the scored liver with necrosis was 4.4±12.5 % across chronic 
paracetamol exposed groups. 
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Figure 3.1 Serum alanine aminotransferase (ALT) concentration and proportion of each 
group with detectable liver necrosis and inflammation for young (A, C, respectively, 4 ± 
0.3 months) and old (B, D, respectively, 26.8 ± 0.5 months) male C57BL/6 mice fed 
either a control diet or paracetamol containing (1.33g/kg feed) diet for 6 weeks, then 
treated with 3 days of saline or paracetamol (250mg/kg x 3/day) plus a single or double 
dose of N-Acetyl Cysteine (NAC) (1200mg/kg) for the paracetamol diet group. Serum 
and liver collected 3 hours after the final paracetamol/saline dose. Serum ALT data 
expressed as mean ± SEM. One-way ANOVA young mice ALT, F(7,44)=5.35 p=0.00. 
One-way ANOVA old mice ALT, F(7,38)=3.77 p=0.003. *p<0.05 compared to 
corresponding saline-treated group with Tukey’s HSD post-hoc test. n=4-8 per group 
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Figure 3.2 DNA Fragmentation in liver homogenate from young (4 ± 0.3 months) and 
old (26.8 ± 0.5 months) male C57BL/6 mice fed either a control diet or paracetamol 
containing (1.33g/kg feed) diet for 6 weeks, then treated with 3 days of saline. Liver 
collected 3 hours after the final saline dose. Data expressed as % relative to young 
control diet ± SEM. n=4-8 per group 
n=8 n=6 n=6 n=6 
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Figure 3.3 Representative Haemotoxylin and Eosin stained liver histology images for 
young (4 ± 0.3 months) and old (26.8 ± 0.5 months) male C57BL/6 mice fed either a 
control diet or paracetamol containing (1.33g/kg feed) diet for 6 weeks, then treated 
with 3 days of saline or paracetamol (250mg/kg x 3/day) plus a single dose of N-Acetyl 
Cysteine (NAC) (1200mg/kg) for the paracetamol diet group. Liver collected 3 hours 
after the final paracetamol/saline dose. Images taken at 100-200X. 
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3.3.3 Assessment of Toxicity with Sub-acute Paracetamol Exposure 
All young mouse groups treated with sub-acute paracetamol had increased serum ALT 
concentrations compared to their corresponding saline-treated groups (p<0.05, Figure 
3.1A). For old mice, sub-acute paracetamol treatment significantly increased ALT 
compared to the corresponding saline treated group only for the paracetamol 
diet+paracetamol group and paracetamol diet+paracetamol+2xNAC group (p<0.05). 
There was a trend towards increased serum ALT with sub-acute paracetamol treatment 
in the other old groups compared to saline controls (control diet+paracetamol group 
p=0.09, paracetamol diet+paracetamol+NAC group p=0.19) (Figure 3.1B). Histological 
grading also showed an increase in the proportion of mice with necrosis and 
inflammation, for all sub-acute paracetamol treated groups compared to the saline-
treated groups (young necrosis p=0.002, inflammation p=0.001; old necrosis p=0.001, 
inflammation p=0.06). The average percentage of the scored liver with necrosis was 
24.0±24.9 % across subacute paracetamol exposed groups. A three-way ANOVA of 
age, diet and treatment group of all mice, showed that treatment was the only significant 
factor associated with serum ALT concentration, with all age and diet interaction terms 
non-significant, implying that neither the age nor diet group of the mice affected the 
degree of sub-acute paracetamol-induced toxicity. 
3.3.4 Assessment of Toxicity with Paracetamol Exposure Plus N-Acetyl 
Cysteine 
In our study, neither treatment with a single nor double dose of NAC was able to reduce 
the degree of toxicity induced by sub-acute paracetamol dosing. A two-way ANOVA 
for each age group, considering only those mice on the paracetamol diet, of sub-acute 
paracetamol/saline treatment and NAC treatment, showed that the interaction term 
between sub-acute treatment and NAC, for ALT serum concentration, was not 
significant (Figure 3.1A and B). There was also no reduction in the proportion of 
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necrosis or inflammation seen in the groups treated with either a single or double dose 
of NAC plus paracetamol, compared to paracetamol alone (young necrosis p=0.72, 
inflammation p=0.69; old necrosis p=0.23, inflammation p=0.23). 
3.3.5 Serum Paracetamol Levels, Liver Glutathione Levels and CYP2E1 
Activity 
We also assessed the serum paracetamol levels for all young (Figure 3.4A) and old 
(Figure 3.4B) mouse groups treated with sub-acute paracetamol or saline. In all saline 
treated mice, even those receiving chronic paracetamol in the diet, paracetamol serum 
levels were below the detectable limit of the test. A one-way ANOVA across treatment 
groups for each mouse group, identified a significant increase in paracetamol serum 
level for young mice treated with sub-acute paracetamol plus NAC, compared to those 
treated with sub-acute paracetamol only (Figure 3.4A) (p=0.036). 
 
 
Figure 3.4 Paracetamol serum concentrations for young (A, 4 ± 0.3 months) and old (B, 
26.8 ± 0.5 months) male C57BL/6 mice fed either a control diet or paracetamol 
containing (1.33g/kg feed) diet for 6 weeks, then treated with 3 days of saline or 
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paracetamol (250mg/kg x 3/day) plus a single or double dose of N-Acetyl Cysteine 
(NAC) (1200mg/kg) for the paracetamol diet group. Serum collected 3 hours after the 
final paracetamol/saline dose. One-way ANOVA young mice, F(7,31)=10.96 p=0.00. 
One-way ANOVA old mice, non-significant. Data are expressed as mean ± SEM. 
*p<0.05 compared to control diet+paracetamol group with Tukey’s HSD post-hoc test. 
n=4-8 per group. 
 
Total liver glutathione levels were reduced with sub-acute paracetamol treatment in 
control fed old mice (p=0.01), but not young mice (p=0.55) (Figure 3.5). This reduction 
in total liver glutathione levels was not seen for old mice fed a paracetamol diet 
followed by sub-acute paracetamol (Figure 3.4). In both young and old mice, there was 
a significant increase in GSH levels with both a single and double dose of NAC, in 
combination with sub-acute paracetamol treatment, compared to sub-acute paracetamol 
treatment alone, for mice on either a control or paracetamol diet (Figure 3.5).  
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Figure 3.5 Total liver glutathione (GSH) concentrations for young (A, 4 ± 0.3 months) 
and old (B, 26.8 ± 0.5 months) male C57BL/6 mice fed either a control diet or 
paracetamol containing (1.33g/kg feed) diet for 6 weeks, then treated with 3 days of 
saline or paracetamol (250mg/kg x 3/day) plus a single or double dose of N-Acetyl 
Cysteine (NAC) (1200mg/kg) for the paracetamol diet group. Liver collected 3 hours 
after the final paracetamol/saline dose. Data are expressed as mean ± SEM. One-way 
ANOVA young mice, F(7,46)=11.91 p=0.00. One-way ANOVA old mice, 
F(7,37)=17.46 p=0.00. *p<0.05 compared to control diet+saline group, #p<0.05 
compared to control diet+paracetamol group, ^p<0.05 compared to paracetamol 
diet+paracetamol group, ~p<0.05 compared to paracetamol diet+paracetamol+NAC 
group  with Tukey’s HSD post-hoc test. n=4-8 per group. 
 
Old mice treated with saline+NAC, paracetamol+NAC or paracetamol+2xNAC had 
significantly lower CYP2E1 activity levels than old mice treated with saline only (on 
either control or paracetamol diet). There was no significant change in CYP2E1 activity 
for young mice with paracetamol or NAC dosing (Figure 3.6), although a similar trend 
towards reduced CYP2E1 levels with NAC treatment was seen for some groups. 
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Figure 3.6 Liver cytochrome (CYP)2E1 activity for young (A, 4 ± 0.3 months) and old 
(B, 26.8 ± 0.5 months) male C57BL/6 mice fed either a control diet or paracetamol 
containing (1.33g/kg feed) diet for 6 weeks, then treated with 3 days of saline or 
paracetamol (250mg/kg x 3/day) plus a single or double dose of N-Acetyl Cysteine 
(NAC) (1200mg/kg) for the paracetamol diet group. Liver collected 3 hours after the 
final paracetamol/saline dose. One-way ANOVA young mice, non-significant. One-way 
ANOVA old mice, F(7,23)=3.08 p=0.019. Data are expressed as mean ± SEM. *p<0.05 
compared to control diet+saline group, #p<0.05 compared to control diet+paracetamol 
group, !p<0.05 compared to paracetamol diet+saline group. n=4-8 per group 
 
A three-way ANOVA of age, diet and treatment group showed that there was no 
significant diet or age effect on paracetamol serum level, total hepatic GSH levels or 
CYP2E1 activity. 
3.3.6 Correlation between Frailty and Paracetamol Toxicity Outcomes 
To assess whether frailty affected the risk or mechanisms of chronic or subacute 
paracetamol hepatotoxicity, we investigated the correlation between frailty index and 
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associated outcomes, for old control diet+saline, paracetamol diet+saline (chronic) and 
control diet+paracetamol (subacute) mice (Figure 3.7). 
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Figure 3.7 Correlation between frailty index and (A) alanine aminotransferase (ALT), 
(B) necrosis, (C) cytochrome (CYP)2E1 activity, (D) total liver glutathione (GSH), (E) 
serum total protein, (F) serum albumin, (G) liver weight (as % body weight), and (H) 
serum alkaline phosphatase (ALP) for old (26.8±0.5 months) male C57BL/6 mice 
treated with either control diet for 6 weeks and 3 days of saline (control group, black), 
paracetamol (1.33g/kg feed) diet for 6 weeks and 3 days of saline (chronic group, light 
grey) or control diet for 6 weeks and 3 days of paracetamol , then (250mg/kg x 3/day) 
(sub-acute group, dark grey). Liver and serum collected 3 hours after the final 
paracetamol/saline dose. n=4-7 per group. 
 
There was no correlation between frailty and serum ALT, percentage of hepatic 
necrosis, microsomal CYP2E1 activity, total liver GSH and serum total protein for 
saline, chronic paracetamol or sub-acute paracetamol treated mice (Figure 3.7). There 
were significant strong negative correlations between frailty index and serum albumin 
(r=-0.80, p=0.05) and ALP (r=-0.92, p=0.01) for sub-acute paracetamol treated old mice 
only. There was a positive correlation between frailty index and liver weight (r=0.96, 
p=0.04) for chronic paracetamol treated old mice only. An ANCOVA showed no 
significant difference between the regression slopes for these outcomes (ALP, albumin, 
liver weight %) for treatment group, when adjusted for frailty index as a covariate. 
3.4 Discussion 
In this chapter, three clinically relevant paracetamol exposure situations were 
successfully modelled in young and old mice: chronic exposure to therapeutic levels of 
paracetamol; sub-acute exposure to supra-therapeutic doses of paracetamol over three 
days (most often an accidental overdose due to confusion with multiple paracetamol 
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containing medications or dose escalation for unrelieved pain); and a combination of 
these two exposures. We also tested whether NAC administered after sub-acute dosing 
to mimic the human clinical situation, would protect against hepatotoxicity. We found 
no effect of age or frailty on susceptibility to paracetamol toxicity from chronic or sub-
acute exposure to paracetamol in mice. We also found that chronic low-dose 
paracetamol exposure did not cause hepatotoxicity, as measured by serum ALT. Three 
days of sub-acute exposure caused significant hepatotoxicity, and neither a single nor 
double dose of NAC protected against this toxicity in young or old mice. 
 
In chapter 2 of this thesis it was found there was no change in the susceptibility of mice 
to paracetamol toxicity induced by acute paracetamol exposure in old age or frailty. As 
older patients are more likely to have non-acute exposures to paracetamol, the current 
chapter explored the effect of age and frailty on paracetamol toxicity risk to chronic or 
sub-acute paracetamol exposures. We found no effect of age of frailty on susceptibility 
to paracetamol toxicity from these types of exposures. Research confirming these 
findings in a clinical setting, would enable the optimisation of the use of chronic or 
repeated dose paracetamol for pain relief in the older population, as a relatively well-
tolerated analgesic, with no increased risk of toxicity in old age. Consistent with the 
results reported in chapter 2, in the current study there was no overall effect of frailty on 
the degree of paracetamol toxicity, microsomal CYP2E1 activity or total liver GSH, 
although there was a significant correlation of frailty index with serum ALP and 
albumin concentrations in the sub-acute paracetamol treated mice, which again may be 
attributed simply to frailty (Schalk et al. 2004; Kitamura et al. 2012). It would be 
interesting to look at the effect of a longer time-frame after paracetamol insult, a more 
functional mouse frailty assessment tool (Liu et al. 2013) or the dichotomisation of mice 
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into frail and non-frail groups on the correlation between frailty and degree of 
hepatotoxicity after non-acute exposures. 
 
Chronic paracetamol exposure in the diet for six weeks did not cause clinically 
detectable hepatotoxicity in young or old mice. There was no elevation in serum ALT, 
or DNA fragmentation, in the paracetamol diet group compared to those fed a control 
diet. Interestingly, however, several samples in the paracetamol diet fed groups, without 
sub-acute paracetamol treatment, had histological evidence of necrosis and/or 
inflammation. Although statistically, this was only a trend compared to the control diet 
group, it does suggest that the paracetamol diet may have caused some low-level 
damage in some mice which is not measurable in the circulation, at least not after 6 
weeks of treatment. Perhaps future studies modeling clinically therapeutic levels of 
paracetamol ingestion, may need to use higher daily doses of paracetamol, or a longer 
treatment period, in order to detect circulating levels of liver toxicity markers. Previous 
animal studies that have dosed once daily, via intraperitoneal injection or oral gavage, 
for 30-99 days with 75-300mg/kg showed no evidence of toxicity as assessed by liver 
function tests (de Meijer et al. 2012; Yisarakun et al. 2014; Kondo et al. 2012). Our 
study, which modelled a more clinically relevant exposure to paracetamol at regular 
intervals over a full day, as it was consumed in the diet, rather than once daily, appears 
to confirm these findings. Paracetamol serum levels were below the detectable level for 
paracetamol diet groups in the current study, despite the mice consuming daily 
paracetamol doses of up to 188mg/kg/day. A more sensitive method of testing serum 
paracetamol levels, such as high-performance liquid chromatography (HPLC), may 
enable the detection of serum paracetamol levels in future studies. Although the clinical 
method of paracetamol serum testing is reliable and accurate for the high paracetamol 
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levels seen in toxicity, it may be limited in detecting changes at lower serum levels. The 
lower limit of the Abbott Architect method used in the current study was 20 mol/L, 
and the lower limit of HPLC protocols to measure serum paracetamol can be 0.4mol/L 
(Jensen et al. 2004).  
 
Sub-acute paracetamol exposure over three days caused significant hepatotoxicity in 
young and old mice, as measured by biochemistry and histology. However, there was 
no clear combinatorial toxicity effect of paracetamol exposure in the diet plus sub-acute 
paracetamol exposure, although dietary pre-exposure to paracetamol certainly did not 
protect against subsequent sub-acute exposure in this study, as has been seen with 
higher dose pre-treatment in other studies (Ghanem et al. 2009; O’Brien et al. 2000; 
Shayiq et al. 1999). Perhaps the daily dose received in the current study was not enough 
to induce the protective pharmacokinetic changes that were seen in the previous studies, 
as we saw no change in total glutathione or CYP2E1 activity with chronic paracetamol 
treatment. Interestingly, despite no combined effect on the degree of paracetamol 
toxicity, it appeared that, in the old mice only, paracetamol diet prevented the reduction 
in total liver glutathione seen with sub-acute paracetamol treatment and control diet 
(Figure 3.4). However, this potentially protective effect did not translate into reduced 
toxicity in this group of old mice. 
 
The pre-treatment protective effect seen in the previous studies (Ghanem et al. 2009; 
O’Brien et al. 2000; Shayiq et al. 1999), was also not seen with the sub-acute 
paracetamol treatment in the current study. Although the mice were receiving doses of 
250mg/kg three times per day for three days, we did not see the protective 
pharmacokinetic changes seen with pre-treatment as reported by other studies. In our 
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study, total liver glutathione concentration was unchanged with sub-acute paracetamol 
treatment in most groups, which is consistent with previous acute paracetamol studies 
for this time frame (Mitchell et al. 1973; McGill et al. 2012). CYP2E1 activity was not 
changed with sub-acute paracetamol treatment in any group. Previous acute studies have 
found CYP2E1 activity to be reduced with 400mg/kg after four hours in mice (Snawder 
et al. 1994). In the studies of multiple paracetamol dose treatment, Shayiq et al. (1999) 
found that eight days of increasingly high daily doses of paracetamol treatment in 
BALB/c mice resulted in increased total liver glutathione levels, and reduced CYP2E1 
activity, which in term contributed to protection against toxicity from a larger acute 
dose on the ninth day. However it is important to note that genetic background can 
affect the outcomes, as Shayiq et al. (1999) saw 100% mortality 24 hours after a dose of 
500mg/kg paracetamol in BALB/c mice, whilst the C57BL/6 mice in the current study 
received 750mg/kg per day for three days with zero mortality. The other multiple 
paracetamol dose studies were conducted in rats, which also have altered paracetamol 
pharmacokinetics and toxicology compared to C57BL/6 mice (McGill et al. 2012), and 
found protection from toxicity with four days of low dose pre-treatment (O’Brien et al. 
2000; Ghanem et al. 2009), but increased toxicity with one moderate pre-treatment dose 
18 hours before a second dose (Kim et al. 2009). These results demonstrate that time-
frame, dose, species and genetic background (strain) can significantly affect 
paracetamol pharmacokinetics and toxicity, and more research is needed to clarify the 
effect of multi-day paracetamol dosing on susceptibility to hepatotoxicity in all ages. 
 
NAC did not protect against hepatotoxicity induced by sub-acute paracetamol exposure 
in young or old mice. As seen in chapter 4 of this thesis (Figure 4.3), and in previous 
studies (James et al. 2003; Daly et al. 2008), concurrent dosing of acute paracetamol 
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and NAC does protect against hepatotoxicity. NAC treatment did result in increased 
total liver glutathione concentrations in all mice, and decreased CYP2E1 activity, in old 
mice. These potentially protective pharmacokinetic changes, did not translate into 
protection in this study. It is likely that with three days of dosing, the paracetamol-
induced liver damage has progressed too far for these mechanisms to be protective. The 
high prevalence of inflammation in the sub-acute paracetamol treated groups would 
imply that the damage has progressed beyond the early stages of covalent protein 
NAPQI binding damage, and into the induction of inflammatory damage (Holt & Ju 
2006). A recent mouse study found that with delayed treatment, NAC also did not 
protect against acute paracetamol induced hepatotoxicity (Soeda et al. 2014).  NAC 
treatment also resulted in increased serum paracetamol levels in the current study, 
which implies reduced absorption of paracetamol into the liver. Perhaps, with 
concurrent paracetamol and NAC gavaging, there was also reduced NAC absorption 
that may have contributed to the lack of protection seen in this study. This finding of a 
lack of protection from NAC against sub-acute paracetamol dosing has important 
clinical implications in treating different types of paracetamol exposures. Our study 
indicates that for those who have taken staggered doses of paracetamol over several 
days, NAC may not be effective at preventing paracetamol hepatotoxicity. This finding 
is particularly important for older patients, as they are more likely to have the type of 
exposures, as explored here, against which NAC does not protect. 
 
In conclusion, this study found that, as we saw with acute paracetamol exposure in 
chapter 2, there is no effect of age or frailty on susceptibility to chronic or subacute 
paracetamol toxicity in mice. This chapter also found that in young and old mice, sub-
acute paracetamol exposure causes severe hepatotoxicity, which NAC does not reverse. 
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Furthermore, chronic low-level paracetamol exposure does not cause toxicity in young 
or old mice. Although it is re-assuring that chronic therapeutic paracetamol exposure 
does not cause toxicity, atleast in a mouse model, the clinical implications of NAC not 
protecting against sub-acute paracetamol induced toxicity are alarming, and highlight 
the need to develop new treatments for sub-acute paracetamol induced toxicity. The 
potential of interventions that delay ageing, as novel therapeutics to protect against 
paracetamol toxicity is explored in chapter four. 
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4 INVESTIGATION OF 
RESVERATROL AS A 
POTENTIAL THERAPY TO 
PROTECT AGAINST 
PARACETAMOL 
HEPATOTOXICITY 
4.1 Introduction 
The current clinically used therapy for paracetamol over-exposure, N-acetyl-cysteine 
(NAC), prevents liver toxicity by increasing glutathione stores to bind and de-toxify 
NAPQI (Corcoran, Racz, et al. 1985). Despite well-developed NAC treatment 
guidelines, there are patients who still develop liver failure from paracetamol toxicity, 
particularly those who present late or have repeated paracetamol ingestion (Craig et al. 
2012; Daly et al. 2008; Ferner et al. 2011). In chapter three of this thesis, it was found 
that NAC does not protect against toxicity induced by sub-acute paracetamol exposure 
in young or old mice. Thus there is a need for new therapies to treat paracetamol 
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toxicity from all types of exposures, and in all age groups. This chapter explores the 
potential for the healthspan increasing intervention, resveratrol, to protect against 
paracetamol hepatotoxicity. 
 
Resveratrol is a polyphenol, often named a calorie-restriction mimetic drug, as it has 
been shown to mimic some of the beneficial effects of calorie restriction. Resveratrol’s 
mechanism of action is direct allosteric activation of the NAD-dependent deacetylase 
sirtuin-1 (SIRT1) enzyme (Hubbard et al. 2013), an enzyme which plays a role in 
longevity and regulation of response to stressors and nutrients (Michan & Sinclair 2007; 
Raynes et al. 2013). Resveratrol may also activate 5’ adenosine monophosphate-
activated protein kinase (AMPK), an enzyme crucial for cellular energy homeostatis 
(Baur et al. 2006; Suchankova et al. 2009; Ido et al. 2015; Hardie 2011). A recent study 
has proposed that activation of these two pathways of resveratrol is dose-dependent, 
whereby low dose resveratrol directly activates SIRT1, which in turn results in 
activation of AMPK, and high-dose resveratrol activates AMPK independently of 
SIRT1 (Price et al. 2012). The protein complex, nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), which regulates DNA transcription in response 
to stimuli such as stress, is thought to be inhibited by resveratrol (Ren et al. 2013). 
 
Resveratrol may have a variety of potentially protective effects upon factors involved in 
the paracetamol toxicity pathway including the potential to reduce CYP2E1 activity 
(Wu et al. 2013), induce NQO1 activity (Hsieh et al. 2006) and induce phase II 
metabolic enzymes (Cao & Li 2004), as well as causing anti-oxidant effects (Yu et al. 
2012), improvements in mitochondrial function (Baur et al. 2006; Lagouge et al. 2006; 
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Hubbard et al. 2013), anti-inflammatory effects (Yoshizaki et al. 2010) and the 
induction of autophagy (Yu et al. 2012). 
Several animal studies have investigated the potential protection with resveratrol from 
paracetamol toxicity and are summarised in section 1.4.5.2. Noticeably the mouse 
strain, paracetamol and resveratrol timing, doses, vehicles and routes of administration 
as well as outcome measurements varied significantly across these studies (detailed in 
Table 1.3). Furthermore only one of these studies investigated the downstream effects 
of resveratrol and confirmed its molecular action in these animal models (Wang et al. 
2015). Thus confirmation and further examination of the mechanisms of the protective 
role of resveratrol against paracetamol toxicity would be beneficial. The potentially 
protective effects of resveratrol in old age versus young have also not been explored, 
and are particularly important given that older people are more at risk of the type of 
over-exposures that the current therapy does not protect against. Furthermore, there are 
changes to SIRT1 and AMPK in old age, which may affect the protective mechanisms 
of resveratrol (Salminen & Kaarniranta 2012). 
 
This study aimed to investigate the potential protection of resveratrol against 
paracetamol toxicity in three models of paracetamol toxicity: primary mouse 
hepatocytes, young animals concurrently exposed to resveratrol and paracetamol, and 
young and old animals pre-treated with resveratrol in their diet then exposed to 
paracetamol. 
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4.2 Methods 
4.2.1 Cell Culture Methods Optimisation 
Optimisation of the cell culture model for paracetamol toxicity required some 
troubleshooting. The conditions tested, with justification and results, are summarised in 
Table 4.1. The final conditions used for the experimental results presented in this 
chapter are explained in more detail in section 4.2.3. 
 
Table 4.1 Optimisation of cell culture model of paracetamol toxicity. DMEM= 
Dulbecco’s modified eagle medium, MTT= 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, FCS= Fetal calf serum, DMSO= dimethyl sulfoxide, 
CYP2E1 = cytochrome 2E1. 
Cell	type	 Conditions	 Justification	 Result	
HepG2	cells,	obtained	
from	the	Kolling	
Institute	
DMEM	medium	with	
10%	FCS,	100U/ml	
penicillin,	0.1mg/ml	
streptomycin,	2mM	L‐
glutamine	
Establishing	confluent	
cells	
Established	confluent	
cells	
HepG2	cells,	obtained	
from	the	Kolling	
Institute	
As	above	plus	4mM	or	
10mM	Paracetamol	
Tested	toxicity	of	cells	
with	MTT	
Establishing	toxicity	
model	
No	reduction	in	cell	
survival	with	
paracetamol	
treatment	
HepG2	cells,	obtained	
from	the	Kolling	
Institute	
Removed	10%	FCS	
from	media,	added	
10mM	paracetamol	
Tested	toxicity	with	
MTT	
Establishing	toxicity	
model	
Approximately	10%	
reduction	in	cell	
survival	with	
paracetamol	
treatment	–	lower	
than	expected	
HepG2	cells,	obtained	
from	the	Kolling	
Institute	
Removed	10%	FCS	
from	media,	added	
10mM	paracetamol	
Tested	toxicity	of	cells	
with	LDH	assay	in	
media	
Testing	different	
toxicity	outcome	
measurement	
No	reduction	in	cell	
survival	with	
paracetamol	
treatment	
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HepG2	cells,	obtained	
from	Concord	Hospital	 As	above	
Testing	different	
source	of	HepG2	cells	
An	increase	in	cell	
survival	with	
paracetamol	
treatment	–	opposite	
to	what	expect	‐	
suspect	paracetamol	is	
interfering	with	the	
LDH	assay	(Xu	et	al.	
2003)	
HepG2	cells,	obtained	
from	Concord	Hospital	
As	above,	plus	20mM	
paracetamol	
Tested	toxicity	of	cells	
with	MTT	assay	
Establishing	toxicity	
model	
20mM	paracetamol	
treatment	reduced	
survival	by	
approximately	30%,	
with	a	lot	of	variability	
HepG2	cells,	obtained	
from	Concord	Hospital	
As	above,	plus	0.5%	
DMSO	and	50µM	
Resveratrol	
Tested	toxicity	of	cells	
with	MTT	assay	
Testing	potential	
resveratrol	protection	
DMSO	as	vehicle	
protects	against	
paracetamol	toxicity	‐	
CYP2E1	inhibitor	
(Jaeschke	et	al.	2011)	
HepG2	cells,	obtained	
from	Concord	Hospital	
As	above,	plus	0.03%	
ethanol	and	50µM	
Resveratrol	
Tested	toxicity	of	cells	
with	MTT	assay	
Testing	potential	
resveratrol	protection,	
and	establishing	
toxicity	model	
Ethanol	as	vehicle	
does	not	affect	
paracetamol	toxicity.	
Reduction	in	viability	
with	paracetamol	
treatment	not	
consistently	seen	–	
HepG2	cells	have	too	
little	CYP2E1	activity	
to	induce	toxicity	
(Zhuge	et	al.	2003).	
Primary	Hepatocytes	
isolated	with	Liberase	
(Roche,	
#5401119001)	
DMEM	medium	with	
10%	FCS,	100U/ml	
penicillin,	0.1mg/ml	
streptomycin,	2mM	L‐
glutamine,	plus	added	
20mM	Paracetamol,	
0.03%	ethanol	and	
50µM	Resveratrol.	
Tested	toxicity	of	cells	
with	MTT	
Testing	new	cell	type	–	
primary	hepatocytes	
Cell	viability	very	low	
for	all	conditions	–	
unsuccessful	
hepatocyte	isolation	
Primary	Hepatocytes	
isolated	with	Liberase	
(Roche,	
#5401119001)	
As	above,	but	washed	
cells	with	Percoll	to	
isolate	only	viable	
hepatocytes,	plated	at	
0.03x106cells/48	well	
and	did	not	treat	cells	
Optimising	isolation	
method	for	primary	
hepatocytes	
Cell	viability	of	control	
cells	much	better	
(greater	than	90%),	
but	amount	of	cells	
isolated	is	low	(over‐
digestion	of	the	liver)	
and	cells	over‐
crowded	and	unevenly	
distributed	in	wells	
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Primary	Hepatocytes	
isolated	with	Liberase	
(Roche,	
#5401119001)	
As	above,	plated	at	
0.015x106cells/48	
well	
Optimising	isolation	
method	for	primary	
hepatocytes	
Not	enough	cell	
numbers	isolated	and	
viability	still	low	
Primary	Hepatocytes	
isolated	with	
Collagenase	(Type	IV,	
Sigma,	C1539)	
As	above,	with	no	
percoll	wash	and	
added	20mM	
Paracetamol,	0.03%	
ethanol,	25nM	NAC	
and	50µM	Resveratrol.	
Tested	toxicity	of	cells	
with	MTT	
Testing	new	
hepatocyte	isolation	
method	
Cell	viability	90%	with	
media,	and	isolated	
lots	of	cells	(liver	not	
over‐digested).	A	lot	of	
variability	in	results	
with	MTT	assay	
Primary	Hepatocytes	
isolated	with	
Collagenase	(Type	IV,	
Sigma,	C1539)	
As	above,	but	plated	
cells	in	24	well	plates	
with	4	wells	per	
condition,	or	96	well	
plates	with	6	wells	per	
condition	at	0.025	x	
106	cells/cm2	to	
reduce	variability	
Establishing	toxicity	
model	
Optimised	conditions	
used	for	rest	of	the	
hepatocyte	
experiments	
4.2.2 Animals 
For the hepatocyte isolation and concurrent resveratrol experiment, male C57BL/6 mice 
were obtained from the Kearns Facility (Sydney, NSW) (hepatocyte experiment age= 
4.0±0.6 months n=10; concurrent experiment age=3.7±0.6 months, n=19). They were 
fed Rat and Mouse Premium Breeder Diet (Gordon’s Specialty Stockfeeds, NSW, 
Australia). These mouse numbers were chosen to allow n=3 per mouse group, as these 
were pilot studies to assess whether a costly and limited group of old mice should be 
used for these experiments. 
 
For the resveratrol pre-treatment experiments, male C57BL/6 mice were aged at the 
National Institute on Aging (NIA, Baltimore, MD) (age=18.1±0.02 months, n=25), and 
young C57BL/6 mice were obtained from the NIA (age=6±0.0 months, n=23). The 
median lifespan of C57BL/6 mice is 26-30 months. They were fed standard feed 
(2018X 18% Protein Diet, Harlan Teklad, Indiannapolis IN). The mouse numbers 
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chosen for this study allowed for n=6 per group. This number was chosen based on 
previous work by Miller et al (2005), to account for expected variability and to detect a 
clinically significant difference in the main outcome of serum ALT. Unfortunately, the 
loss of more old mice than expected before the experimental timeframe required the use 
of n=4-5 for some old mouse groups.  
 
All mice were group housed in cages of 4-5 with ad libitum access to food and water. 
Animal rooms were maintained on a 12 hr light/dark cycle at 20-22°C, and 30-70% 
humidity. Animals were randomly assigned to treatment or control groups prior to the 
treatment day. All animal protocols were approved by the Animal Care and Use 
Committee of the National Institute on Aging (429-TGB-2017 and 405-TGB-2016) or 
the Animal Care Ethics Committee at Royal North Shore Hospital. 
4.2.3 Hepatocyte Isolation and Treatment 
Primary hepatocytes were isolated from male 4-month-old C57BL/6 mice by 
collagenase perfusion (Seglen 1976). Mice were anaesthetized with an i.p injection of 
ketamine (75 mg/kg, Cenvet Australia, #K1500) and xylazine (10 mg/kg, Cenvet 
Australia, #X5010). A midline laparotomy was performed and 150U Heparin (Pfizer, 
#2112105) injected into the Inferior Vena Cava. The portal vein was then cannulated 
with a 23G intravenous catheter (Becton Dickinson, Sydney, Australia) through which 
the liver was perfused in-situ at 1–1.5 mL/min/g of liver with Hanks Balanced Salt 
Solution without Ca2+ (HBSS/- Ca2+, 37°C, Life Technologies #14170161), to clear the 
liver of blood. The liver was then perfused with a solution of 0.67mg/ml Collagenase IV 
(Sigma #C5139) and 5% fetal calf serum (FCS, Gibco #10082-147) in Hanks Balanced 
Salt Solution with Calcium (HBSS/+Ca2+, 37°C, Life Technologies #14025134) to 
digest the liver. The liver was quickly removed with sterile surgical equipment, 
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transferred to a biohood, and macerated in a sterile petri dish with approximately 15mls 
of the collagenase solution supplemented with 0.04μL/ml DN’ase (Invitrogen, 
#18047019). The solution was incubated for 10 minutes in humidified 5% CO2, 95% air 
at 37°C, then filtered through a 100μm filter. The solution was centrifuged for 5 minutes 
at room temperature at 70g, before removing the supernatant, and re-suspending the cell 
pellet in approximately 45 mls of dulbecco’s phosphate-buffered saline (DPBS)/+Ca2+ 
(Invitrogen, #14040182). This wash step was repeated three times. Cells were 
resuspended in approximately 3mls of dulbecco’s modified eagle medium (DMEM) 
(low-glucose, phenol-red free, Sigma Aldrich #D5921), supplemented with 10% FCS, 
2mM L-glutamine (Invitrogen), 100U/ml penicillin and 0.1mg/ml streptomycin 
(Invitrogen). Isolated cell viability was determined by trypan blue exclusion assay, 
immediately after isolation, and only cell preparations with viability greater than 80% 
were plated. Hepatocytes were plated on type 1 collagen coated 96 or 24-well culture 
dishes (Life Technologies, #A1142802), at a density of 0.025 x 106 cells/cm2, in 
supplemented medium. Hepatocytes were incubated in humidified 5% CO2, 95% air at 
37°C for 2.5 hours, then the culture medium was changed to FCS-free supplemented 
medium and cells incubated overnight (16 hours). 
 
Paracetamol toxicity was induced in the hepatocytes by adding 20mM paracetamol in 
DMEM, either alone or in combination with the treatments. The treatments were 
resveratrol (1-100µM in 0.5% Ethanol, Sigma #R5010), NAC (20mM in 0.5% ethanol, 
Sigma #A9165) or vehicle (0.5% ethanol). Hepatocytes were plated in 6 separate wells 
per condition for 96 well plates, and 4 wells per condition for 24 well plates. 
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4.2.4 Cell Viability Assays 
Hepatocyte survival was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay 24 hours post paracetamol administration. 
Media containing MTT (0.001g /ml, Sigma Aldrich #M5655) was added to the 
hepatocytes, and they were incubated at 37°C for 1 hr 15 mins. The supernatant was 
collected, 250ul propanol added to cells, and cells shaken at room temperature for 20 
mins. 100ul from each sample was added to an eppendorf containing 450ul propanol 
and 35ul NaOH. The absorbance of each sample was read at 595nm. Cell viability was 
calculated as a mean % of DMEM control for each condition on each 96 well plate and 
2-10 hepatocyte isolations and treatments were completed for each condition. 
 
Hepatocyte survival was confirmed with propidium iodide staining. Cells were fixed 
with 4% paraformaldehyde for two hours, 24 hours after paracetamol administration. 
Cells were then washed with PBS, incubated with a 1g/l solution of propidium iodide 
(Invitrogen #P3566), and then visualized on an inverted fluorescence microscope (Leica 
DM LB 100T microscope with attached Leica DFC480 digital camera, Sydney, 
Australia). As propidium iodide is membrane impermeant in viable cells, cells with 
strong nuclear staining were identified as non-viable. 
4.2.5 Concurrent Resveratrol and Paracetamol Treatment of Animals 
Male C57BL/6J mice from the Kearns facility were fasted overnight (16 hours), then 
dosed with 700mg/kg paracetamol or saline vehicle via oral gavage between 8am and 
10am. Immediately following this mice were dosed with a second oral gavage of either 
resveratrol (30mg/kg in corn oil), corn oil (vehicle, Sigma Aldrich, #C8267), or NAC 
(1200mg/kg in saline). Food was returned to the mice after dosing. Six hours after 
dosing mice were anaesthetized with an i.p injection of ketamine (75 mg/kg, Cenvet 
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Australia, #K1500) and xylazine (10 mg/kg, Cenvet Australia, #X5010). A midline 
laparotomy was performed and blood taken from the Inferior Vena Cava. The portal 
vein was then cannulated with a 21G intravenous catheter (BD, Sydney, Australia) 
through which the liver was perfused in-situ at 1–1.5 mL/min/g of liver with 
oxygenated Krebs-Henseleit bicarbonate buffer (95% O2–5% CO2, 37°C). Sections of 
the liver were snap frozen in liquid nitrogen for subsequent enzyme activity assays, 
protein extraction and fixed in 10% neutral formalin for subsequent histopathological 
analysis. 
 
This paracetamol dose is higher (700mg/kg) than the dose used to induce acute 
hepatotoxicity in experiments done on mice sourced from the NIA (300mg/kg) (See 
sections 2.2.3, 4.2.6, 5.2.2). Pilot experiments were conducted in young male C57BL/6 
mice, sourced from the Kearns facility, to determine the dose at which there was 
consistent (seen in all treated mice) severe hepatotoxicity (as assessed by serum ALT 
levels >5 times the upper limit of normal = 275U/L). The number of mice assessed at 
each dose, and the resultant ALT results are shown in Table 4.2. The dose of 700mg/kg 
(Panadol Color-free Baby Drops, 100mg/ml, GlaxoSmithKline, Australia) given via 
oral gavage, with euthanasia at 6 hours, gave consistent severe hepatotoxicity results, 
and was used for the rest of the experiments. 
 
Table 4.2 Pilot experiments to determine the acute paracetamol dose necessary to 
induce consistent severe hepatotoxicity in young male C57BL/6 mice sourced from the 
Kearns facility. ALT = Alanine aminotransferase. 
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Paracetamol	dose	
and	route	of	
administration	 Time	of	euthanasia	
Number	of	mice	
tested	
ALT	results	for	all	
mice	(U/L)	
500mg/kg	in	saline,	i.p	 4	hours	 3	 95/270/38	
600mg/kg	(Panadol	
Color‐free	Baby	Drops,	
100mg/ml,	
GlaxoSmithKline),	
orally	
6	hours	 3	 118/9728/321	
700mg/kg	(Panadol	
Color‐free	Baby	Drops,	
100mg/ml,	
GlaxoSmithKline),	
orally	
6	hours	 3	 531/2960/5876	
 
4.2.6 Dietary Resveratrol Treatment of Animals 
Male C57BL/6J mice from the NIA were randomized at 6 months of age (young group) 
or 18 months of age (old group) to either a standard AIN-93G diet (SD; Dyets, Inc, 
Bethlehem PA) (young n=12, old n=16), or an AIN-93G diet supplemented with 
resveratrol (RSV) at a concentration of 1.33g/kg feed, (approx. 100mg/kg/day for mice) 
(young n=11, old n=9), both diets fed ad libitum. Mice remained on their respective 
diets for 3-4 months, at which time they were fasted overnight (16 hours), then dosed 
with 300mg/kg paracetamol (Panadol Color-free Baby Drops, 100mg/ml, 
GlaxoSmithKline, Australia) or saline vehicle via oral gavage. This paracetamol dose 
was chosen as a standard dose to induce toxicity in C57BL/6 mice (McGill et al. 2012). 
Six hours after treatment serum and tissue were collected as described above. Body 
weight and food intake for all mice was monitored biweekly whilst on the experimental 
diets. 
4.2.7 Serum Biochemistry 
Blood was stored and serum extracted as detailed in section 2.2.4, serum liver function 
tests (total protein, albumin, bilirubin, alkaline phosphatase (ALP), gamma 
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glutamyltransferase (GGT)) and serum paracetamol concentrations were measured by a 
National Association of Testing Authorities accredited hospital laboratory, PaLMS 
(Pacific Laboratory Medicine Services) at Royal North Shore Hospital (Sydney, 
Australia) using an Architect i1000SR immunoassay analyser (Abbott Diagnostics, IL, 
USA). The lower limit of the paracetamol serum concentration test was 20μmol/L. 
Vitamin B6 is added to the ALT activity assay to accommodate for the age related 
decline in this vitamin, an integral cofactor for the assay (Krishnamurthy et al. 1967; 
Bordoni et al. 1998). 
 
4.2.8 Histology 
Fixed liver tissue was embedded in paraffin, 5µm sections were cut on a microtome and 
mounted on slides. Slides were stained with Haemotoxylin and Eosin in the National 
Association of Testing Authorities accredited hospital laboratory of the Pathology 
department of Royal Prince Alfred Hospital, Sydney, Australia. Histopathology was 
scored by an anatomical pathologist, who was blinded to the age and treatment of the 
samples. Necrosis was scored as a percentage of the liver tissue on each slide. Images 
were taken on an Olympus BX51 microscope connected to an Olympus DP26 camera 
(Olympus, Sydney, Australia). 
4.2.9 Biochemical Examination of Frozen Liver Samples 
Liver microsomes were isolated according to the method of Shoaf et al. (1987) and 
CYP2E1 activity was measured according to the method of Roberts et al. (1995) and 
Mach et al. (2014), as detailed in section 2.2.6. 
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Liver concentrations of total glutathione were determined with a Glutathione Assay kit 
(Cayman Chemicals, #703002) as detailed in section 2.2.6. 
4.2.10 Biochemical Examination of Hepatocytes 
Hepatocyte concentrations of total glutathione were determined with a Glutathione 
Assay kit (Cayman Chemicals, #703002), as detailed above, 24 hours after paracetamol 
treatment. Cells for each treatment (4 wells of a 24 well plate) were prepared according 
to the manufacturer’s instructions. Cells were scraped off plates in media and the 
supernatant and cell suspension for each condition collected into an eppendorf. The 
cells were centrifuged for 10mins at 1500g at 4°C and the supernatant discarded. The 
cells were re-suspended in PBS supplemented with 1mM EDTA, then frozen at -80°C 
for 30 mins, and thawed at room temperature for 30 minutes. Cells were then 
homogenised, centrifuged at 10,000g for 15 minutes at 4°C and the supernatant 
collected. Standards and samples were added to a 96 well plate (50ul), then 150 ul of 
assay cocktail (MES buffer plus cofactor mixture, enzyme mixture, and DTNB) was 
added and the plates incubated in the dark with absorbance measured at 405nm after 25 
minutes. 
4.2.11 Western Blots 
AMPK and phosphorylated AMPK (pAMPK) protein levels were measured in liver 
from the concurrent resveratrol and paracetamol experiment mice. Liver was 
homogenized with lysis buffer (radioimmunoprecipitation (RIPA) buffer with protease 
inhibitor (complete EDTA-free, Roche, #05892953001), 100uM Na3Vo4 and 50mM 
NaF) then centrifuged at 10,000g for 10 minutes at 4ºC and the supernatant collected. 
Protein levels in the cell lysate were measured with a Pierce bicinchoninic acid (BCA) 
Protein Assay Kit (Life Technologies, #23225). Samples were then diluted into a 0.75 
mg/mL concentration with 25% Laemmli buffer and 10% dithiothreitol (DTT). 15g of 
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proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) under reducing conditions and then transferred to nitrocellulose 
membranes. Membranes were blocked for one hour in 5% skim milk in 0.1% Tween-20 
tris-buffered saline (TBS-T). Membranes were washed in TBS-T, and incubated 
overnight at 4ºC in primary antibody solution (5% bovine serum albumin (BSA), TBS-
T). Primary antibodies used were AMPK (1:1000, Cell Signaling, #CS2532) p-AMPK 
(1:1000, cell signalling, #CS2531), and 14-3-3 (1:1000 cell signalling, 
#8312). Membranes were washed and incubated for one hour in secondary antibody 
solution (5% skim milk in TBS-T, rabbit secondary antibody 1:10,000, cell signalling, 
#7074P2). Membranes were washed and analysed on a ImageQuant LAS 4000 machine 
(GE Healthcare Life Sciences). Densitometry was performed using ImageJ (v 1.47) and 
14-3-3 was used as the loading control. 
 
SIRT1, AMPK, p-AMPK, NFB and p-NFB protein levels were measured in liver 
from the resveratrol diet experiment mice. Liver was homogenised in lysis buffer (RIPA 
buffer supplemented with EDTA and ethylene glycol tetraacetic acid (EGTA) (Boston 
BioProducts), protease inhibitor cocktail (Sigma-Aldrich #P8340), phosphatase 
inhibitor Cocktail 2 and 3 (Sigma-Aldrich #P5726 and #P0044), and Trichostatin A 
(Sigma-Aldrich #T1952)) then centrifuged at 14,000g for 15 minutes at 4ºC, and the 
supernatant collected. Protein concentration was quantified using the Quickstart 
Bradford assay (Bio-Rad, #500-0201). 30g of protein was separated by SDS-PAGE 
under reducing conditions and then transferred to nitrocellulose membranes. 
Membranes were blocked in 5% BSA for one hour at room temperature, and then 
incubated overnight at 4ºC with the primary antibody in 5% milk. Primary antibodies 
used were SIRT1 (1:1000, Sigma, #S5196), AMPK (1:1000, Cell Signaling, #CS2532), 
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p-AMPK (1:1000, Cell Signaling, #CS2531), NFB (1:2000, Abcam, #ab32536;), p-
NFB (1:1000, Cell Signaling, #CS3031s). Membranes were washed, then incubated in 
secondary antibody solution (5% skim milk in PBS-T, rabbit secondary antibody 
1:5,000, GE healthcare, Pascataway, NJ) for one hour at room temperature. The 
membranes were washed then visualization of the immunoreactive bands was 
performed using the ECL Prime Western blotting detection system (GE Healthcare, 
Pascataway, NJ). Densitometry was performed using ImageJ (v 1.47). Ponceau S 
(Sigma Aldrich, St Louis MO) was used as a loading control and data of each group was 
normalized to the young control diet fed saline treated group. 
4.2.12 Statistics 
Data are expressed as mean ± SEM unless otherwise indicated. Differences between 
mean values across groups for hepatocyte and concurrent resveratrol/paracetamol 
experiments were calculated with a Kruskal-Wallis non-parametric test, then Mann-
Whitney U-tests where appropriate, due to non-normal distribution of the data. 
Differences between mean values across groups for resveratrol diet experiments were 
calculated with one- two- or three- way ANOVA with Tukey’s HSD post-hoc test or t-
tests where appropriate. The prevalence of necrosis in each treated group compared to 
the corresponding saline group was compared with Chi squared tests. Data analysis was 
completed using the statistics program SPSS (Version 21.0, SPSS Inc., Chicago, 
Illinois, USA) and GraphPad Prism (Version 6.04, GraphPad Software, La Jolla 
California USA). 
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4.3 Results 
4.3.1 Primary Hepatocyte Results 
Treatment of primary mouse hepatocytes with 20mM paracetamol resulted in a reduced 
cell viability of 60.7±6.2% compared to treatment with media alone (p<0.001). The 
addition of 0.5% ethanol (resveratrol vehicle) to the media did not reduce cell viability, 
and 0.5% ethanol plus 20mM paracetamol treatment resulted in similar cell viability to 
20mM paracetamol alone. As such, 0.5% ethanol was used as the control for the rest of 
the experiments. Concurrent treatment with 20mM NAC and 20mM paracetamol (with 
0.5% ethanol), maintained cell viability at control levels (Figure 4.1A). 
 
Treatment of primary mouse hepatocytes with 1-100µM resveratrol did not change cell 
viability compared to control (Figure 4.1B). Concurrent treatment with 20mM 
paracetamol and 1-100µM resveratrol resulted in no increase in cell viability compared 
to treatment with 20mM paracetamol, in 0.5% ethanol, alone (Figure 4.1B).  
 
Hepatocyte total glutathione concentration was reduced by approximately 35% with 
20mM paracetamol treatment compared to control (p=0.05). Compared to control, 
glutathione concentration was also decreased in cells with 20mM paracetamol plus 5, 25 
and 100uM resveratrol (p<0.05), whilst treatment with 20mM paracetamol plus 20mM 
NAC did not result in decreased cell glutathione concentration (Figure 4.1B). 
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Figure 4.1 Primary mouse hepatocyte viability as a percentage of dulbecco’s modified 
eagle medium (DMEM) control (A, B), and total hepatocyte glutathione (GSH) (C) with 
ethanol (0.5%), N-acetyl cysteine (NAC, 20mM) and/or resveratrol (0.5% ethanol 
vehicle, 1-100µM) alone or plus paracetamol (20mM) treatment after 24 hours. Primary 
hepatocytes isolated from 4 month old male C57BL/6 mice via collagenase perfusion. 
Viability measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. All data are presented as mean ± SEM of n=3-9 animals per group. 
#p<0.05 compared to DMEM treatment only, *p<0.05 compared to ethanol treatment 
group 
 
The cell viability results as measured by the MTT assay were confirmed with propidium 
iodide (PI) staining. 20mM paracetamol treatment resulted in increased nuclear PI 
* * * * * * 
*
* 
# 
* * *
* * *
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staining, than treatment with vehicle (0.5% ethanol) alone. Treatment with 20mM NAC, 
either alone or with paracetamol, did not result in nuclear PI staining. Increased nuclear 
PI staining was also seen with 25uM resveratrol plus paracetamol treatment, but not 
with 25uM resveratrol treatment alone (Figure 4.2). 
 
 
Figure 4.2 Representative images of primary mouse hepatocytes treated with (A) 
Vehicle (0.5% ethanol), (B) 20mM Paracetamol  + 0.5% ethanol, (C) 20mM N-acetyl 
cysteine (NAC, in 0.5% ethanol), (D) 25uM Resveratrol (in 0.5% ethanol), (E) 20mM 
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NAC + 20mM Paracetamol + 0.5% ethanol or (F) 25uM Resveratrol (in 0.5% ethanol) 
+ 20mM Paracetamol, for 24 hours, fixed and stained with propidium iodide. Red 
arrows indicate nuclear PI staining. Primary hepatocytes isolated from 4 month old male 
C57BL/6 mice via collagenase perfusion. Images taken at 200X magnification on a 
Leica DM LB 100T microscope with attached Leica DFC480 digital camera (Leica, 
Sydney, Australia). 
4.3.2 Concurrent Resveratrol and Paracetamol Treatment in Mice Results 
Weights and serum biochemistry results for each mouse treatment group are shown in 
Table 4.3. A Kruskal-Wallis test across the six treatment groups, with Mann-Whitney 
post-hoc testing, showed no difference in weights, or total protein, albumin, ALP or 
GGT results across any of the groups. Serum bilirubin was significantly increased in 
paracetamol+corn oil treated mice compared to all saline treated groups (p=0.006). 
 
Table 4.3 Weights and serum biochemistry results for young (3.7±0.6 months) male 
C57BL/6 mice treated with 700mg/kg paracetamol (via oral gavage) or saline control, 
and concurrent corn oil vehicle, resveratrol (RSV, 30mg/kg in corn oil), or N-acetyl 
cysteine (NAC, 1200mg/k). Serum and liver collected 6 hours after dosing. Data 
expressed as mean (SD). *p<0.05 compared to all saline treated groups. ALP= Alkaline 
phosphatase, GGT= Gamma glutamyltransferase. 
Treatment	1	 Saline	 Paracetamol	
Treatment	2	 Corn	Oil	
n=3	
NAC	
n=3	
RSV	
n=3	
Corn	Oil	
n=4	
NAC	
n=3	
RSV	
n=3	
Total	protein	
(g/L)	 46	(2.8)	 48.7	(2.1)	 51.0	(3.6)	 57	(7.5)	 49.3	(1.5)	 57.0	(9.5)	
Albumin	
(g/L)	 25.5	(2.1)	 27.3	(1.5)	 27.3	(0.6)	 33.0	(4.9)	 28.0	(1.0)	 33.0	(6.0)	
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Bilirubin	
(umol/L)	 2.0	(0.0)	 2.3	(0.6)	 1.3	(0.6)	 22.5	(4.2)*	 4.3	(0.6)	 12.0	(3.0)	
ALP	(U/L)	 124.0	(25.5)	 124.3	(6.4)	
131.0	
(9.5)	 157	(16.9)	 133	(15.7)	
192.7	
(95.4)	
GGT	(U/L)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 12.0	(15.6)	
Body	weight	
(g)	 21.7	(0.5)	 23.1	(1.2)	 23.5	(1.0)	 23.2	(2.8)	 24.1	(0.6)	 23.6	(1.1)	
Liver	weight	
(%	body	
weight)	
5.7	(0.1)	 5.4	(0.3)	 5.6	(0.4)	 5.0	(0.4)	 5.1	(0.2)	 4.7	(0.3)	
 
A Kruskal-Wallis non-parametric test shows a significant difference across treatment 
groups for serum ALT (p=0.024) (Figure 4.3). Treatment with acute paracetamol 
resulted in a trend towards increased ALT serum concentration, compared to saline 
treated controls (p=0.06), whilst concurrent NAC treatment maintained ALT serum 
concentration at control levels (Figure 4.3). Concurrent resveratrol treatment also 
resulted in a trend towards increased ALT serum concentration, compared to saline 
treated controls (p=0.08). Although the post-hoc statistics were only trending towards 
significance, due to small sample size, the degree of protection against paracetamol 
toxicity seen with NAC treatment and the lack of protection with resveratrol treatment, 
is convincing.  
 
Histopathological analysis showed that paracetamol+corn oil treatment resulted in 
detectable necrosis six hours after treatment in one mouse, and one mouse in the 
paracetamol+resveratrol group showed mild detectable inflammation. 
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Figure 4.3 Serum alanine aminotransferase (ALT) concentration for young (3.7±0.6 
months) male C57BL/6 mice treated with 700mg/kg paracetamol (via oral gavage) or 
saline control, and concurrent corn oil vehicle, resveratrol (RSV, 30mg/kg in corn oil), 
or N-acetyl cysteine (NAC, 1200mg/k). Serum collected 6 hours after dosing. Data 
expressed as mean±SEM. *=p<0.10 compared to saline+corn oil group. n= 3-4 per 
group. 
 
Total liver glutathione was reduced in the paracetamol+corn oil, and 
paracetamol+resveratrol groups compared to all other groups (p=0.008) (Figure 4.4A). 
There was no difference in CYP2E1 activity across any treatment group (Figure 4.4B). 
 
* 
*
* *
n=3 n=4 n=3 n=3 n=3 n=3
n=3 n=4 n=3 n=3 n=3 n=3
n=3 n=4 n=3 n=3 n=3 n=3
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Figure 4.4 Total liver glutathione (GSH) (A) and liver cytochrome (CYP)2E1 activity 
(B) for young (3.7±0.6 months) male C57BL/6 mice treated with 700mg/kg 
paracetamol (via oral gavage) or saline control, and concurrent corn oil vehicle, 
resveratrol (RSV, 30mg/kg in corn oil), or N-acetyl cysteine (NAC, 1200mg/k). Liver 
collected 6 hours after dosing. Data expressed as mean±SEM. *=p<0.05 compared to 
saline+corn oil, saline+N-acetyl cysteine, saline+resveratrol and paracetamol+N-acetyl 
cysteine groups. n= 3-4 per group. 
 
Western blots for pAMPK and AMPK protein expression for mice treated with 
paracetamol or saline and corn oil or resveratrol are shown in Figure 4.5. Although it 
appears that there was a trend towards an increase in the ratio of pAMPK to AMPK 
expression in the paracetamol groups compared to their corresponding saline treated 
groups, this was not significant (Figure 4.6). 
 
 
Figure 4.5 Western blots for 5' adenosine monophosphate-activated protein kinase 
(AMPK), phosphorylated AMPK, and loading control 14-3-3 for young (3.7±0.6 
months) male C57BL/6 mice treated with 700mg/kg paracetamol (via oral gavage) or 
saline control, and concurrent corn oil vehicle or resveratrol (RSV, 30mg/kg in corn 
oil). Liver collected 6 hours after dosing.  
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Figure 4.6 phosphorylated 5' adenosine monophosphate-activated protein kinase 
(pAMPK)/AMPK protein expression ratio for young (3.7±0.6 months) male C57BL/6 
mice treated with 700mg/kg paracetamol (via oral gavage) or saline control, and 
concurrent corn oil vehicle or resveratrol (RSV, 30mg/kg in corn oil). Liver collected 6 
hours after dosing. Data expressed as mean±SEM normalised to saline-treated control. 
n=2-3 per group. 
4.3.3 Dietary Pre-Treatment with Resveratrol Results 
Weights, food consumed and serum biochemistry results for each mouse treatment and 
diet group are shown in Table 4.4 for young mice and Table 4.5 for old mice. A one 
way ANOVA across the four treatment groups for each age group, showed no 
difference in weights, or total protein, albumin or GGT results across any of the groups. 
For both young diet groups, and the old control diet group, bilirubin was significantly 
increased with paracetamol treatment compared to saline treatment (Table 4.4 and 
Figure 4.4). For old resveratrol diet mice only, ALP was significantly increased with 
paracetamol treatment compared to saline treatment (Figure 4.4). A three-way ANOVA 
of diet, treatment and age showed a significant age*treatment interaction effect only for 
serum bilirubin. 
 
n=4 n=3 n=3 n=3 
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Table 4.4 Weights and serum biochemistry results for young (6.0±0.0 months) male 
C57BL/6 mice exposed to either control diet or resveratrol diet (RSV, 1.33g/kg feed) 
for 3-4 months, then treated with paracetamol (300mg/kg via oral gavage) or saline. 
Liver and serum collected after 6 hours. Data expressed as mean (SD). *p<0.05 
compared to corresponding saline treated group. ALP= Alkaline phosphatase, GGT= 
Gamma glutamyltransferase.  
	
Control	Diet	 Resveratrol	Diet	 One	way	
ANOVA	
Saline	
n=6	
Paracetamol	
n=6	
Saline	
n=5	
Paracetamol	
n=6	
Total	protein	
(g/L)	 50.2	(1.6)	 49.6	(3.3)	 47.6	(1.1)	 47.5	(1.3)	
NS	
Albumin	(g/L)	 27.0	(1.1)	 28.0	(1.6)	 25.4	(1.1)	 26.5	(0.6)	 NS	
Bilirubin	
(umol/L)	 2.3	(0.5)	 6.8	(3.0)*	 2.0	(0.7)	 8.0	(7.4)*	
F(3,19)=3.49,	
p=0.04	
ALP	(U/L)	 62.0	(5.2)	 70.0	(13.9)	 65.4	(8.1)	 62.0	(8.8)	 NS	
GGT	(U/L)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 NS	
Body	weight	(g)	 34.9	(3.1)	 35.2	(2.9)	 33.8	(4.6)	 35.0	(4.8)	 NS	
Liver	weight	(%	
body	weight)	 3.7	(0.4)	 5.8	(0.7)*	 4.0	(0.3)	 5.8	(0.6)*	
F(3,22)=25.88
p=0.00	
Food	eaten	(g)	 2.4	(0.0)	 2.4	(0.0)	 2.4	(0.0)	 2.5	(0.0)*	 F(3,22)=21.24	p=0.00	
RSV	dose	
consumed	
(mg/kg	
mouse/day)	
‐	 ‐	 85.8	(11.1)	 96.5	(8.6)	
	
NS	
 
Table 4.5 Weights and serum biochemistry results for old (18.0±0.0 months) male 
C57BL/6 mice exposed to either control diet or resveratrol diet (RSV, 1.33g/kg feed) 
for 3-4 months, then treated with paracetamol (300mg/kg via oral gavage) or saline. 
Liver and serum collected after 6 hours. Data expressed as mean (SD). *p<0.05 
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compared to corresponding saline treated group. ALP= Alkaline phosphatase, GGT= 
Gamma glutamyltransferase. 
	
Control	Diet	 Resveratrol	Diet	 One	way	
ANOVA	
Saline	
n=8	
Paracetamol	
n=8	
Saline	
n=4	
Paracetamol	
n=5	
Total	protein	
(g/L)	 55.8	(11.0)	 51.2	(4.8)	 46.5	(3.9)	 54.0	(4.1)	 NS	
Albumin	(g/L)	 27.8	(5.4)	 27.6	(2.1)	 24.3	(2.1)	 27.4	(1.1)	 NS	
Bilirubin	
(umol/L)	 1.4	(0.7)	 4.0	(2.4)*	 1.0	(0.0)	 2.2	(0.8)	
F(3,23)=5.28	
p=0.008	
ALP	(U/L)	 65.3	(21.6)	 82.2	(16.8)	 59.8	(4.0)	 101.2	(29.8)*	 F(3,23)=4.21	p=0.018	
GGT	(U/L)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 3.0	(0.0)	 NS	
Body	weight	(g)	 37.1	(6.9)	 41.2	(4.2)	 35.8	(3.0)	 41.4	(5.7)	 NS	
Liver	weight	(%	
body	weight)	 5.2	(3.3)	 4.8	(0.7)	 4.0	(0.3)	 5.0	(0.5)	 NS	
Food	eaten	(g)	 2.2	(0.1)	 2.4	(0.0)	 2.3	(0.0)	 2.6	(0.2)*	 F(3,22)=9.26	p=0.001	
RSV	dose	
consumed	
(mg/kg	
mouse/day)	
‐	 ‐	 82.7	(9.9)	 82.2	(12.3)	 NS	
 
Serum ALT, and percentage of liver necrosis, was significantly increased in young 
paracetamol-treated mice of both diet groups, compared to saline treated mice (Figure 
4.7A, C). For the old mice, serum ALT and percentage of liver necrosis, were only 
significantly increased with paracetamol treatment in mice on the control diet, not in 
those on the resveratrol diet (Figure 4.7B, D). In old mice, a two-way ANOVA of diet 
and treatment showed a significant diet*treatment effect on percentage of liver necrosis 
(p=0.000). A three-way ANOVA of age, diet and treatment showed that age, treatment 
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and an age x treatment interaction effect were related to serum ALT and percentage of 
liver necrosis. 
 
Figure 4.7 Serum alanine aminotransferase (ALT) concentration and percentage of liver 
with necrosis for young (A, C; 6.0±0.0 months) and old (B, D; 18.0±0.0 months) male 
C57BL/6 mice exposed to either control diet or resveratrol diet (RSV, 1.33g/kg feed) 
for 3-4 months, then treated with paracetamol (300mg/kg via oral gavage) or saline. 
Liver and serum collected after 6 hours. Data expressed as mean±SEM. One-way 
ANOVA young ALT F(3,20)=12.00 p=0.00. One-way ANOVA old ALT, F(3,24)=4.96 
p=0.009. One-way ANOVA young necrosis F(3,21)=14.974 p=0.00. One-way ANOVA 
old necrosis, F(3,22)=13.14 p=0.00. *p<0.05 compared to corresponding saline group 
#p<0.05 compared to control diet+paracetamol group with Tukey’s HSD post-hoc test. 
n=4-8 per group. 
 
* * 
* 
* * 
* # 
n=6 n=6 n=5 n=6 n=8 n=5 n=4 n=8 
n=6 n=6 n=5 n=6 n=8 n=5 n=4 n=8 
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Figure 4.8 Representative Haemotoxylin and Eosin stained liver histology images for 
young (6.0±0.0 months) and old (18.0±0.0 months) male C57BL/6 mice exposed to 
either control diet or resveratrol diet (RSV, 1.33g/kg feed) for 3-4 months, then treated 
with paracetamol (300mg/kg via oral gavage) or saline. Liver collected after 6 hours. 
Images taken at 100X. 
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Total liver GSH was decreased in young and old mice treated with paracetamol 
compared to saline, for both control and resveratrol diets (Figure 4.9A, B). A three-way 
ANOVA of diet, treatment and age showed a significant effect of age, treatment and an 
age x treatment interaction effect on total liver GSH (p=0.000). There was no significant 
change in CYP2E1 activity for young or old mice of either diet group with paracetamol 
treatment compared to saline treatment, although there was a trend towards a decrease 
in young control diet mice (p=0.10) (Figure 4.9C, D). 
 
 
Figure 4.9 Liver total glutathione (GSH) levels and cytochrome (CYP)2E1 activity for 
young (A, C; 6.0±0.0 months) and old (B, D; 18.0±0.0 months) male C57BL/6 mice 
exposed to either control diet or resveratrol diet (RSV, 1.33g/kg feed) for 3-4 months, 
then treated with paracetamol (300mg/kg via oral gavage) or saline. Liver collected 
after 6 hours. Data expressed as mean±SEM. One-way ANOVA young GSH 
F(3,22)=47.33 p=0.00. One-way ANOVA old GSH, F(3,24)=29.07 p=0.00. One-way 
* *
* 
* 
n=6 n=6 n=5 n=6 n=8 n=5 n=4 n=8 
n=6 n=6 n=5 n=6 n=8 n=5 n=4 n=8 
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ANOVA young CYP2E1, non-significant. One-way ANOVA old CYP2E1, non-
significant. *p<0.05 compared to corresponding saline group. n=4-8 per group with 
Tukey’s HSD post-hoc test. 
 
Western blot results for SIRT1, pAMPK/AMPK ratio and NF-κB expression in young 
and old mice are shown in Figure 4.10. SIRT1 mRNA expression was increased with 
resveratrol diet compared to control diet, for saline treated old but not young mice 
(Figure 4.10A, B). The ratio of phosphorylated AMPK to AMPK, indicating activation 
of AMPK, was increased with resveratrol diet compared to control diet for saline treated 
young but not old mice (Figure 4.10C, D). Paracetamol treatment reduced SIRT1 
mRNA expression in old resveratrol diet mice treated with paracetamol compared to 
saline (Figure 4.10B), and increased the ratio of phosphorylated AMPK to AMPK, in 
both old diet groups (Figure 4.10D). 
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Figure 4.10 Sirtuin 1 (SIRT1), phosphorylated 5' adenosine monophosphate-activated 
protein kinase (pAMPK)/AMPK ratio and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) protein expression for young (A, C, E; 6.0±0.0 months) and 
old (B, D, F; 18.0±0.0 months) male C57BL/6 mice exposed to either control diet or 
resveratrol diet (RSV, 1.33g/kg feed) for 3-4 months, then treated with paracetamol 
(300mg/kg via oral gavage) or saline. Liver collected after 6 hours. Data expressed as 
mean±SEM, normalised to saline-treated young control. One-way ANOVA young 
SIRT1, non significant. One-way ANOVA old SIRT1, F(3,19)=7.14 p=0.003. One-way 
* 
* 
* 
# 
#
* 
n=6 n=6 n=5 n=6 n=6 n=5 n=3 n=6 
n=6 n=6 n=5 n=6 n=6 n=5 n=3 n=6 
n=6 n=6 n=5 n=6 n=6 n=5 n=3 n=6 
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ANOVA young pAMPK/AMPK, F(3,22)=21.92 p=0.00. One-way ANOVA old 
pAMPK/AMPK, F(3,19)=13.71 p=0.00. One-way ANOVA young NF-κB, 
F(3,22)=2.48 p=0.092. One-way ANOVA old NF-κB, non-significant. *p<0.05 
compared to corresponding saline group, #p<0.05 compared to control diet saline group 
with Tukey’s HSD post-hoc test. n=3-6 per group. 
4.4 Discussion 
This study found that resveratrol did not protect against paracetamol hepatotoxicity in 
three different models: primary hepatocytes; concurrently treated young mice; and 
young and old mice pre-treated with resveratrol in the diet. Paracetamol toxicity was 
induced in each model, and the positive control, NAC, protected against toxicity. 
Changes in downstream resveratrol targets could not be confirmed in the concurrent 
model, implying a pharmacokinetic explanation for the lack of protection. The 
mechanisms behind the lack of resveratrol protection in the pre-treatment study appear 
to be age-differential and require further research. Overall, these results suggest that 
resveratrol is not a good candidate as a novel therapeutic to protect against paracetamol 
toxicity. 
 
In the primary hepatocyte model, paracetamol toxicity was induced in the cells at a level 
similar to other rat studies (Lewerenz et al. 2003), but not to the same extent as seen in 
other mouse studies (Jemnitz et al. 2008). In the current study, cells are washed prior to 
all tests, so only those cells still attached to the cell culture plates are measured for 
outcomes. This may bias the results towards those cells that are viable enough not to 
become unattached, and underestimate the toxic effects we observed. The reduction in 
viability we did see with paracetamol, however, was completely reversed by adding 
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NAC, the current clinical treatment for paracetamol toxicity and thus a good positive 
control, concurrently to the media, indicating the validity of our model.  
 
Concurrent paracetamol treatment with any resveratrol dose did not increase hepatocyte 
viability compared to paracetamol alone. It is possible, that the lack of protection seen 
in this model was in fact due to a lack of permeability of the hepatocytes to resveratrol, 
and this should be confirmed in further studies with measurement of downstream 
resveratrol target protein expression, to confirm whether or not resveratrol was able to 
enter the hepatocytes in cell culture. It is also possible, however, that these findings 
suggest that the protective effects of resveratrol against paracetamol toxicity observed in 
animal studies (Sener et al. 2006; Du et al. 2015) may not be due to the drug acting 
directly on hepatocytes. Some of the protective properties of resveratrol seen in other 
studies, such as anti-inflammatory actions, reducing neutrophil infiltration, acting on the 
endothelium, and preventing platelet aggregation (Pace-Asciak et al. 1995; Yoshizaki et 
al. 2010), would not be observed in isolated hepatocyte experiments. In order to answer 
these questions the experiments were continued in in vivo toxicity models. 
 
Concurrent treatment of young C57BL/6 mice with high dose paracetamol and 
resveratrol also did not result in protection against paracetamol induced hepatotoxicity. 
As with our primary hepatocytes, we were able to establish a good model of 
paracetamol hepatotoxicity assessed by increased serum ALT and bilirubin and 
decreased total liver GSH with paracetamol treatment, which is consistent with other 
mouse studies (Mitchell et al. 1973; McGill et al. 2012). The positive control, NAC, 
concurrently given, was able to completely protect against liver toxicity, but resveratrol, 
concurrently given with paracetamol, had no protective effect on serum ALT or total 
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liver GSH. In this in vivo model, it is possible the lack of protection may be due to the 
pharmacokinetics of resveratrol. Resveratrol has a very short half life, and undergoes 
significant phase II metabolism (Yu et al. 2012; Vitrac et al. 2003; Marier et al. 2002), 
implying that a single dose may be metabolised too quickly to exert downstream 
protective changes. Western blot analysis of liver tissue in this study showed no change 
for resveratrol treated mice, compared to saline treated mice, in the ratio of 
phosphorylated AMPK to total AMPK protein expression, a known target of resveratrol 
(Baur et al. 2006; Suchankova et al. 2009; Ido et al. 2015; Hardie 2011) which would 
support this hypothesis. Previous mouse studies that did see protection against 
paracetamol toxicity with resveratrol treatment, gave resveratrol 1-1.5 hours post 
paracetamol treatment, and one study administered resveratrol at two time-points, 
indicating that delayed treatment or more doses may be necessary for protection (Du et 
al. 2015; Masubuchi et al. 2009). All previous studies also gave resveratrol via a 
different route of administration (intraperitoneal injection), and in different vehicles 
(Masubuchi et al. 2009; Sener et al. 2006; Wang et al. 2015; Du et al. 2015) to the 
current study which may affect absorption, bioavailability and metabolism (Walle 
2011). Interestingly, one study saw protection against hepatotoxicity at eight hours after 
paracetamol treatment (and two hours after the final resveratrol dose), but not after 24 
hours, so perhaps continued dosing of resveratrol is necessary to maintain the protective 
effects, or resveratrol may delay but not prevent toxicity (Masubuchi et al. 2009). Two 
of the previous studies that saw protection against paracetamol toxicity with resveratrol 
treatment were conducted in different mouse strains (BALB/c mice, (Sener et al. 2006) 
and CD1 mice, (Masubuchi et al. 2009)), which are known to be less susceptible to 
paracetamol toxicity, and have a different mechanism of toxicity response to C57BL/6 
mice. Further studies that measured resveratrol and its metabolites in the serum and 
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liver after concurrent dosing with paracetamol, would determine whether 
pharmacokinetics may explain the lack of protection seen in the current study. 
 
The final experiment in this study looked at the effect of long-term dietary pre-treatment 
of both young and old mice with resveratrol. Six weeks of exposure to resveratrol, also 
did not protect young or old mice from an acute dose of paracetamol. In old mice there 
was not a statistically significant increase in serum ALT with paracetamol treatment for 
resveratrol diet mice, and there was a statistically significant interaction between diet 
and treatment for percentage necrosis. These statistical results may imply that in old 
mice, resveratrol diet was associated with less hepatotoxicity from paracetamol, 
compared to control diet. However the clinical significance of this is negligible as the 
mean serum ALT for this mouse group was still almost 5000U/L, well above the upper 
limit of normal. 
  
As in our other models, in the study of long-term dietary pretretament with resveratrol, 
paracetamol toxicity was induced as demonstrated by histology, increased serum ALT 
and decreased liver GSH. It was found that resveratrol in the diet, does cause 
downstream target changes in protein expression, implying that resveratrol is entering, 
and exerting some effect in the liver, but still not protecting against paracetamol 
toxicity. This negative result may be due to a limited number of outcome measures and 
it would be beneficial to measure a wider range of paracetamol toxicity-associated 
outcomes such as inflammatory cytokine response. Measurement of resveratrol in the 
serum or liver to confirm the ingestion of the drug from the diet would also be 
beneficial in understanding the lack of protection from resveratrol against paracetamol 
toxicity seen in this model. Interestingly, however, there was a differential effect of 
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resveratrol exposure on protein expression across the age groups. In young mice there 
was an increased pAMPK/AMPK protein expression ratio with resveratrol, but no 
change to SIRT1 protein expression. In old mice, resveratrol caused increased SIRT1 
protein expression, but no change in activation of AMPK as assessed via the 
pAMPK/AMPK ratio. Previous studies have shown reduced AMPK pathway 
responsiveness in old age (Salminen & Kaarniranta 2012) and age-dependent effects of 
resveratrol on other liver protein markers (Tung et al. 2015). Studies have also 
identified differential activation of these two pathways in response to different 
resveratrol doses (Price et al. 2012). Low dose resveratrol directly activates SIRT1, as 
seen in our old mice, while high-dose resveratrol activates AMPK independently of 
SIRT1, as seen in our young mice (Price et al. 2012). Pharmacokinetic changes in old 
age, such as potentially reduced transfer of resveratrol across the aged liver sinusoidal 
endothelium (Le Couteur et al. 2001; Le Couteur et al. 2008) may partly explain this 
finding.  Previous studies have shown that activation of AMPK is protective against 
paracetamol toxicity (King et al. 2015), but this was not seen for young mice in the 
current study. Wang et al. (2015) dosed young mice twice per day for three days with 
resveratrol, to investigate the protective effects of resveratrol against paracetamol 
toxicity. They found increased SIRT1 protein expression with resveratrol treatment 
alone, which was slightly decreased with resveratrol plus paracetamol treatment, as we 
saw in the old mice only in the current study (Wang et al. 2015). Future research needs 
to look at other downstream protein markers involved in these pathways to understand 
the mechanisms of these age-related differences.  
 
Interestingly, an increase in the pAMPK/AMPK protein expression ratio was seen in 
paracetamol treated old mice in the pre-exposure experiment, and there was a trend 
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towards this in the concurrently treated mice. Previous studies have found either no 
activation of AMPK in mice treated with low-dose paracetamol (King et al. 2015), or a 
down regulation in pAMPK with high dose paracetamol (Saberi et al. 2014). Saberi et al 
(2014) used a lower paracetamol dose and shorter time-frame than in the current study, 
and this may explain the different results. The AMPK pathway is known to be 
associated with cell stress (Salminen & Kaarniranta 2012) so the increase seen in our 
study may be due to the severe cell toxicity induced by paracetamol. 
 
Limitations of this study include the technical difficulties with establishing our cell 
culture model, which highlight the need to carefully consider cell type and source, 
vehicles, media and the type of outcome measurement for all cell culture experiments, 
as small changes in methodologies and conditions can significantly impact results, as 
has been seen in other in vitro studies (Clement et al. 2001). There were also some 
baseline differences in the two C57BL/6 mouse cohorts used in this study including 
different locations of breeding and housing and different base diets, requiring the use of 
different paracetamol doses to induce toxicity. It is possible that the C57BL/6 mice 
sourced from the Kearns facility compared to those sourced from the NIA are 
genetically different sub-strains due to genetic drift in the colonies, and as such have 
differences in susceptibility to paracetamol toxicity (Bourdi et al. 2011; Zurita et al. 
2011; Mekada et al. 2009). This warrants further investigation. Another limitation in 
this study is the lack of absolute measures of resveratrol levels in the serum and tissue, 
or other downstream target outcomes such as inflammatory or oxidative response 
measures, which would be beneficial for future experiments, and allow better 
understanding of the mechanisms behind the lack of protection seen with resveratrol in 
this study. Furthermore, the negative result seen in this chapter is based on a limited 
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number of outcome measures, and it would be beneficial to confirm these findings by 
looking The strength of this study is the use of three models of paracetamol and 
resveratrol exposure, with positive controls where possible. 
 
Overall, this study induced paracetamol toxicity in three different models, and showed 
that resveratrol does not protect against paracetamol toxicity in mice, even with six 
weeks of dietary pre-exposure. Dietary exposure to resveratrol was found to increase 
pAMPK/AMPK protein expression in young mice, and caused increased SIRT1 protein 
expression in old mice. High dose paracetamol was also found to increase the ratio of 
pAMPK/AMPK protein expression in the liver. The role of SIRT1 in paracetamol 
toxicity will be further explored in chapter 5 in a study of young and old transgenic 
SIRT1 mice treated with paracetamol. 
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5 THE ROLE OF SIRT1 IN 
PARACETAMOL 
HEPATOTOXICITY IN YOUNG 
AND OLD MICE 
5.1 Introduction 
The results presented in chapter three of this thesis demonstrate the inability of NAC to 
protect against non acute paracetamol toxicity, and there is also clinical evidence of 
patients who still develop liver failure from paracetamol toxicity, particularly those who 
present late or have repeated paracetamol ingestion (Craig et al., 2011; Daly et al., 2008; 
Ferner et al., 2011). These findings highlight the need to develop new therapies and 
evidence to guide treatment of different clinical presentations of paracetamol 
hepatotoxicity, other than acute single high dose exposure. This is particularly crucial 
for the older population who are more at risk of liver failure (Schmidt 2005) and who 
are more likely to have non-acute exposures to paracetamol (Kane et al. 2012). 
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Animal studies have shown that calorie restriction (CR) (Harper et al. 2006) and the 
CR-mimetic resveratrol (Sener et al. 2006), protect against paracetamol toxicity, 
although the mechanisms are not well understood. These interventions are believed to, 
either directly or indirectly, activate the NAD-dependent deacetylase sirtuin-1 (SIRT1) 
pathway (B. P. Hubbard et al. 2013; Cohen et al. 2004; Lagouge et al. 2006). SIRT1 is 
thought to play an important role not only in longevity and delaying age-related 
changes, but also in regulation of response to stressors and nutrients (Michan & Sinclair 
2007; Raynes et al. 2013). In particular, it has been shown to play a role in the 
regulation of inflammation (Purushotham et al. 2009; Yoshizaki et al. 2010), apoptosis 
(Wang et al. 2006; Yamakuchi et al. 2008) and mitochondrial function (Price et al. 
2012); all important factors in the development of paracetamol hepatotoxicity. Thus it is 
hypothesised that it is activation of the lifespan-related SIRT1 pathway that may 
provide a protective mechanism against paracetamol toxicity. 
 
In chapter four of this thesis we saw that resveratrol did not protect against paracetamol 
toxicity in three different in vitro and in vivo models. Differences in drug vehicles, route 
and timing of administration and mouse species between previous studies (Sener et al. 
2006; Masubuchi et al. 2009; Du et al. 2015; Wang et al. 2015) and our work, suggest a 
potential role of resveratrol pharmacokinetics in explaining the different results. Future 
studies of absolute measures of resveratrol levels in the serum and tissue, or other 
downstream target outcomes such as inflammatory or oxidative response would allow 
for the mechanisms behind the lack of protection to be understood. However, in order to 
unambiguously address the original hypothesis of whether SIRT1 plays an underlying 
protective role in paracetamol toxicity, we can use young and old SIRT1 transgenic 
mice treated with acute paracetamol. 
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The aim of this study is to investigate the role of SIRT1 in paracetamol hepatotoxicity, 
in young and old mice. Understanding the potentially protective role of the SIRT1 
pathway in paracetamol hepatotoxicity, and the effect of age on this protection, could 
provide insight into new potential protective therapeutics, for all ages. 
 
5.2 Methods 
5.2.1 Animals 
Male liver-specific SIRT1 knock-out mice (SIRT1 KO) were developed by crossing 
Albumin Cre-Lox C57BL/6 mice with floxed SIRT1Δex4 mice (Chen et al. 2008). Liver-
specific SIRT1 over expressor mice (SIRT1 OE) were developed by crossing Albumin 
Cre-Lox C57BL/6 mice with SIRT1 transgenic mice (Price et al. 2012). Young SIRT1 
KO (age=6.7±0.0 months, n=13) and SIRT1OE mice (age=6.8±0.0 months, n=11) were 
bred at the NIA (Baltimore, MD). Old SIRT1 KO (age=18.4±2.1 months, n=11) and 
SIRT1OE mice (age=20.3±1.7 months, n=8) were bred and agedat the NIA (Baltimore, 
MD). Young (age=7.3±0.3 months, n=23) and old (age=18.9±2.3 months, n=25) male 
control littermates, and C57BL/6 wild-type mice were also bred and aged at the NIA 
(Baltimore, MD). Animals were randomly assigned to treatment or control groups prior 
to the treatment day. The mouse numbers were determined by a sample of convenience 
as the transgenic mice were excess from another experiment that were re-assigned to 
this study. However we believe the mouse numbers were still powered to detect a 
clinically significant change in our primary outcome of serum ALT. 
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Mice were group housed in cages of four with ad libitum access to food and water. Mice 
were fed a 2018 Teklad Global 18% Protein Rodent diet (Harlan laboratories). Animal 
rooms were maintained on a 12 hr light/dark cycle at 20-22°C, and 30-70% humidity. 
All animal protocols were approved by the Animal Care and Use Committee of the 
National Institute on Aging (429-TGB-2017 and 405-TGB-2016).  
5.2.2 Paracetamol Treatment and Tissue Collection 
Animals were fasted overnight (16 hours), then dosed with 300mg/kg paracetamol 
(Panadol Color-free Baby Drops, 100mg/ml, GlaxoSmithKline, Australia) or saline 
vehicle via oral gavage between 8 and 10am. This paracetamol dose was chosen as a 
standard dose to induce toxicity in C57BL/6 mice (McGill et al. 2012). Food was 
returned to the mice two hours after dosing. Six hours after dosing mice were 
anaesthetized with an i.p injection of ketamine (75 mg/kg, DVR Pharmacy, Bethesda 
MD) and xylazine (10 mg/kg, DVR Pharmacy Bethesda MD). A midline laparotomy 
was performed and blood taken from the Inferior Vena Cava. The portal vein was then 
cannulated with a 21G intravenous catheter (Becton Dickinson, Sydney, Australia) 
through which the liver was perfused in-situ at 1–1.5 mL/min/g of liver with 
oxygenated Krebs-Henseleit bicarbonate buffer (95% O2–5% CO2, 37°C). Sections of 
the liver were snap frozen in liquid nitrogen for subsequent enzyme activity assays, 
protein and RNA extraction and fixed in 10% neutral formalin for subsequent 
histopathological analysis. 
5.2.3 Serum Biochemistry to Assess Liver and Renal Function 
Blood was stored and serum extracted as detailed in section 2.2.4, serum liver function 
tests (total protein, albumin, bilirubin, alkaline phosphatase (ALP), gamma 
glutamyltransferase (GGT)) and creatinine were measured by a National Association of 
Testing Authorities accredited hospital laboratory, PaLMS (Pacific Laboratory 
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Medicine Services) at Royal North Shore Hospital (Sydney, Australia) using an 
Architect i1000SR immunoassay analyser (Abbott Diagnostics, IL, USA). Vitamin B6 
is added to the ALT activity assay to accommodate for the age related decline in this 
vitamin, an integral cofactor for the assay (Krishnamurthy et al. 1967; Bordoni et al. 
1998). 
 
5.2.4 Liver Histology 
Fixed liver tissue was embedded in paraffin and 5µm sections were cut on a microtome 
and mounted on slides. Slides were stained with Haemotoxylin and Eosin in the 
National Association of Testing Authorities accredited hospital laboratory of the 
Pathology department of Royal Prince Alfred Hospital, Sydney, Australia.  
Histopathology was scored by an anatomical pathologist, who was blinded to the age, 
SIRT1 group and treatment of the samples. Necrosis was scored as a percentage of the 
liver tissue on each slide, which was then converted to a dichotomous variable (present 
or not present) for analysis. Images were taken on an Olympus BX51 microscope 
connected to an Olympus DP26 camera (Olympus, Sydney, Australia). 
5.2.5 Biochemical Examination of Enzymes and Glutathione in Frozen 
Liver Samples 
Liver microsomes were isolated according to the method of Shoaf et al. (1987), and 
CYP2E1 activity was measured according to the method of Roberts et al. (1995) and 
Mach et al. (2014), as detailed in section 2.2.6. 
 
NQO1 activity was measured in the cytosol as described by Aleksunes et al. (2006), and 
detailed in section 2.2.6. 
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Liver concentrations of total glutathione were determined with a Glutathione Assay kit 
(Cayman Chemicals, #703002) as detailed in section 2.2.6. 
5.2.6 Western Blots 
SIRT1 protein levels were measured in liver from all mice. Liver was homogenised in 
lysis buffer (RIPA buffer supplemented with EDTA and EGTA (Boston BioProducts), 
protease inhibitor cocktail (Sigma-Aldrich #P8340), phosphatase inhibitor Cocktail 2 
and 3 (Sigma-Aldrich #P5726 and #P0044), and Trichostatin A (Sigma-Aldrich 
#T1952)) then centrifuged at 14,000g for 15 minutes at 4ºC, and the supernatant 
collected. Protein concentration was quantified using the Quickstart Bradford assay 
(Bio-Rad, #500-0201). 30g of protein was separated by SDS-PAGE under reducing 
conditions and then transferred to nitrocellulose membranes. Membranes were blocked 
in 5% BSA for one hour at room temperature, and then incubated overnight at 4ºC with 
the primary antibody SIRT1 (1:1000, Sigma, #S5196) in 5% BSA. Membranes were 
washed, then incubated in secondary antibody solution (5% skim milk in TBS-T, mouse 
secondary antibody 1:5,000, GE Healthcare, Pascataway, NJ) for one hour at room 
temperature. The membranes were washed then visualization of the immunoreactive 
bands was performed using the ECL Prime Western blotting detection system (GE 
Healthcare, Pascataway, NJ). Densitometry was performed using ImageJ (v 1.47). 
Ponceau S was used as a loading control and data of each group was normalized to the 
young wild-type saline treated group. 
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5.2.7 mRNA Expression Measurement with qPCR 
RNA was extracted, and qPCR run to assess mRNA expression of CYP2E1, NQO1, 
TNF-α, IL-1β, IL-10, NF-κB, Caspase 3, BAX, PGC-1α, PGC-1β (primer sequences in 
Appendix 2), as detailed in section 2.2.7. 
5.2.8 Statistics 
Data are expressed as mean ± SEM unless otherwise indicated. Differences between 
mean values across groups were calculated with one-way ANOVA with Tukey’s HSD 
post-hoc test, or a 2 or 3 way ANOVA to compare the effect of age, treatment and 
SIRT1 groups. The prevalence of necrosis in each treated group compared to the saline 
group was compared with Chi squared. The calculation of mRNA expression was 
performed by the 2-CT method. Data analysis was completed using the statistics 
program SPSS (Version 21.0, SPSS Inc., Chicago, Illinois, USA) and GraphPad Prism 
(Version 6.04, GraphPad Software, La Jolla California USA). 
5.3 Results 
5.3.1  Animal and Genotype Details 
Weights and ages for all mouse groups are shown in Table 5.1. Numbers per group are 
as stated in table unless specified elsewhere. Five old mice had evidence of lymphoma 
(n=3 wild-type, n=2 SIRT1 over-expressors). 
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Table 5.1 Weights and serum biochemistry results for young and old male wild-type C57BL/6, liver specific SIRT1 overexpressor, and liver specific 
SIRT1 knock out mice treated with 300mg/kg paracetamol (para; via oral gavage) or saline. Mice were euthanized, and liver and serum collected after 
6 hours. Data expressed as mean (SD). ALP= Alkaline phosphatase, GGT= Gamma glutamyltransferase. 
	
Young		
Wild‐Type	
Old		
Wild‐Type	
Young		
Over‐Expressor	
Old		
Over‐Expressor	
Young		
Knock‐Out	
Old		
Knock‐Out	
Saline	
n=10	
Para	
n=13	
Saline	
n=10	
Para	
n=15	
Saline	
n=5	
Para	
n=6	
Saline	
n=4	
Para	
n=4	
Saline	
n=6	
Para	
n=7	
Saline	
n=5	
Para	
n=6	
Age	(months)	 7.2	(0.3)	 7.5	(0.0)	 19.1	(1.8)	
18.8	
(2.7)	 6.8	(0.0)	 6.8	(0.0)	
20.5	
(1.8)	 22.1	(4.7) 6.7	(0.0)	 6.7	(0.0)	
17.9	
(1.9)	 18.9	(2.4)
Pre‐dosing	
Weight	(g)	
27.6	
(1.7)	
27.8	
(3.3)	
41.0	
(6.7)	
39.2	
(7.2)	 28.0	(1.5)	 28.6	(1.8)	
37.8	
(3.1)	 39.0	(6.6)
29.8	
(1.7)	 30.2	(2.3)
36.6	
(8.6)	 36.3	(6.2)
Total	protein	
(g/L)	
50.00	
(2.94)	
50.67	
(3.08)	
52.30	
(5.1)	
49.83	
(5.89)	
50.80	
(3.42)	
47.00	
(7.87)	
55.50	
(7.55)	
53.25	
(0.96)	
47.50	
(3.78)	
41.67	
(16.16)	
51.00	
(4.24)	
47.50	
(3.45)	
Albumin	(g/L)	 26.50	(1.27)	
27.75	
(1.82)	
27.60	
(2.55)	
24.92	
(3.94)	
26.20	
(2.59)	
25.80	
(3.63)	
27.75	
(1.89)	
28.25	
(1.26)	
24.00	
(2.10)	
20.83*	
(7.88)	
25.75	
(1.71)	
24.00	
(2.76)	
Bilirubin	
(umol/L)	
1.60	
(0.52)	
2.45	
(0.52)	
1.70	
(0.48)	
2.58	
(1.08)	
1.20	
(0.45)	
2.20	
(0.45)	
2.00	
(1.15)	
3.50	
(1.91)	
2.83	
(2.56)	
2.50	
(1.05)	
3.00	
(3.37)	
2.50	
(2.26)	
ALP	(U/L)	 73.00	(10.19)	
87.00	
(19.05)	
91.10	
(20.09)	
85.25	
(30.18)	
73.80	
(20.28)	
73.50	
(18.51)	
79.00	
(10.2)	
101.25	
(31.58)	
66.17	
(9.47)	
62.83	
(25.53)	
72.80	
(15.11)	
84.00	
(15.94)	
GGT	(U/L)	 3.00	 3.00	 3.00	 3.08	 3.00	 3.00	 5.75	 3.00	 3.00	 4.67	 3.00	 3.00	
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(0.00)	 (0.00)	 (0.00) (0.29) (0.00) (0.00) (5.5) (0.00) (0.00) (4.08) (0.00) (0.00)
Creatinine	
(umol/L)	
33.40	
(2.76)	
33.09	
(4.06)	
41.40	
(16.08)	
47.25	
(31.19)	
32.60	
(4.04)	
32.80	
(3.63)	
78.75	
(86.84)	
33.75	
(4.72)	
31.40	
(3.36)	
29.60	
(1.95)	
32.50	
(1.29)	
29.60	
(3.65)	
Liver	weight	
(%	body	
weight)	
4.83	
(0.60)	
5.38	
(0.43)	
4.40	
(0.73)	
4.99	
(0.86)	
4.85	
(0.40)	
5.22	
(0.77)	
4.57	
(0.11)	
4.89	
(1.01)	
4.59	
(0.39)	
5.68	
(0.90)	
4.54	
(0.51)	
4.84	
(0.36)	
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SIRT1 mRNA expression in the liver was reduced 10-fold in both young and old KO 
mice, compared to wild types (p<0.001) (Figure 5.1A) confirming the SIRT1 KO 
phenotype. Young and old SIRT1 OE mice had a trend towards an increase in SIRT1 
mRNA compared to wild types (p>0.05). A two way ANOVA showed a significant 
SIRT group effect on SIRT1 mRNA expression, but no age effect. Western blot analysis 
of SIRT1 showed an expected downward shift in the band for SIRT1 in both young and 
old KO mice, consistent with the KO generated by Price et al (2012), and a trend 
towards an increase in protein intensity for young and old SIRT1 OE mice, compared to 
WTs (Figure 5.1B), indicating increased protein expression. 
 
* * 
A 
B 
SIRT1 
Ponceau S 
  WT   KO   OE  WT   KO   OE 
      Young                   Old 
* * 
8 5 5 10 3 5 
8 4 4 9 3 5 
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Figure 5.1 Liver sirtuin 1 (SIRT1) mRNA expression (A), and protein expression (B), 
for young and old male C57BL/6 wild-type (WT), liver-specific SIRT1 over-expressor 
(OE) and liver-specific SIRT1 knock-out (KO) mice, 6 hours after treatment with 
300mg/kg paracetamol (via oral gavage) or saline. Data expressed as mean relative to 
young wild type control±SEM. One-way ANOVA SIRT1 mRNA, F(5,26)=4.66 
p=0.004. One-way ANOVA SIRT1 protein, F(5,27)=4.27 p=0.005. *=p<0.05 compared 
to corresponding age wild-type with Tukey’s HSD post-hoc test. n=3-10 per group for 
mRNA, n=5-6 per group for western blot (shown on graph). 
5.3.2 Assessment of Paracetamol Toxicity 
Table 5.1 shows blood test results, liver weight and post-fast weights for all mouse 
groups. There was no difference across any group for total protein, albumin, bilirubin, 
ALP, GGT, creatinine or liver weight (as percentage of body weight). 
 
All paracetamol treated groups had increased mean ALT when compared to their 
corresponding saline treated groups (p<0.05), except for old SIRT1 OE mice where this 
was not significant (p=0.15) (Figure 5.2). 71-85% of samples in all paracetamol treated 
groups had evidence of necrosis, with one sample in the saline treated young SIRT1 
knock-out showing necrosis (Figure 5.3). The average percentage of the scored liver 
with necrosis was 22.0±20.6 % across all groups. A three way ANOVA showed that 
treatment was the only significant factor affecting serum ALT, with no significant 
SIRT1 or age effect on the degree of hepatotoxicity. 
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Figure 5.2 Serum alanine aminotransferase (ALT) concentrations for young and old 
male C57BL/6 wild-type (WT), liver-specific SIRT1 over-expressor (OE) and liver-
specific SIRT1 knock-out (KO) mice, 6 hours after treatment with 300mg/kg 
paracetamol (via oral gavage) or saline. Data expressed as mean±SEM. One-way 
ANOVA, F(11,85)=5.38 p=0.000. *=p<0.05 compared to corresponding saline treated 
group with Tukey’s HSD post-hoc test. n=4-15 per group. 
 
 
* 
* * * * 
* 
* 
* 
* 
* 
10 13 10 15 5 6 4 4 6 7 5 6 
10 13 10 15 5 6 4 4 7 6 5 6 
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Figure 5.3 Prevalence of necrosis (as a percentage of each group) for young and old 
male C57BL/6 wild-type (WT), liver-specific SIRT1 over-expressor (OE) and liver-
specific SIRT1 knock-out (KO) mice, 6 hours after treatment with 300mg/kg 
paracetamol (via oral gavage) or saline. Data expressed as % of group. *=p<0.05 
compared to corresponding saline treated group. n=4-15 per group. 
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Figure 5.4 Representative Haemotoxylin and Eosin stained liver histology images for 
young and old male C57BL/6 wild-type, liver-specific SIRT1 over-expressor and liver-
specific SIRT1 knock-out mice, 6 hours after treatment with 300mg/kg paracetamol (via 
oral gavage) or saline. Images taken at 100X. 
5.3.3 Assessment of Factors Influencing Paracetamol Pharmacokinetics 
CYP2E1 activity was significantly reduced in paracetamol treated young and old wild-
type mice, and young SIRT1 knock-out mice compared to saline controls (Figure 5.5A). 
CYP2E1 mRNA expression was reduced for old wild-type and old SIRT1 over-
expressors treated with paracetamol, compared to saline controls (p<0.05) (Figure 
5.5B). 
 
Figure 5.5 Cytochrome (CYP)2E1 activity (A) and CYP2E1 mRNA expression (B) for 
young and old male C57BL/6 wild-type (WT), liver-specific SIRT1 over-expressor 
* * 
* 
* * 
B 
A 
n=6 n=6 
10 13 10 15 5 6 4 4 5 6 7 6 
8 10 10 10 5 5 4 5 5 5 3 5 
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(OE) and liver-specific SIRT1 knock-out (KO) mice, 6 hours after treatment with 
300mg/kg paracetamol (via oral gavage) or saline. For activity graph, data is expressed 
as mean ±SEM; for mRNA graph, data is expressed as mean normalized to young wild-
type saline group ±SEM. One-way ANOVA CYP2E1 activity, F(11,83)=2.62 p=0.007. 
One-way ANOVA CYP2E1 mRNA, F(11,67)=4.91 p=0.000. *=p<0.05 compared to 
saline treated group group with Tukey’s HSD post-hoc test. n=4-15 per group for 
activity, n=3-10 per group for mRNA. 
 
Saline treated old wild-type and SIRT1 OE mice had significantly greater NQO1 
activity than their comparative young groups (p<0.05) (Figure 5.6A) and there was a 
trend towards increased NQO1 activity in all other old mouse groups compared to their 
comparative young groups (p>0.05). A three way ANOVA of treatment, age and SIRT1 
group, showed that age was the only significant factor affecting NQO1 activity (Figure 
5.6B). Interestingly, NQO1 mRNA expression was significantly increased in all 
paracetamol treated groups compared to their saline controls (p<0.05), but there was no 
SIRT1 or age effect (Figure 5.6B). 
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Figure 5.6 NAD(P)H:quinone oxidoreductase 1 (NQO1) activity (A) and NQO1 
mRNA expression (B) for young and old male C57BL/6 wild-type (WT), liver-specific 
SIRT1 over-expressor (OE) and liver-specific SIRT1 knock-out (KO) mice, 6 hours 
after treatment with 300mg/kg paracetamol (via oral gavage) or saline. For activity 
graph, data is expressed as mean ±SEM; for mRNA graph, data is expressed as mean 
normalized to young wild-type saline group ±SEM. One-way ANOVA NQO1 activity, 
F(11,83)=3.09 p=0.002. One-way ANOVA NQO1 mRNA, F(11,71)=6.75 p=0.000. 
*=p<0.05 compared to saline treated group, #=p<0.05 compared to young treated group, 
$=p<0.05 compared to young saline group with Tukey’s HSD post-hoc test. n=4-15 per 
group for activity, n=3-10 per group for mRNA. 
 
* 
$ 
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# 
* 
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* 
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A 
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Liver total GSH did not significantly change across any SIRT1, age or treatment group 
(Figure 5.7). 
 
Figure 5.7 Total liver glutathione (GSH) for young and old male C57BL/6 wild-type 
(WT), liver-specific SIRT1 over-expressor (OE) and liver-specific SIRT1 knock-out 
(KO) mice, 6 hours after treatment with 300mg/kg paracetamol (via oral gavage) or 
saline. Data is expressed as mean ±SEM. n=4-15 per group. 
5.3.4 mRNA expression of Inflammatory Markers 
The mRNA expression of the pro-inflammatory cytokine TNF-α was increased in young 
and old wild-type and knock-out mice treated with paracetamol compared to saline 
controls (p<0.05) (Figure 5.8A). A similar trend was seen for anti-inflammatory 
cytokine IL-10 (Figure 5.8C). Old wild-type mice treated with paracetamol had a larger 
increase in TNF-α and IL-10 mRNA expression than young wild-type mice treated with 
paracetamol (p<0.05) (Figure 5.8A, C). IL-1β mRNA expression had a trend towards an 
increase with paracetamol treatment compared to saline treatment in old wild-type but 
not young wild-type mice (Figure 5.8B). NF-κB mRNA expression was increased in old 
wild type and old SIRT1 knock-out mice treated with paracetamol, compared to their 
saline treated groups (p<0.05) whilst there was no increase in NF-κB mRNA expression 
with paracetamol treatment in any of the young mouse groups (Figure 5.8D). 
10 13 10 15 5 6 7 6 6 5 4 4 
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Figure 5.8 mRNA expression of inflammatory markers; (A) Tumor necrosis factor 
(TNF)-α, (B) Interleukin (IL)-1β, (C) IL-10 and (D) Nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) mRNA expression for young and old male 
C57BL/6 wild-type (WT), liver-specific SIRT1 over-expressor (OE) and liver-specific 
SIRT1 knock-out (KO) mice treated with saline or paracetamol (300mg/kg via oral 
gavage). Data expressed as mean normalized to young wild-type saline group ±SEM. 
One-way ANOVA TNFα, F(11,71)=4.08 p=0.000. One-way ANOVA IL-1β, 
F(11,71)=1.71 p=0.09. One-way ANOVA IL-10, F(11,71)=2.66 p=0.008. One-way 
ANOVA NF-κB, F(11,71)=2.51 p=0.011. *=p<0.05 compared to saline treated group, 
#=p<0.05 compared to young treated group with Tukey’s HSD post-hoc test. n=3-10 
per group. 
5.3.5 mRNA expression of Apoptosis and Mitochondrial Function Markers 
The mRNA expression of Caspase 3, a protein activated in apoptosis, showed no change 
with treatment, SIRT1 group or age. The mRNA expression of apoptosis promoting 
8 10 10 10 5 5 5 4 3 5 5 5 
8 10 10 5 5 4 3 5 5 5 10 5 
8 10 10 5 4 3 5 5 5 5 5 10 
8 5 4 5 5 5 5 10 10 10 3 5 
Chapter 5: The Role of SIRT1 in Paracetamol Hepatotoxicity in Young and Old 
Mice 
Alice Kane - March 2016 166
protein, BAX, was only increased in old wild type mice and young SIRT1 OE mice 
treated with paracetamol, compared to saline treated controls (p<0.05) (Figure 5.9B). 
 
Figure 5.9 mRNA expression of Caspase 3 (A) and BAX (B) for young and old male 
C57BL/6 wild-type (WT), liver-specific SIRT1 over-expressor (OE) and liver-specific 
SIRT1 knock-out (KO) mice treated with saline or paracetamol (300mg/kg via oral 
gavage). Data expressed as mean normalized to young wild-type saline group ±SEM. 
One-way ANOVA BAX, F(11,71)=2.64 p=0.008. One-way ANOVA Caspase 3, non-
significant. *=p<0.05 compared to saline treated group, #=p<0.05 compared to young 
treated group with Tukey’s HSD post-hoc test.. n=3-10 per group. 
 
 
A 
B 
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The only significant change in mRNA expression of the mitochondrial regulator 
proteins PGC1-α and PGC1-β was a decrease and increase respectively in old wild type 
mice treated with paracetamol, compared to old saline treated controls (p<0.05) (Figure 
5.10C, D). There was no effect observed in young mice. 
 
Figure 5.10 mRNA expression of peroxisome proliferator-activated receptor gamma 
coactivator 1 (PGC1)-α (A) and PGC1-β (B) for young and old male C57BL/6 wild-
type (WT), liver-specific SIRT1 over-expressor (OE) and liver-specific SIRT1 knock-
out (KO) mice treated with saline or paracetamol (300mg/kg via oral gavage). Data 
expressed as mean normalized to young wild-type saline group ±SEM. Three-way (Age, 
SIRT1, Treatment) ANOVA PGC1-α – Treatment group F(1,60)=4.01 p=0.05. Three-
* 
A 
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way ANOVA PGC1-β – Treatment group F(1,60)=4.06 p=0.048, Age group 
F(1,60)=4.91 p=0.03. *=p<0.05 compared to saline treated group, #=p<0.05 compared 
to young treated group. n=3-10 per group. 
 
In both young and old wild-type mice there was an increase in SIRT1 mRNA 
expression in the paracetamol treated mice compared to saline treated mice (p=0.006 
young, p=0.01 old) (Figure 5.11E). 
 
Figure 5.11 mRNA expression of sirtuin 1 (SIRT1) for young and old male C57BL/6 
wild-type (WT), liver-specific SIRT1 over-expressor (OE) and liver-specific SIRT1 
knock-out (KO) mice treated with saline or paracetamol (300mg/kg via oral gavage). 
Data expressed as mean normalized to young wild-type saline group ±SEM. One-way 
ANOVA, F(11,71)=4.94 p=0.000.  *=p<0.05 compared to saline treated group. n=3-10 
per group. 
5.4 Discussion 
This comprehensive investigation utilising young and old wild type, SIRT1 knockout 
and SIRT1 over expressing mice demonstrates that SIRT1 does not play a protective 
role in paracetamol induced hepatotoxicity in our model. Furthermore this study shows 
* 
* 
8 10 10 10 5 5 5 5 5 5 4 3 
Chapter 5: The Role of SIRT1 in Paracetamol Hepatotoxicity in Young and Old 
Mice 
Alice Kane - March 2016 169
the induction of SIRT1 mRNA expression with high dose paracetamol treatment 
implying a role of the SIRT1 pathway in paracetamol hepatotoxicity. 
 
This study found no effect of SIRT1 knock-out or overexpression on the risk of 
paracetamol hepatotoxicity. This finding was unexpected as previous studies of CR and 
resveratrol, intervention known to activate SIRT1, have shown protection against 
paracetamol hepatotoxicity (Harper et al. 2006; Sener et al. 2006; Du et al. 2015). This 
may imply that the protection from CR and resveratrol seen in previous studies, 
although not this thesis, is through a SIRT1 independent mechanism. Recent studies 
have shown SIRT1-independent activation of anti-oxidant and anti-inflammatory 
pathways by resveratrol in other situations (Kitada et al. 2011; Minagawa et al. 2014). 
Interestingly, a recent study found that SIRT3 knockout mice were protected against 
paracetamol-induced toxicity, and that direct deacytalation of mitochondrial protein 
targets by SIRT3 exacerbated hepatotoxicity (Lu et al. 2011), implying a potentially 
paradoxical role of the different sirtuin proteins in paracetamol toxicity. Further 
research into SIRT1 independent potential protective pathways against paracetamol 
toxicity is warranted and may help in finding new therapeutics to protect against 
paracetamol toxicity. It is also possible that increasing SIRT1 expression alone, without 
a concurrent increase in important co-factors such as NAD+, will not be protective 
against stressors. Recent evidence is supporting an increasing protective role for 
increased NAD+ levels, independent of SIRT1 activity (Cantó & Auwerx 2012). 
Interestingly, induction of NQO1 activity, which we see with old age in all groups in the 
current study, has been shown to increase cellular NAD+ levels (Kim et al. 2014). 
Another possibility is that the degree of toxicity induced in our model was too severe to 
see protection from the SIRT1-induced mechanisms. Recent studies in cancer cells have 
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found beneficial effects of SIRT1 activation only at sublethal doses of chemotherapeutic 
agents (Wang et al. 2013; Luo et al. 2001). Further research into the role of SIRT1 in 
protecting against lower-dose, or chronic paracetamol exposure would answer these 
questions.  
 
As SIRT1 plays a central role in the lifespan-related pathways, and activation of SIRT1 
has been theorized as a potential mechanism for increasing longevity with interventions 
such as calorie restriction or resveratrol exposure (Baur & Sinclair 2006), it was 
hypothesised that it would be interesting to investigate the effect of genetic 
manipulation of SIRT1 and paracetamol toxicity in ageing. The current study found no 
interaction effect of SIRT1 and age on any of the measured outcomes, and no 
differential effect of SIRT1 status on paracetamol toxicity in old age compared to 
young. This further confirms that activation of SIRT1 does not play a protective role in 
paracetamol toxicity in C57BL/6 mice, even in old age when SIRT1 expression and 
activity have been shown to be reduced (Jin et al. 2011; Ramsey et al. 2008). 
 
SIRT1 status did not affect any of the pharmacokinetic factors measured in this study. 
However, in young mice there was an increase in mRNA expression of IL-1β, but no 
increase in TNF-α with paracetamol treatment in the SIRT1 OE mice with the opposite 
being observed in the KO mice. This implies a greater anti-inflammatory response to 
paracetamol in the SIRT1 OE mice, and a more pro-inflammatory response in the 
SIRT1 KO mice. A similar result was seen in another study, which found that SIRT1 
overexpressor mice fed a high fat diet did not see the increase in pro-inflammatory 
cytokine mRNA expression levels, seen in wild type mice (Pfluger et al. 2008). It is 
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interesting, however, that this differential inflammatory response did not translate into a 
different degree of paracetamol toxicity. 
 
Despite the hypothesised therapeutic interventions of resveratrol treatment and genetic 
SIRT manipulation not protecting against paracetamol toxicity, there is still a need to 
develop new therapies to treat or prevent paracetamol hepatotoxicity. Possible targets 
for paracetamol toxicity therapeutics that could be investigated in future studies may 
include other age-related mechanisms such as increasing NQO1 activity (Mach et al. 
2014), increasing autophagy via manipulation of the mTOR pathways (Ni et al. 2012) 
and further investigation of the potentially anti-oxidant, anti-inflammatory and NAD+ 
manipulating effects of the other ageing-related pathways such as AMPK (Speakman & 
Mitchell 2011). 
 
In this study we observed, for the first time, an increase in SIRT1 mRNA expression 
levels with high-dose paracetamol treatment. Certain stressors have been shown to 
induce SIRT1 activity and protein expression (Raynes et al. 2013; Kwon & Ott 2008). 
In our study it is possible that paracetamol-induced cellular damage may be faciliating 
the transcription of SIRT1 mRNA. In chapter 4 of this thesis, we saw an increase in 
phosphorylated AMPK protein expression with paracetamol treatment, which may be 
related as the stress response SIRT1 and AMPK pathways are tightly linked (Price et al. 
2012). It would be interesting to explore whether therapeutic paracetamol dosing also 
affects these pathways. One rat study suggested a potentially age-delaying role for 
paracetamol in the aorta (Rice et al. 2012), and another paper showed that paracetamol 
had a protective affect in mouse models of diabetes, the pathways of which are closely 
associated with the SIRT1-AMPK pathways (Shertzer et al. 2008). 
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Changes seen with high-dose paracetamol treatment were overall consistent with the 
previously published literature. Decreased CYP2E1 activity has been previously 
reported in mice after acute paracetamol treatment (Snawder et al. 1994). Previous 
studies have shown, following paracetamol treatment total glutathione is maximally 
reduced at 0.5-1 hour post acute treatment, and steadily recovers back to baseline over 
the following hours, as was seen in our study (Mitchell et al. 1973; Jaeschke et al. 
2012). In the current study, NQO1 mRNA expression was increased with treatment for 
all groups, whereas NQO1 activity was essentially unchanged with treatment. A 
previous human study showed an increase in liver NQO1 activity and protein levels 
after paracetamol treatment (Aleksunes et al. 2006), whilst a recent mouse study showed 
a reduction in NQO1 protein expression 6 hours after paracetamol treatment (Fan et al. 
2014). The differences between these studies may be due to time frame or species 
differences and more research is needed into the effect of paracetamol on NQO1 
expression and activity. The effect of high-dose paracetamol treatment on the mRNA 
expression of pro and anti- inflammatory cytokines TNF-α and IL-10 was also 
consistent with previous literature (Gardner et al. 2002; Ishida et al. 2002). In this study 
paracetamol treatment resulted in an increase in caspase 3 mRNA expression, perhaps 
implying changes in the regulation of the apoptosis pathway (Boulares & Ren 2004), 
which a recent clinical review has shown plays a role in paracetamol toxicity (Lancaster 
et al. 2014). 
 
The strength of this study is the use of transgenic mice to test the absolute role of SIRT1 
in paracetamol toxicity for the first time, and the use of both young and old mice to see 
the effect of age. A limitation of this study is the small sample sizes for some mouse 
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groups which may reduce the power to draw statistical conclusions, and the moderate 
degree of SIRT1 overexpression in the livers of the SIRT1 transgenic mice. 
Furthermore as this study was conducted in male C57BL/6 mice the applicability to 
other animal strains and species, and clinically, still needs to be confirmed. 
Additionally, the qPCR results in this experiment identify some interesting downstream 
effects of paracetamol and the transgenic mice on mRNA expression of proteins 
including SIRT1, inflammatory cytokines and caspase 3, but to fully understand the 
mechanisms behind and consequences of these changes it would be important to also 
look at protein expression, enzyme activity and further downstream markers related to 
these proteins. 
 
This chapter shows for the first time that SIRT1 does not play a role in protecting 
against paracetamol hepatotoxicity in C57BL/6 mice. This important negative finding 
highlights the importance of thoroughly investigating potential toxicity therapeutics in 
animal models, and suggests that SIRT1 may not be a good therapeutic target for 
protection against paracetamol toxicity. Despite SIRT1 not playing a protective role, 
this study did show the induction of SIRT1 mRNA expression with high dose 
paracetamol treatment, implying some role of SIRT1 in paracetamol toxicity 
development mechanisms. 
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6 FRAILTY: EFFECT OF 
PARACETAMOL, 
RESVERATROL, CALORIE 
RESTRICTION AND MOUSE 
STRAIN 
6.1 Introduction 
In chapters two and three of this thesis, it was shown that frailty does not effect the risk 
of paracetamol toxicity in old mice. This chapter will investigate the inverse 
relationship, to determine whether paracetamol may affect frailty in mice. We will also 
examine whether the lifespan and healthspan interventions (tested for their potential 
paracetamol protective effects in chapters four and five), of resveratrol and calorie 
restriction, can affect frailty status. 
 
Frailty is a state of high vulnerability for adverse health outcomes. The prevalence of 
frailty increases with increasing age, resulting in a higher risk of disability, falls, 
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hospitalization and mortality (Clegg et al. 2013). In humans, frailty can be assessed 
using a number of scales with varying degrees of difficulty and clinical applicability (de 
Vries et al. 2011). Two of the mostly commonly used and cited definitions are the 
phenotype model and the frailty index. The phenotype model defines frailty as the 
presence of three or more criteria including unintentional weight loss, self-reported 
exhaustion, weakness measured by grip strength, slow walking speed, and low physical 
activity (Fried et al. 2001). The frailty index (Mitnitski et al. 2002) measures the 
proportion of accumulated deficits in a patient, and focuses on the number of deficits 
rather than the precise nature of the deficits. 
 
Validated animal models to study frailty are lacking, and are summarised in section 
1.3.2. The mouse frailty index (Whitehead et al. 2014) is an important tool that could be 
used to assess the effect of any intervention on the important clinical outcome of frailty 
in an animal model. 
 
The main factors known to affect the lifespan and healthspan of mice are strain, diet and 
pharmaceutical interventions. Of the inbred mouse strains, the DBA/2J substrain is 
considered to be short-lived, with studies showing median lifespan for males to be 23-
25 months, compared to 26-30 months for male C57BL/6J mice (Goodrick 1975; 
Forster et al. 2003; Yuan et al. 2011). DBA/2J mice have also been shown to be 
unresponsive to interventions that extend lifespan, such as calorie restriction (Forster et 
al. 2003). C57BL/6J mice are the classical inbred mouse strains commonly used for 
ageing research due to the wealth of phenotypic and genotypic information available 
(source: http://phenome.jax.org/). Furthermore, they are responsive to interventions that 
extend lifespan such as calorie restriction and pharmaceuticals (Sohal & Weindruch 
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1996; Baur et al. 2006). Calorie restriction, the daily reduction in calories without 
malnutrition, has long been known to increase the lifespan and healthspan of mice 
(Weindruch et al. 1986). Pharmaceutical agents that mimic the beneficial lifespan 
and/or healthspan effects of calorie restriction have also been investigated. Rapamycin 
and metformin have shown lifespan extension in mice on standard diets (Harrison et al. 
2009; Martin-Montalvo et al. 2013), but there are some concerns about side effects. 
Resveratrol has shown healthspan improvements in standard diet fed mice (Pearson et 
al. 2008), and lifespan extension in high-fat diet mice (Baur et al. 2006). Recently, there 
has been an increasing focus on improving healthspan and quality of life, rather than 
lifespan, and assessment of frailty would provide a valuable measure of this in animal 
studies. 
 
Paracetamol is commonly prescribed and used in the older population, as an analgesic 
(Pearson et al. 2007). The effect of therapeutic paracetamol on healthspan outcomes has 
not been extensively investigated. The induction of mRNA expression of SIRT1, and 
protein expression of phosphorylated AMPK, important proteins affected by other 
lifespan and healthspan interventions, was seen with acute high-dose paracetamol 
treatment in chapters 4 and 5 of this thesis. Furthermore, recent studies have suggested a 
potentially age-delaying role for paracetamol in the rat aorta (Rice et al. 2012) and in 
aged skeletal muscle (Wu et al. 2010), and another paper showed that paracetamol had a 
protective effect in mouse models of diabetes, the pathways of which are closely 
associated with the ageing pathways (Shertzer et al. 2008). A longevity screening study 
in mammalian neurons, also identified paracetamol as reducing an age-related increase 
in mortality rate (Lublin et al. 2011). Thus there is some evidence to suggest that 
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paracetamol may also be an intervention that is able to improve healthspan or delay 
frailty. 
 
The primary aim of this chapter is to investigate the effect of an example of each of 
these effective lifespan and healthspan interventions – DBA/2J (short lived) vs. 
C57BL/6J (long lived) strain, calorie restriction vs. ad libitum feeding, and resveratrol 
vs. placebo – as well as the effect of chronic therapeutic paracetamol exposure, on the 
mouse frailty index (Whitehead et al. 2014) in male and female mice. The secondary 
aims of this chapter are to correlate the frailty index with functional outcomes in mice, 
and determine the inter-rater variability in assessment of frailty index. 
6.2 Methods 
6.2.1 Animals 
Three cohorts of mice were used to assess the effect of interventions on frailty index in 
this study. The first cohort was made up of male C57BL/6 mice obtained from, and 
housed at the Kearns Facility (Sydney, NSW). Mice were group housed in cages of five. 
Mice were randomized at 26.8±0.5 months of age (n=56) to either a control diet 
(Standard Meat Free Mouse and Rat Feed, 20 % Protein, 60% Carbohydrate, 5% Fat, 
Specialty Feeds, Australia), or control diet supplemented with paracetamol at a 
concentration of 1.33g/kg feed, both diets fed ad libitum. Before beginning their 
experimental diet periods, the frailty index (described below) was scored for each 
mouse (pre-treatment). Mice remained on their respective diets for six weeks, at which 
time the frailty index was scored for each mouse again (post-treatment). 
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The second cohort of mice was made up of male and female C57BL/6J (n=18 males, 
n=21 females) and DBA/2J (n=16 males, n=19 females) mice that were obtained from 
the Jackson Laboratory (Bar Harbor, ME) and bred in house at the National Institute on 
Aging (Baltimore, MD). Mice were group housed in cages of four. At six months of age 
mice were randomized to either an ad libitum (AL) diet group, or a calorie restricted 
(CR; 40% of ad libitum) diet group for the remainder of their lives (Curtis & Cabo 
2013). CR mice were fed daily at 7.30am (± 1 hour) on the floor of the cage, while AL 
mice received food in the hopper. Mice were fed 2918 Teklad Global 18% Protein 
Rodent Diet (Harlan Teklad, Indiannapolis IN). At 19 months of age the frailty index 
was scored for each mouse. This time-frame was chosen based on a previously reported 
study of DBA2/J mice (Forster et al. 2003) to correlate with the time at which we see a 
drop in survival for calorie restricted DBA2/J mice to approximately 75%. 
 
The third cohort was made up of male C57BL/6J mice that were obtained from the NIA 
Aging Colony (Charles Rivers) at 2 months of age, and then aged in house at the NIA 
(Baltimore, MD). Mice were fed standard feed (2018X 18% Protein Diet, Harlan 
Teklad, Indiannapolis IN) ad libitum until they reached 18 months of age. These mice 
were then randomized to either a standard AIN-93G diet (SD; Dyets, Inc, Bethlehem 
PA) (n=16), or an AIN-93G diet supplemented with resveratrol (RSV) at a dose of 
100mg/kg (n=9), both diets fed ad libitum. This timeframe was chosen to emulate the 
conditions of previous studies in which resveratrol showed beneficial outcomes even 
when started late in life (Baur et al. 2006; Pearson et al. 2008). Mice remained on their 
respective diet until they reached 24 months of age at which time the frailty index 
(described below) was scored. This time-frame was chosen as Forster and colleagues 
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(Forster et al. 2003) previously found survival in ad libitum fed C57BL/6 mice was 
approximately 75% at 24 months. 
 
Body weight and food intake for all mice was monitored biweekly, and all groups had 
ad libitum access to water. Animal rooms were maintained on a 12 hr light/dark cycle at 
20-22°C, and 30-70% humidity. All animal protocols were approved by the Animal 
Care and Use Committee of the National Institute on Aging (429-TGB-2017 and 405-
TGB-2016) or the Animal Care Ethics Committee at Royal North Shore Hospital. 
6.2.2 Frailty Index Assessment 
The Mouse Clinical Frailty Index was used to assess frailty as detailed in section 2.2.2. 
Young (12 week) C57BL/6J and DBA/2J weight and temperature means and standard 
deviations were obtained from the Jacksons Laboratory 
(http://jaxmice.jax.org/support/weight/000664.html). 
 
For cohort one, mice were assessed for frailty, before randomization to treatment group 
and then after six weeks on their experimental diets. Frailty testing was carried out by 
two raters (raters 1 and 2) over one day. The raters were blinded to treatment group of 
the mice, and the scores assigned by the other rater.  
 
For the second mouse cohort, 19 month old male DBA/2J and C57BL/6J mice were 
assessed by four raters (raters 1, 3, 4 and 5). Each mouse was brought to a quiet 
assessment room and allowed to acclimatize for 30 minutes prior to the assessment. The 
mouse was weighed, subcutaneous body temperature was obtained (average of two 
readings) using a subcutaneous implanted transponder (BDMS, Seaford, DE), and then 
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each mouse was scored for each item in the frailty index by each rater. The mice were 
scored over two days. The raters were blinded to the diet group of the mice and to the 
scores assigned by the other rater.  
 
For the third mouse cohort, 24 month old male C57BL/6J mice were assessed by two 
raters (Raters 1 and 3). Mice were scored over one day, and the raters were blinded to 
the treatment group of the mice and to the score assigned by the other rater. 
Temperatures were not measured for these mice, so their final frailty index score was 
calculated for a 30 item scale only. 
6.2.3 Examiners/Raters 
Five raters with varying degrees of animal handling experience performed frailty 
assessments. Raters 1, 2 and 3 are scientists with 3-7 years of animal handling 
experience. Raters 4 and 5 are animal research technicians with 10 years animal 
handling experience.  
6.2.4 Functional Assessments 
At 16 months of age a subset of the cohort 1 DBA/2J (male n=5, female n=10) and 
C57BL/6J (male n=9, female n=11) mice had functional assessments performed (see 
timeline in supplemental figure 1). Motor co-ordination, balance, and endurance were 
assessed by the rotarod; forelimb and hindlimb strength using the cagetop test and 
forelimb and neuromuscular strength were assessed using the wirehang test. For all 
assessments mice were bought to the testing room and allowed to acclimitise for 15 
minutes prior to the commencement of testing. 
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For rotatord measurements the ability to run on the rotarod was measured as described 
previously (Mitchell et al. 2014). Mice were given a habituation trial at a constant speed 
of four rpm for one min before the first trial. Mice were then placed on the rotarod, 
which accelerated from 4 to 40 rpm over a period of 5 min, and latency to fall was 
recorded. A total of three trials were given on the same day, separated by 30 min rest 
periods. The average latency to fall was taken over all three trials. 
 
For cagetop measurements, the ability to hang upside down from a wire screen was 
tested as previously described (McDonald et al. 2001). This was modified from the 
Kondziella's inverted screen test (Kondziella 1964). The mouse was place on the wire 
lid of a mouse cage which was turned upside down. The cage top was then turned until 
the mouse was hanging from the cage top with all four limbs grasping the bars, and the 
latency to fall was recorded. Each mouse was given three trials with a maximum 
possible latency of 60 seconds. If the mouse fell before 10 seconds, the trial was 
repeated two more times. The average latency to fall was taken over all three trials. 
 
For wirehang measurements, a 55 cm wide 2-mm thick metallic wire was secured to 
two vertical stands approximately one metre above a thick foam pad. Mice were raised 
by their tail above the wire, slowly lowered until the mouse grasped the center of the 
wire with both front paws, then slowly lowered until the body was below the wire and 
released.  The latency time that the mouse remained on the wire was recorded for three 
trials, with a maximum of 60 seconds. If the mouse fell before 10 seconds the test was 
repeated. If on the 3rd trial the mouse still fell before 10 seconds, the best latency out of 
three trials was recorded. The average latency to fall was taken over all three trials. 
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6.2.5 Statistics 
Data are expressed as mean ± SEM unless otherwise indicated. The primary aim was 
assessed by taking the mean of the frailty index scores for two raters (raters 1 and 2 for 
cohort 1, and raters 1 and 3 for cohort 2 and 3), for each mouse. The data was assessed 
as normal using a D'Agostino & Pearson omnibus normality test, and thus differences 
between frailty index scores across groups were calculated with one-way ANOVA with 
Tukey’s HSD post-hoc test or t-tests where appropriate. The proportion of mice scored 
0, 0.5 or 1 for an individual frailty index item, by raters 1 and 3, was compared across 
cohort 2 and 3 mouse groups using a Chi-squared test. To determine whether functional 
outcomes were correlated with frailty index scores, the pearson correlation coefficient 
(r) was calculated, and linear regression was used to calculate slopes of best fit for each 
treatment group. Inter-rater reliability was assessed with the 2-way random, 
consistency, average intraclass correlation coefficient (ICC). The inter-rater reliability 
for specific items of the frailty index across raters was assessed by calculating the 
percentage of mice from cohorts 2 and 3 scored in agreement for each item across either 
across 2 or 4 raters. The percentage agreement was reported instead of Cohen’s or 
Fleiss’ kappa coefficient, as the nature of the index (only 3 possible scores, some scores 
used very infrequently) resulted in kappa values that severely underestimated the 
agreement (Mchugh 2012). Data analysis was completed using the statistics program 
SPSS (Version 21.0, SPSS Inc., Chicago, Illinois, USA) and GraphPad Prism (Version 
6.04, GraphPad Software, La Jolla California USA).  
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6.3 Results 
6.3.1 Effect of Paracetamol, Strain, Calorie Restriction and Resveratrol on 
Frailty Index Scores 
Six weeks of dietary paracetamol did not affect frailty index scores in male C57BL/6 
mice. There was no change in frailty index scores over the experimental period for 
control diet or paracetamol diet fed mice, and there was no difference in frailty index 
scores between control and paracetamol diet groups at either time point (Figure 6.1). 
 
Figure 6.1 Frailty index scores for old (26.8±0.5 months) male C57BL/6 mice pre and 
post six weeks of being fed either a control diet, or a diet supplemented with 
paracetamol (approximately 100mg/kg mouse/day, ‘Para’). Data is presented as mean ± 
25 and 75% quartiles. n=14-40 per group. 
 
Male CR DBA/2J mice had higher frailty index scores than male CR C57BL/6J mice 
(p=0.01) (Figure 6.2). There was no change in frailty index scores in the male and 
female AL-fed DBA/2J mice, and female CR DBA/2J mice compared to sex-matched 
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C57BL/6J mice (Figure 6.2).  In male C57BL/6J mice, CR significantly reduced the 
frailty index score, relative to their AL-fed counterparts (p=0.04). There was a trend 
towards reduced frailty index in calorie restricted female C57BL/6J, male DBA/2J and 
female DBA/2J mice compared to the sex and strain matched AL-fed groups (Figure 
6.2). There was no significant sex-effect upon frailty index with no change in frailty 
index observed in all female groups compared to the diet and strain matched male 
groups (Figure 6.2). 
 
 
Figure 6.2 Frailty index scores for (A) male C57BL/6 and DBA/2J mice fed either an 
AL diet, or a 40% CR diet from age 6 months (19±2 months age, n=8-9) and (B) female 
C57BL/6 and DBA/2J mice fed either an AL diet, or a 40% CR diet  (19±1 months age, 
n=9-11) from age 6 months. Data is presented as mean ± 25 and 75% quartiles. One-
way ANOVA female mice, non-significant. One-way ANOVA male mice, 
F(3,30)=4.84 p=0.007. M= male; F= female; C57= C57BL/6; DBA= DBA/2J; AL= ad 
libitum; CR= calorie restricted; * p < 0.05 with Tukey’s HSD post-hoc test. 
 
A 
B 
* * 
A 
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In the third cohort of mice, 6 months of resveratrol treatment significantly reduced the 
frailty index in C57BL/6J mice relative to SD-fed mice (p=0.01) (Figure 6.3). 
 
 
Figure 6.3 Frailty index scores for male C57BL/6 mice fed either a standard AIN-93G 
diet (SD), or an AIN-93G diet supplemented with resveratrol (RSV) (100mg/kg 
mouse/day) (n=16 SD, n=9 RSV, 24±0 months age) for 6 months from age 19 months. 
Data is presented as mean ± 25 and 75% quartiles. * p < 0.05. 
6.3.2 Effect of Strain, Calorie Restriction and Resveratrol on Specific 
Frailty Index Item Scores 
The proportion of mice scored 0, 0.5 or 1 was determined for each sex, strain and diet 
group, for each item (Table 6.1 for males and Table 6.2 for females). There were some 
interesting strain and diet effects on the scoring of specific items. Temperature and body 
weight scores greater than 0 were more common in AL-fed mice of both strains and 
sexes, than in the CR groups. AL-fed male mice were also more likely to have rectal 
prolapse than the male mice on the CR diet. Alopecia was more common in the male 
and female DBA/2J mice, whilst loss of fur colour was more common in the C57BL/6J 
mice of both sexes. Male and female DBA/2J mice were much more likely to have 
* 
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hearing loss with 100% of male mice from both diet groups scoring 0.5 or 1. Compared 
to both diet groups of male C57BL/6J mice, male DBA/2J mice were also more likely 
to have microphthalmia, a change in breathing rate and piloerection (Table 6.1). Female 
DBA/2J mice were more likely than female C57BL/6J mice to have kyphosis, tremor 
and a change in breathing rate. Distended abdomen was more common in female 
C57BL/6J mice than in female DBA/2J mice. Coat condition was more likely to be 
scored as normal in female C57BL/6J CR mice, than female ad libitum fed C57BL/6J 
mice or either female diet group of DBA/2J mice (Table 6.2) 
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Table 6.1 The percentage of scores by raters 1 and 3, for cohort 1 male C57BL/6 and DBA/2J mice fed either an AL diet, or a 40% CR diet from age 6 
months (19±2 months age), that fell into each score category (0, 0.5, 1) for each item of the frailty index. 
	
Male	DBA2/J		
Calorie	Restricted	
Male	DBA2/J		
Ad	Libitum	Fed	
Male	C57BL/6J		
Calorie	Restricted	
Male	C57BL/6J		
Ad	Libitum	Fed	
Chi	
Squared	
Frailty	Index	Item	 0	 0.5	 1	 0	 0.5	 1	 0	 0.5	 1	 0	 0.5	 1	 P	value	
Temperature	Score	 71.4	 14.3	 14.3	 57.1	 42.9	 	 100.0	 	 	 62.5	 37.5	 	 0.006	
Body	Weight	Score	 85.7	 14.3	 	 42.9	 42.9	 14.3	 90.0	 10.0	 	 12.5	 12.5	 75.0	 0.000	
Alopecia	 57.1	 42.9	 	 56.3	 43.8	 	 95.0	 5.0	 	 75.0	 25.0	 	 0.030	
Loss	of	fur	colour	 100.0	 	 	 93.8	 6.3	 	 25.0	 75.0	 	 43.8	 56.3	 	 0.000	
Dermatitis	 100.0	 	 	 100.0	 	 	 100.0	 	 	 81.3	 6.3	 12.5	 NS	
Loss	of	whiskers	 100.0	 	 	 75.0	 12.5	 12.5	 90.0	 10.0	 	 62.5	 18.8	 18.8	 NS	
Coat	condition	 35.7	 64.3	 	 25.0	 68.8	 6.3	 60.0	 40.0	 	 43.8	 31.3	 25.0	 0.020	
Tumours	 100.0	 	 	 87.5	 12.5	 	 100.0	 	 	 100.0	 	 	 NS	
Distended	abdomen	 100.0	 	 	 87.5	 12.5	 	 95.0	 5.0	 	 87.5	 12.5	 	 NS	
Kyphosis	 28.6	 50.0	 21.4	 37.5	 31.3	 31.3	 45.0	 50.0	 5.0	 62.5	 31.3	 6.3	 NS	
Tail	stiffening	 35.7	 50.0	 14.3	 12.5	 31.3	 56.3	 15.0	 65.0	 20.0	 25.0	 56.3	 18.8	 NS	
Gait	disorders	 100.0	 	 	 100.0	 	 	 100.0	 	 	 93.8	 6.3	 	 NS	
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Tremor	 71.4	 28.6	 	 75.0	 25.0	 	 95.0	 5.0	 	 87.5	 12.5	 	 NS	
Forelimb	grip	strength	 35.7	 50.0	 14.3	 18.8	 31.3	 50.0	 30.0	 60.0	 10.0	 25.0	 50.0	 25.0	 NS	
Body	condition	score	 57.1	 35.7	 7.1	 50.0	 50.0	 	 60.0	 35.0	 5.0	 37.5	 37.5	 25.0	 NS	
Vestibular	disturbance	 78.6	 21.4	 	 81.3	 18.8	 	 50.0	 45.0	 5.0	 68.8	 25.0	 6.3	 NS	
Hearing	loss	 		 28.6	 71.4	 		 31.3	 68.8	 70.0	 10.0	 20.0	 50.0	 18.8	 31.3	 0.000	
Cataracts	 92.9	 	 7.1	 93.8	 6.3	 	 80.0	 5.0	 15.0	 75.0	 6.3	 18.8	 NS	
Corneal	capacity	 100.0	 	 	 93.8	 6.3	 	 85.0	 15.0	 	 75.0	 12.5	 12.5	 NS	
Eye	discharge/swelling	 78.6	 14.3	 7.1	 37.5	 56.3	 6.3	 60.0	 35.0	 5.0	 68.8	 25.0	 6.3	 NS	
Microphthalmia	 35.7	 7.1	 57.1	 56.3	 31.3	 12.5	 95.0	 5.0	 	 81.3	 12.5	 6.3	 0.000	
Vision	loss	 50.0	 14.3	 35.7	 31.3	 25.0	 43.8	 20.0	 55.0	 25.0	 25.0	 43.8	 31.3	 NS	
Menace	reflex	 78.6	 21.4	 	 75.0	 25.0	 	 90.0	 10.0	 	 68.8	 18.8	 12.5	 NS	
Nasal	discharge	 100.0	 	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
Malocclusions	 100.0	 	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
Rectal	prolapse	 100.0	 	 	 68.8	 31.3	 	 95.0	 5.0	 	 68.8	 31.3	 	 0.022	
Vaginal/penile	prolapse	 57.1	 42.9	 	 50.0	 50.0	 	 80.0	 20.0	 	 75.0	 25.0	 	 NS	
Diarrhoea	 100.0	 	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
Breathing	rate/depth	 42.9	 35.7	 21.4	 43.8	 50.0	 6.3	 80.0	 20.0	 	 75.0	 12.5	 12.5	 NS	
 Alice Kane - March 2016 189 
Mouse	grimace	scale	 64.3	 14.3	 21.4	 50.0	 25.0	 25.0	 55.0	 40.0	 5.0	 43.8	 37.5	 18.8	 NS	
Pilo	erection	 21.4	 78.6	 		 18.8	 81.3	 		 65.0	 35.0	 		 56.3	 43.8	 		 0.007	
 
Table 6.2 The percentage of scores by raters 1 and 3, for cohort 1 female C57BL/6 and DBA/2J mice fed either an AL diet, or a 40% CR diet  (19±1 
months age, n=9-11) from age 6 months, that fell into each score category (0, 0.5, 1) for each item of the frailty index. 
	
Female	DBA2/J		
Calorie	Restricted	
Female	DBA2/J		
Ad	Libitum	Fed	
Female	C57BL/6J		
Calorie	Restricted	
Female	C57BL/6J		
Ad	Libitum	Fed	
Chi	
Squared	
Frailty	Index	Score	 0	 0.5	 1	 0	 0.5	 1	 0	 0.5	 1	 0	 0.5	 1	 P	value	
Temperature	Score	 100.0	 	 	 85.7	 14.3	 	 82.4	 17.6	 	 80.0	 10.0	 10.0	 0.017	
Body	Weight	Score	 90.0	 10.0	 	 25.0	 25.0	 50.0	 47.4	 42.1	 10.5	 		 	 100.0	 0.000	
Alopecia	 85.0	 15.0	 	 61.1	 38.9	 	 60.0	 35.0	 5.0	 50.0	 27.3	 22.7	 0.027	
Loss	of	fur	colour	 100.0	 	 	 100.0	 	 	 65.0	 35.0	 	 63.6	 31.8	 4.5	 0.005	
Dermatitis	 100.0	 	 	 100.0	 	 	 100.0	 	 	 90.9	 9.1	 	 NS	
Loss	of	whiskers	 100.0	 	 	 94.4	 5.6	 	 90.0	 10.0	 	 95.5	 4.5	 	 NS	
Coat	condition	 40.0	 60.0	 	 38.9	 61.1	 	 95.0	 5.0	 	 45.5	 50.0	 4.5	 0.003	
Tumours	 100.0	 	 	 100.0	 	 	 95.0	 5.0	 	 100.0	 	 	 NS	
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Distended	abdomen	 100.0	 	 	 100.0	 	 	 85.0	 5.0	 10.0	 68.2	 31.8	 	 0.001	
Kyphosis	 40.0	 45.0	 15.0	 38.9	 55.6	 5.6	 55.0	 45.0	 	 77.3	 22.7	 	 0.048	
Tail	stiffening	 25.0	 65.0	 10.0	 11.1	 66.7	 22.2	 30.0	 60.0	 10.0	 31.8	 59.1	 9.1	 NS	
Gait	disorders	 95.0	 5.0	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
Tremor	 50.0	 50.0	 	 77.8	 22.2	 	 95.0	 5.0	 	 100.0	 	 	 0.000	
Forelimb	grip	strength	 40.0	 60.0	 	 38.9	 38.9	 22.2	 40.0	 55.0	 5.0	 63.6	 31.8	 4.5	 NS	
Body	condition	score	 50.0	 35.0	 15.0	 44.4	 55.6	 	 60.0	 35.0	 5.0	 59.1	 31.8	 9.1	 NS	
Vestibular	disturbance	 90.0	 10.0	 	 83.3	 16.7	 	 75.0	 20.0	 5.0	 77.3	 18.2	 4.5	 NS	
Hearing	loss	 5.0	 30.0	 65.0	 6.3	 18.8	 75.0	 85.0	 10.0	 5.0	 72.7	 13.6	 13.6	 0.000	
Cataracts	 90.0	 	 10.0	 88.9	 	 11.1	 85.0	 5.0	 10.0	 90.9	 	 9.1	 NS	
Corneal	capacity	 100.0	 	 	 100.0	 	 	 95.0	 5.0	 	 90.9	 9.1	 	 NS	
Eye	discharge/swelling	 65.0	 30.0	 5.0	 44.4	 44.4	 11.1	 65.0	 30.0	 5.0	 50.0	 40.9	 9.1	 NS	
Microphthalmia	 75.0	 10.0	 15.0	 66.7	 11.1	 22.2	 50.0	 45.0	 5.0	 50.0	 22.7	 27.3	 NS	
Vision	loss	 35.0	 40.0	 25.0	 38.9	 44.4	 16.7	 45.0	 35.0	 20.0	 36.4	 54.5	 9.1	 NS	
Menace	reflex	 90.0	 10.0	 	 83.3	 16.7	 	 85.0	 15.0	 	 86.4	 13.6	 	 NS	
Nasal	discharge	 100.0	 	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
Malocclusions	 100.0	 	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
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Rectal	prolapse	 100.0	 	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
Vaginal/penile	prolapse	 85.0	 15.0	 	 100.0	 	 	 100.0	 	 	 95.5	 4.5	 	 NS	
Diarrhoea	 100.0	 	 	 100.0	 	 	 100.0	 	 	 100.0	 	 	 NS	
Breathing	rate/depth	 65.0	 35.0	 	 38.9	 61.1	 	 80.0	 20.0	 	 86.4	 13.6	 	 0.008	
Mouse	grimace	scale	 80.0	 10.0	 10.0	 61.1	 33.3	 5.6	 80.0	 20.0	 	 63.6	 36.4	 	 NS	
Pilo	erection	 35.0	 65.0	 		 11.1	 88.9	 		 90.0	 10.0	 		 81.8	 18.2	 		 NS	
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The only significant effect of resveratrol on scores of frailty index items, was an 
increase in the proportion of mice with an above 0 score for corneal opacity in the SD-
fed group (34%) compared to the resveratrol diet group (0%, p=0.005) (Table 6.3). 
 
Table 6.3 The percentage of scores by raters 1 and 3, for cohort 2 old (24±0 months) 
male C57BL/6 mice fed either a control diet (AIN-93G), or an AIN-93G diet 
supplemented with resveratrol (RSV) (100mg/kg mouse/day) (n=16 SD, n=9 RSV,) for 
6 months from age 19 months, that fell into each score category (0, 0.5, 1) for each item 
of the frailty index. 
	
Male	C57BL/6J	Mice	with	
Resveratrol	Diet	
Male	C57BL/6J	Mice	with	
Control	Diet	
Chi	
Squared
Frailty	Index	Score	 0	 0.5	 1	 0	 0.5	 1	 P	value	
Body	Weight	Score	 	 	 100.0	 	 	 100.0	 NS	
Alopecia	 100.0	 	 	 100.0	 	 	 NS	
Loss	of	fur	colour	 50.0	 50.0	 	 25.0	 71.9	 3.1	 NS	
Dermatitis	 100.0	 	 	 100.0	 	 	 NS	
Loss	of	whiskers	 100.0	 	 	 100.0	 	 	 NS	
Coat	condition	 38.9	 61.1	 	 37.5	 59.4	 3.1	 NS	
Tumours	 100.0	 	 	 100.0	 	 	 NS	
Distended	abdomen	 72.2	 27.8	 	 62.5	 37.5	 	 NS	
Kyphosis	 88.9	 11.1	 	 71.9	 25.0	 3.1	 NS	
Tail	stiffening	 33.3	 38.9	 27.8	 18.8	 59.4	 21.9	 NS	
Gait	disorders	 94.4	 5.6	 	 100.0	 	 	 NS	
Tremor	 100.0	 	 	 93.8	 6.3	 	 NS	
Forelimb	grip	strength	 33.3	 44.4	 22.2	 22.6	 41.9	 35.5	 NS	
Body	condition	score	 55.6	 33.3	 11.1	 46.9	 34.4	 18.8	 NS	
Vestibular	disturbance	 50.0	 50.0	 	 31.3	 56.3	 12.5	 NS	
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Hearing	loss	 61.1	 22.2	 16.7	 50.0	 26.7	 23.3	 NS	
Cataracts	 94.4	 5.6	 	 100.0	 	 	 NS	
Corneal	capacity	 100.0	 	 	 65.6	 34.4	 	 0.005	
Eye	discharge/swelling	 55.6	 44.4	 	 56.3	 37.5	 6.3	 NS	
Microphthalmia	 94.4	 5.6	 	 96.9	 3.1	 	 NS	
Vision	loss	 5.6	 38.9	 55.6	 12.9	 38.7	 48.4	 NS	
Menace	reflex	 55.6	 44.4	 	 48.4	 41.9	 9.7	 NS	
Nasal	discharge	 94.4	 5.6	 	 100.0	 	 	 NS	
Malocclusions	 100.0	 	 	 100.0	 	 	 NS	
Rectal	prolapse	 100.0	 	 	 100.0	 	 	 NS	
Vaginal/penile	prolapse	 100.0	 	 	 100.0	 	 	 NS	
Diarrhoea	 100.0	 	 	 100.0	 	 	 NS	
Breathing	rate/depth	 38.9	 61.1	 	 18.8	 75.0	 6.3	 NS	
Mouse	grimace	scale	 50.0	 50.0	 	 34.4	 65.6	 	 NS	
Pilo	erection	 88.9	 11.1	 	 81.3	 18.8	 	 NS	
 
6.3.3 Correlation between Frailty Index Scores and Functional Outcomes 
Figure 2 shows the correlation between frailty index scores and the functional outcome 
measures of latency to fall for rotarod, wire hang and cage top, for a small subset of the 
CR and AL-fed male and female DBA/2J and C57BL/6J mice. Standard correlation 
analysis showed no significant correlation between frailty index scores and any 
functional outcomes measured in this subset of animals. 
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Figure 6.4 The correlation between frailty index and latency to fall for (A1) rotarod, 
(A2) wire hang, and (A3) cage top functional testing in old (19±2 months) male 
C57BL/6 and DBA/2 mice (n=14) and the correlation between frailty index and latency 
to fall for (B1) rotarod, (B2) wire hang, and (B3) cage top functional testing in old 
(19±1 months) female C57BL/6 and DBA/2 mice (n=21). None of the correlations 
showed a significant association (p>0.05). 
6.3.4 Inter-Rater Reliability 
The inter rater correlation coefficient across raters 1 and 2 for all mice from cohort 1 
was moderate for both pre-treatment (ICC=0.522[CI 0.181-0.721]) and post-treatment 
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(ICC=0.488[CI 0.244-0.652]) assessments. The inter rater correlation coefficient across 
raters 1 and 3 for all mice from cohort 2 and 3 was excellent (ICC = 0.88, 95% CI [0.80, 
0.92]). The mean frailty index scores presented in the data above for cohorts 2 and 3 
were determined from the scores of raters 1 and 3 as they were the only raters to assess 
both cohorts of mice. 
 
In order to look at the effect of background and training of the raters on the inter rater 
reliability of the mouse clinical frailty index, the inter rater correlation coefficient was 
also calculated for the four raters of cohort 2. The inter rater correlation coefficient 
across the 4 raters for the mice in cohort 2 indicated moderate to excellent agreement 
(ICC = 0.65, 95% CI [0.48, 0.77]). The inter rater correlation coefficients between each 
pair of raters was calculated (Table 6.4). Interestingly, although there was excellent 
correlation between raters 1 and 3 (ICC = 0.88, 95% CI [0.80, 0.92]), and moderate 
correlation between raters 4 and 5 (ICC = 0.61, 95% CI [0.34, 0.76]), there was only 
poor or poor-moderate correlation between the other combinations of raters.  
 
Table 6.4 Inter rater correlation of frailty index scores for male and female old (19±2 
months) DBA/2 and C57BL/6 mice from cohort 1, between each combination of 2 
raters (2-way random, consistency, average intraclass correlation coefficient, with 95% 
confidence intervals). 
Raters		 1	 3	 4	 5	
3	 0.88	(0.80‐0.92)	 ‐	 ‐	 ‐	
4	 0.20	(‐0.30‐.51)	 ‐0.06	(‐0.73‐0.35)	 ‐	 ‐	
5	 0.49	(0.17‐0.69)	 0.451	(0.11‐0.66)	 0.605	(0.34‐0.76)	 ‐	
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The average percentage agreement was calculated for each item of the frailty scale as 
explained in the methods section. This agreement was calculated for raters 1 and 3, and 
for raters 1, 3, 4 and 5, across all mice scored in cohorts 2 and 3 (Figure 6.5). The items 
of the scale which had the worst agreement across all raters were coat condition, pilo-
erection, body condition score, hearing loss, kyphosis, tail stiffening, vision loss and 
forelimb grip strength, with less than 75% agreement. Between raters 1 and 2 the items 
with less than 75% agreement were coat condition, body condition score, vision loss, 
forelimb grip strength and menace reflex. 
 
Figure 6.5 The percentage agreement of scoring for each item of the frailty index for all 
old male and female C57BL/6 and DBA/2J mice in cohort 1 across all 4 raters (black), 
and across raters 1 and 3 (grey). The dotted line shows a percentage agreement of 75%. 
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6.4 Discussion 
In this chapter we found that six weeks of dietary paracetamol exposure did not affect 
frailty index in mice. We also found that both calorie restriction from age 6 months, and 
6 months of dietary resveratrol, significantly reduced the frailty index in old C57BL/6J 
male mice, compared to those fed control ad libitum diets. Interestingly, frailty index 
scores were also higher for male calorie restricted DBA/2J mice compared to age and 
diet -matched C57BL/6J mice. 
 
Old C57BL/6 mice (27 months) exposed to chronic low-dose paracetamol treatment for 
6 weeks showed no change in frailty index, either over time, or compared to control-diet 
fed mice. There is some evidence to show that paracetamol may play a role in protecting 
against age-related changes (Rice et al. 2012; Wu et al. 2010; Lublin et al. 2011), 
however these studies were investigating specific isolated tissues, rather than a systemic 
measure, such as the frailty index. It is possible that six weeks of paracetamol exposure 
was insufficient to see changes in frailty index, especially as the treatment was not 
started until late in the mouse lifespan, and it would be interesting in future studies to 
look at the effect of longer term exposure to paracetamol, started earlier in life, on 
healthspan and frailty outcomes. 
 
Old C57BL/6J mice (24 months) with chronic resveratrol treatment had a lower frailty 
index than ad libitum fed mice. Long term treatment with resveratrol in mice fed a 
standard diet has previously been shown to delay functional decline, and increase 
healthspan, without increasing lifespan (Pearson et al. 2008). The mouse frailty index 
may provide a new and important healthspan measure to be used as an outcome in 
interventional longevity studies. Consistent with previous studies, we found that the 
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resveratrol diet group had a decreased proportion of mice with corneal opacity 
compared to the control diet group (Pearson et al. 2008; Baur et al. 2006). 
 
Old male C57BL/6J mice (19 months) with calorie restriction from age six months had 
a lower frailty index than ad libitum fed male C57BL/6J mice. This is consistent with 
previous studies demonstrating that calorie restriction both delays age-related decline 
and increases lifespan in mice (Weindruch et al. 1986; Mattson & Wan 2005). There 
has, however, been some recent controversy about whether the effects of calorie 
restriction on mice are universally positive (Swindell 2012; Liao et al. 2010; Sohal & 
Forster 2014). The age of initiation of calorie restriction (Cheney et al. 1980), the mouse 
strain (Swindell 2012; Liao et al. 2010), and the composition of the diet (Solon-Biet et 
al. 2014) are increasingly being recognized as important. It would be interesting in 
future studies to look at the effect of calorie restriction on frailty in a non-inbred mouse 
strain, and at the effect of dietary composition of calorie restriction on clinical mouse 
frailty index. 
 
Consistent with a previous study showing DBA/2J mice are not responsive to the 
lifespan extension effects of calorie restriction (Forster et al. 2003), we found that frailty 
scores did not significantly change with calorie restriction in male and female DBA/2J 
mice. Earlier studies did find there was an effect of 40% calorie restriction in DBA2/J 
mice on longevity (Turturro et al. 1999), and on delaying age-related pathologies 
(Bronson & Lipman 1991). The lack of change in frailty index scores for calorie 
restricted DBA/2J mice in this study would suggest that calorie restriction may not 
delay age-related decline, or increase the healthspan of this strain of mice. The 
difference in frailty scores between the short-lived DBA/2J strain and the C57BL/6J 
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strain was not as substantial as expected. This cohort of mice were younger (19 months) 
than the resveratrol-fed mice (24 months) so perhaps the effects of interventions on the 
frailty index may be more clearly seen with increasing age. We observed less variability 
in frailty scores at 24 months of age in our study (coefficient of variation for male ad 
libitum fed C57BL/6J was 0.16 at 24 months and 0.30 at 19 months), which is 
consistent with previous findings in mice (Whitehead et al. 2014) and humans 
(Rockwood et al. 2005). On the other hand, it may indicate that although the DBA/2J 
strain are up to 6 months short-lived than the C57BL/6J strain (Yuan et al. 2011), 
perhaps they have a comparatively longer healthspan, as indicated by moderate frailty 
scores. It is also possible that the frailty index scale may need to be tailored to include 
strain-specific ageing deficits for use in different mouse strains. The high prevalence of 
factors like hearing loss in the 19 month old DBA/2J mice both in this study and in 
much younger mice (2-3 weeks) in other studies (Willott et al. 2005) suggest that this 
deficit saturates too early to be useful as a deficit in assessment of a frailty index in this 
strain. Early saturation has previously been identified as a reason an item should be 
excluded as a deficit in clinical frailty studies (Searle et al. 2008). 
	
There were some interesting changes in the specific items of the frailty index across the 
strain and diet groups. Calorie restriction brought the body weight and temperature 
scores of both DBA/2J and C57BL/6J mice back to the ‘normal’ 12 week old mouse 
range, compared to the ad libitum fed groups. This is consistent with previous studies in 
which ad libitum feeding caused young and middle-aged mice of both strains to gain 
weight, and this effect was stopped by calorie restriction (Sohal & Ferguson 2009). 
Temperature is also known to increase with feeding and decrease with calorie restriction 
(Rikke & Johnson 2007) and decreased core temperature is also associated with 
increased longevity (Conti et al. 2006). 
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The correlation between the functional outcomes of latency to fall for rotarod, wire hang 
and cage top and the frailty index was investigated for a subset of cohort 1 C57BL/6J 
and DBA/2J mice. There were no significant associations between any of the measured 
functional outcomes and frailty index. This is consistent with human data, as clinically 
the patients identified as frail with the frailty index, are not always identified as frail 
with the phenotype approach that includes measures of functional performance, and vice 
versa (Rockwood et al. 2007; Kulminski et al. 2008). Furthermore, as this study was 
completed as part of a larger study, the functional outcome testing was done at 16 
months, whilst the frailty assessment was done at 19 months. The smaller sample size 
and the difference in time for assessment may explain the lack of correlation, and it 
would be interesting to explore this further, with both functional assessment and frailty 
index assessment completed at the same time. Graber et al (2014) developed a 
composite score, called a frailty intervention assessment value that they used to evaluate 
the effect of exercise intervention on frailty. Future studies could calculate a similar 
score from functional assessments, such as those measured in the current study, to 
determine the effect of interventions such as paracetamol, resveratrol and calorie 
restriction on frailty interventions. 
 
One of our secondary aims of this study was look at the inter-rater variability in 
assessment of the mouse clinical frailty index. Interestingly, we found that the 
professional background and baseline animal training of the raters, was a main factor in 
affecting the inter-rater reliability. The inter-rater reliability between the animal 
technicians, with extensive training and experience, and researchers, with limited 
training and experience, was poor, despite moderate inter-rater reliability between the 
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technicians and moderate to excellent inter-rater reliability between the scientists. This 
suggests that the selection of raters for the mouse clinical frailty index must be done 
carefully, and preference given to raters with the same training/background if 
comparisons are to be made between and across mouse groups and studies. 
 
The percentage correlation for the specific items of the frailty index was calculated to 
determine if there were certain items on which raters were more likely to disagree. The 
items of the scale which had the worst agreement across all raters were coat condition, 
piloerection, menace reflex, body condition score, hearing loss, kyphosis, tail stiffening, 
vision loss and forelimb grip strength. These items all seem to have an element of 
subjectivity, where the rater is required to judge the reaction of the mouse compared to 
‘normal’ rather than an objective criteria such as ‘more than 25% hair loss’ for example. 
Feridooni et al. published a recent study also investigating the reliability of the mouse 
clinical frailty index, and also identified the majority of these items as those with the 
most discrepancies between raters (Feridooni et al. 2014). They found that after a 
discussion period between raters about discrepancies in scoring, inter-rater correlation 
increased. The use of a training and/or discussion period, or a more detailed scoring 
manual may have further improved the inter rater correlation in the current study. There 
is currently much research into the search for frailty biomarkers clinically (Darvin et al. 
2014), which could provide additional objective items for the frailty index, but would 
add complexity and cost to the assessment. 
 
Strengths of this study include the novelty of reporting for the first time on the impact 
of strain, dietary and pharmaceutical interventions on the mouse clinical frailty index 
(Whitehead et al. 2014), the rigorous and blinded data collection, and quality of the 
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animal cohorts. Some of the limitations of this study include the lack of temperature 
scores for one mouse cohort, and the time and sample size differences between the 
functional outcome scoring and the frailty index scoring. Furthermore, the short 
timeframe of the paracetamol exposure group does not allow us to conclude on the 
potential long-term frailty effects of paracetamol. It would also be interesting, in future 
studies, to assess the frailty index score on the same mice over time, and to assess the 
association of frailty prospectively with other markers of healthspan and lifespan. 
 
In summary, the study explored in this chapter was the first to investigate the effect of 
mouse strain and dietary and pharmaceutical interventions on the novel clinical frailty 
index in mice. Whilst chronic paracetamol exposure did not affect the frailty index, 
resveratrol treatment and calorie restriction reduced the frailty index in ageing male 
C57BL/6J mice. This chapter also investigated the inter-rater reliability of the mouse 
clinical frailty index across several raters of varied backgrounds, and identified some 
aspects of the index that could be improved. The mouse clinical frailty index provides 
an invaluable tool for studies in ageing mice to assess the impact of interventions on 
frailty, as was explored in this chapter, or the impact of frailty on response to 
interventions, as was explored in chapters 2 and 3. 
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7 CONCLUSIONS 
The objective of this thesis was to help improve the safety of paracetamol for patients of 
all ages by adding evidence to the body of knowledge on the changing risks of 
paracetamol toxicity in ageing, frailty and non-acute exposures, and the potential for 
lifespan and healthspan increasing interventions to provide novel mechanisms of 
paracetamol hepatotoxicity protection. Furthermore, this thesis aimed to investigate the 
potential of both paracetamol, and lifespan and healthspan interventions in delaying or 
preventing frailty. 
 
Methods used to investigate these aims included: the use of C57BL/6 mice as ageing 
models; the assessment of frailty with the novel mouse clinical frailty index; the 
investigation of dietary and pharmaceutical interventions, either toxic or therapeutic, in 
mouse ageing models; the use of SIRT1 transgenic mice to investigate mechanisms; the 
use of primary cell cultures; and the assessment of outcomes using a variety of 
biochemical and molecular techniques including realtime quantitative PCR, western 
blots, enzymatic activity assays and biochemical and histological assessments. 
 
Chapter 7: Conclusions 
Alice Kane - March 2016 204
Overall the work presented in this thesis contributed to three main findings with 
significant clinical significance, and several secondary findings. 
 
Firstly, we demonstrated that there is no increase in susceptibility to paracetamol 
toxicity in old age or frailty, with either acute, chronic or sub-acute paracetamol 
exposure. This implies that paracetamol may be a safe analgesic option for use in the 
older and frail population, as a well-tolerated analgesic at therapeutic doses, with no 
increased risk of toxicity in old age, although more research is needed to confirm these 
findings in the clinical setting. 
 
Secondly, an important finding of this thesis with significant clinical implications, was 
that the currently used paracetamol hepatotoxicity therapy, NAC, does not protect 
against toxicity induced by sub-acute paracetamol exposure. This highlights the need 
for more research into other potential therapies to protect against or treat paracetamol 
hepatotoxicity induced by all exposure types. Studies in this thesis investigated the 
potential of the lifespan and healthspan increasing mechanism of SIRT1 activation as a 
paracetamol hepatotoxicity therapy, and found that neither pharmacological or genetic 
activation of SIRT1 was protective. This was confirmed with in vitro, concurrent and 
pre-dosing studies in mice, and in transgenic SIRT1 knock-out and overexpressor mice. 
Potential future targets for paracetamol toxicity therapeutics may include increasing 
NQO1 activity, increasing autophagy, or further investigation of the potentially 
protective effects of the other ageing-related pathways such as mTOR and AMPK. 
 
Thirdly, this thesis found that the lifespan and healthspan increasing interventions of 
resveratrol and calorie restriction, but not therapeutic paracetamol, were able to delay 
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frailty in aged C57BL/6 mice. This study was the first to investigate dietary and 
pharmaceutical interventions on the novel clinical frailty index in mice, and provides 
the pre-clinical evidence for testing these interventions on frailty in humans. 
 
There were other secondary findings of the studies presented in this thesis. These 
included the age-related changes of increased NQO1 activity in old mice and an age-
related increase in pro and anti-inflammatory cytokines, and the mRNA expression of 
BAX and PGC1β, in response to acute paracetamol in old mice. These are potentially 
paracetamol hepatotoxicity protective mechanisms that interestingly, did not translate 
into a protection against paracetamol hepatotoxicity in our studies.  
 
We also found that high-dose paracetamol induced phosphorylated AMPK protein 
expression, and SIRT1 mRNA expression in the liver, which implies a role of these 
pathways in paracetamol toxicity mechanisms. This requires more research and would 
be interesting to investigate with therapeutic paracetamol exposure.  
 
Furthermore, these studies showed a differential protein expression response to long-
term resveratrol treatment in young compared to old mice. This finding confirms the 
complexity of these pathways in age and with interventions and more research is needed 
to understand the reasons for and implications of this finding.  
 
Finally, the studies presented in this thesis added to the body of research using the novel 
mouse clinical frailty index as an effective ageing research tool. We were the first to use 
this index to look at both frailty as an outcome and as a potential mediator of toxicity. 
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We also identified some important factors to consider when using the index, such as the 
background and training of the raters, and the subjectivity of some of the index items. 
Furthermore, we showed in mice a negative correlation between the frailty index and 
serum protein, albumin and ALP, low levels of which have been identified as potential 
frailty biomarkers in humans. 
 
In conclusion, the work presented in this thesis used a series of mouse models, to 
identify that age and frailty do not increase the risk of paracetamol hepatotoxicity, even 
for non-acute exposures. We also showed that NAC does not protect against 
paracetamol toxicity induced by sub-acute exposure, and that SIRT1 activation does not 
provide an alternative protective mechanism. Finally, we showed that the interventions 
of resveratrol and calorie restriction can delay frailty in mice. 
 
The findings of this thesis represent important contributions to the bodies of work both 
on optimising the safety of medication use in old age and frailty, as well as increasing 
the healthspan and quality of life of older people by delaying the onset of frailty. There 
is, however, still much work to be done in both of these important areas of research. 
 
Older people have the most need for the beneficial effects of and are the largest users of 
medications, yet they are also at the most risk of adverse effects from medications. 
Despite this, they continue to be excluded from clinical trials, and prescribed 
medications and medication doses without guiding empirical evidence. Research into 
optimising the benefits of, and perhaps even more importantly reducing the potential 
risks and harms from, medications in older and frail people is hugely important, but has 
not to date been a priority for research. This thesis added some relevant findings on this 
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issue, but this is still a lot to be done to ensure that all older people are treated 
appropriately and safely with medications. 
 
The optimisation of a person’s healthspan, in order to ensure that people live happily, 
healthily and with high quality of life for as long as possible, should be the ultimate goal 
and focus of all medical research. The ethical, social and personal implications of the 
focus upon improving our maximum lifespan, without a focus on the quality of that 
lifespan are serious. Research into longevity mechanisms and interventions, should 
continue the recent shift of focus onto investigating person-relevant outcomes such as 
quality of life, independence, function, and resilience, rather than just longevity. 
Research into delaying the onset of frailty, such as that presented in this thesis, provides 
one way to contribute to this focus. 
 
“The quality, not the longevity, of one’s life is what is important.” Martin Luther King, 
Jr 
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System/	
Parameter	
Clinical	assessment	of	deficit		 Scoring			
Integument	
Alopecia		 Gently	restrain	the	animal	and	
inspect	it	for	signs	of	fur	loss.		
0	=	normal	fur	density	
0.5	=	<	25%	fur	loss	
1	=	>25%	fur	loss	
Loss	of	fur	colour	 Note	any	change	in	fur	colour	from	
black	to	grey	or	brown.		
0	=	normal	colour	
0.5	=	focal	grey/brown	changes	
1	=	grey/brown	fur	throughout	
body	
Dermatitis	 Document	skin	lesions.		 0	=	absent	
0.5	=	focal	lesions	(e.g.	neck,	flanks,	
under	chin)	
1	=	widespread	or	multifocal	lesions	
Loss	of	whiskers	 Inspect	the	animal	for	signs	of	a	
reduction	in	the	number	of	whiskers.	
0	=	no	loss	
0.5	=	reduced	number	of	whiskers	
1	=	absence	of		whiskers	
Coat	condition	 Inspect	the	animal	for	signs	of	poor	
grooming.			
0	=	smooth,	sleek,	shiny	coat	
0.5	=	coat	is	slightly	ruffled	
1	=	unkempt	and	un‐groomed,	
matted	appearance	
Physical/	
Musculoskeletal	
Tumours	
	
Observe	the	mice	to	look	for	
symmetry.		Hold	the	base	of	the	tail	
and	manually	examine	mice	for	
visible	or	palpable	tumours.		
0	=	absent	
0.5	=	<1.0	cm	
1	=	>1.0	cm	or	multiple	smaller	
tumours	
Distended	abdomen	 Hold	the	mouse	vertically	by	the	
base	of	their	tail	and	tip	backwards	
over	your	hand.		Excess	fluid	visible	
as	a	bulge	below	the	rib	cage.		
0	=	absent	
0.5	=	slight	bulge		
1	=	abdomen	clearly	distended		
Kyphosis	
	
Inspect	the	mouse	for	curvature	of	
the	spine	or	hunched	posture.		Run	
your	fingers	down	both	sides	of	the	
spine	to	detect	abnormalities.		
0	=	absent	
0.5	=	mild	curvature	
1	=	clear	evidence	of	hunched	
posture							
Tail	stiffening	 Grasp	the	base	of	the	tail	with	one	
hand,	and	stroke	the	tail	with	a	
finger	of	the	other	hand.		The	tail	
should	wrap	freely	around	the	finger	
when	mouse	is	relaxed.		
0	=	no	stiffening	
0.5	=	tail	responsive	but	does	not	
curl	
1	=	tail	completely	unresponsive						
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Gait	disorders	 Observe	the	freely	moving	animal	to	
detect	abnormalities	such	as	
hopping,	wobbling,	circling,	wide	
stance	and	weakness.		
0	=	no	abnormality	
0.5	=	abnormal	gait	but	animal	can	
still	walk	
1	=	marked	abnormality,	impairs	
ability	to	move		
Tremor	 	 Observe	the	freely	moving	animal	to	
detect	tremor,	both	at	rest	and	when	
the	animal	is	trying	to	climb	up	an	
incline.		
0	=	no	tremor	
0.5	=	slight	tremor	
1	=	marked	tremor;	animal	cannot	
climb		
Forelimb	grip	
Strength	
Hold	the	mouse.		Allow	it	to	grip	the	
bars	on	the	cage	lid.		Lift	animal	by	
the	base	of	the	tail	to	assess	grip	
strength.		
0	=	sustained	grip	
0.5	=	reduction	in	grip	strength	
1	=	no	grip	strength,	no	resistance		
Body	condition	
score	
Place	mouse	on	flat	surface,	hold	tail	
base	and	manually	assess	the	
flesh/fat	that	covers	the	sacroiliac	
region	(back	and	pubic	bones).			
0	=	bones	palpable,	not	prominent	
0.5	=	bones	prominent	or	barely	felt	
1	=	bones	very	prominent	or	not	felt	
due	to	obesity	
Vestibulocochlear/	
Auditory	
Vestibular	
disturbance	
Hold	the	base	of	the	tail	and	lower	
mouse	towards	a	flat	surface.		
Inspect	for	head	tilt,	spinning,	
circling,	head	tuck	or	trunk	curling.		
0	=	absent	
0.5	=	mild	head	tilt	and/or	slight	
spin	when	lowered	
1	=	severe	disequilibrium							
Hearing	loss	
	 	
Test	startle	reflex.		Hold	a	clicker	
~10	cm	from	mouse,	sound	it	3	
times	and	record	responses.		
0	=	always	reacts	(3/3	times)	
0.5	=	reacts	1/3	or	2/3	times	
1	=	unresponsive	(0/3	times)				
Cataracts	 Visual	inspection	of	the	mouse	to	
detect	opacity	in	the	centre	of	the	
eye.			
0	=	no	cataract	
0.5	=	small	opaque	spot	
1	=	clear	evidence	of	opaque	lens	
Eye	
discharge/swelling	
Visual	inspection	of	the	mouse	to	
detect	ocular	discharge	and	swelling	
of	the	eyes.		
0	=	normal	
0.5	=	slight	swelling	and/or	
secretions	
1	=	obvious	bulging	and/or	
secretions				
Microphthalmia	 Inspect	eyes.		 0	=	normal	size	
0.5	=	one	or	both	eyes	slightly	small	
or	sunken	
1	=	one	or	both	eyes	very	small	or	
sunken	
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Corneal	opacity	 Visual	inspection	of	the	mouse	to	
superficial	white	spots	and/or	
clouding	of	the	cornea.		
0	=	normal	
0.5	=	minimal	changes	in	cornea	
1	=	marked	clouding	and/or	
spotting	of	cornea	
Vision	loss	
	
Lower	mouse	towards	a	flat	surface.		
Evaluate	the	height	at	which	the	
mouse	reaches	towards	the	surface.		
0	=	reaches	>8	cm	above	surface	
0.5	=	reaches	2‐8	cm	above	surface	
1	=	reaches	<2	cm	above	surface	
Menace	reflex	
	
Move	an	object	towards	the	mouse's	
face	3	times.		Record	whether	the	
mouse	blinks	in	response		
0	=	always	responds	
0.5	=	no	response	to	1or	2	
approaches	
1	=	no	response	to	3	approaches	
Nasal	discharge	 Visual	inspection	of	the	mouse	to	
detect	nasal	discharge.		
0	=	no	discharge	
0.5	=	small	amount	of	discharge	
1	=	obvious	discharge,	both	nares	
Digestive/	
Urogenital	
Malocclusions	
	
Grasp	the	mouse	by	the	neck	scruff,	
invert	and	expose	teeth.		Look	for	
uneven,	overgrown	teeth.			
0	=	mandibular	longer	than	
maxillary	incisors	
0.5	=	teeth	slightly	uneven	
1	=	teeth	very	uneven	and	
overgrown	
Rectal	prolapse	 Grasp	the	mouse	by	the	base	of	the	
tail	to	detect	signs	of	rectal	prolapse.		
0	=	no	prolapse	
0.5	=	small	amount	of	rectum	visible	
below	tail	
1	=	rectum	clearly	visible	below	tail.	
Vaginal/uterine/	
penile	prolapse	
Grasp	the	mouse	by	the	base	of	the	
tail	to	detect	signs	of	vaginal/uterine	
or	penile	prolapse.			
0	=	no	prolapsed	
0.5	=	small	amount	of	prolapsed	
tissue	visible	
1	=	prolapsed	tissue	clearly	visible	
Diarrhoea	
	
Grasp	the	mouse	and	invert	it	to	
check	for	signs	of	diarrhoea.		Also	
look	for	fecal	smearing	in	home	cage.		
0	=	none	
0.5	=	some	feces	or	bedding	near	
rectum	
1	=	fecesplus	blood	and	bedding	
near	rectum,	home	cage	smearing	
Respiratory	
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Breathing	
rate/depth	
	
Observe	the	animal.		Note	the	rate	
and	depth	of	breathing	as	well	as	any	
gasping	behaviour.			
0	=	normal	
0.5	=	modest	change	in	breathing	
rate	and/or	depth	
1	=	marked	changes	in	rate/depth,	
gasping	
Discomfort	
Mouse		
Grimace	Scale	
	
	
Note	facial	signs	of	discomfort:	1)	
orbital	tightening,	2)	nose	bulge,	3)	
cheek	bulge,	4)	ear	position	(drawn	
back)	or	5)	whisker	change	(either	
backward	or	forward).		
0	=	no	signs	present	
0.5	=	1	or	2	signs	present	
1	=	3	or	more	signs	present		
Piloerection	
	
Observe	the	animal	and	look	for	
signs	of	piloerection,	in	particular	on	
the	back	of	the	neck.		
0	=	no	piloerection	
0.5	=	involves	fur	at	base	of	neck	
only	1	=	widespread	piloerection		
Other	
Temperature	
	
Measure	surface	body	temperature	
with	an	infrared	thermometer	
directed	at	the	abdomen	(average	of	
3	measures).		Compare	with	
reference	values	from	sex‐matched	
adult	animals.			
0	=	differs	by	<1	SD	from	reference	
value	
0.25	=	differs	by	1	SD	
0.5	=	differs	by	2	SD	
0.75	=	differs	by	3	SD	
1	=	differs	by	>3	SD			
Weight	 Weigh	the	mouse.		Compare	with	
reference	values	from	sex‐matched	
adult	animals.			
0	=	differs	by	<1	SD	from	reference	
value	
0.25	=	differs	by	1	SD	
0.5	=	differs	by	2	SD	
0.75	=	differs	by	3	SD	
1	=	differs	by	>3	SD			
Source: Whitehead et al (2014) 
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APPENDIX 2 – PRIMER SEQUENCES 
	 Forward	 Reverse	
SIRT1	 5’‐	CAG	TGT	CAT	GGT	TCC	TTT	GC‐3’	 5’‐	CAC	CGA	GGA	ACT	ACC	TGA	T	‐3’	
CYP2E1	 5’‐	CGC	ATG	GAA	CTG	TTT	CTG	C‐3’	 5’‐CAA	TTG	TAA	CAG	GGC	TGA	GGT	C‐3’	
NQO1	 5’‐GAG	TGC	TCG	TAG	CAG	GAT	TTG‐3’	 5’‐ACC	CCC	AGT	GGT	GAT	AGA	AAG‐3’	
TNF‐α	 5’‐TAC	TGA	ACT	TCG	GGG	TGA	TTG	GTC	C‐3’	 5’‐	CAG	CCT	TGT	CCC	TTG	AAG	AGA	ACC‐3’	
IL‐1β	 5’‐CTG	TGG	CAG	CTA	CCT	GTG	TC‐3’	 5’‐GTC	ACA	GAG	GAT	GGG	CTC	TT	‐3’	
IL‐10	 5’‐GCA	ACT	GTT	CCT	GAA	CTC	AAC	T‐3’	 5’‐ATC	TTT	TGG	GGT	CCG	TCA	ACT‐3’	 
NF‐κB	 5′‐CCT	CTG	GCG	AAT	GGC	TTT	AC‐3′		 5′‐GCT	ATG	GAT	ACT	GCG	GTC	TGG‐3′	
Caspase	
3	 5’‐TGA	CTG	GAA	AGC	CGA	AAC	TC‐3’	 5’‐ATC	TTC	TGG	CAA	GCC	ATC	TC‐3’	
BAX	 5’‐CAA	GAA	GCT	GAG	CGA	GTG	TCT‐3’	 5’‐GTG	TCC	ACG	TCA	GCA	ATC	AT	‐3’	
PGC‐1α	 5′‐CCT	GGC	CGA	GTT	CTT	TGA	A‐3	 5′‐GCC	AGA	TTT	GCT	TGT	TTG	G‐3′	
PGC‐1β	 5'‐TGG	AAA	GCC	CCT	GTG	AGA	GT	‐3'	 5'‐TTG	TAT	GGA	GGT	GTG	GTG	GG	‐3'	
GAPDH	 5’‐CAC	CAA	CTG	CTT	AGC	CCC‐3’	 5’‐TCT	TCT	GGG	TGG	CAG	TGA	TG‐3’	
 
